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Abstract
Despite the success achieved in identifying mutations causing Mendelian forms of 
epilepsy, little progress has been made in illuminating variation contributing to the 
development of more common forms of the condition. The aim of this thesis was to improve 
methodology that would aid the detection of variation functional in the development and
treatment of common forms of epilepsy.
Attempted replication of previous claims of association with common forms of epilepsy 
allowed resolution of true effects from false positive results and illustrated shortcomings in 
the application of association based genetic mapping. Where effects looked real, 
haplotype-based fine mapping techniques were applied to identify candidate causal 
variation. The tagging SNP method was applied to HapMap data in an attempt to identify 
variation that might guide the safe prescription of Vigabatrin, an effective antiepileptic drug
limited by a serious adverse drug reaction.
Results outlined here show all previous claims of association with temporal lobe epilepsy 
and febrile seizures are likely to be false positives. However, supportive evidence is 
presented that common genetic variation predisposes to juvenile myoclonic epilepsy in a 
population specific manner. Evidence is also presented that variation that could be 
considered clinically relevant for the safe administration of Vigabatrin does not exist in the 
candidate genes examined here. Finally, a study design is proposed that seeks to 
significantly increase genetic power of detection through the incorporation of lessons
learned from previous studies.
In conclusion, epilepsy appears to be as genetically complex as the phenotypic spectrum 
of the condition would suggest. This work illustrates key areas in study design that require 
improvement and presents methodological developments in genetic mapping techniques 
which together provide a solid platform for future success.
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Chapter 1 Introduction
1.1 An introduction to the background and classification of epilepsy
1.1.1 What is an epileptic seizure? What is epilepsy?
An epileptic seizure is a transient experience commonly defined as the unprovoked, 
coordinated excessive firing of neurons in the brain. A seizure is an isolated event.
Epilepsy itself is a syndrome defined as a disorder of the brain characterised by an 
enduring predisposition to generate epileptic seizures [2]. In the context of epilepsy two or 
more constitute ‘enduring’, thus an individual who has experienced two or more epileptic 
seizures is diagnosed as having epilepsy
Epilepsy is the most common serious neurological condition and occurs worldwide, across 
all age groups. In Europe, the syndrome is observed with a prevalence of 3-8 cases per
1.000 individuals, and an incidence of 43-82 per 100,000 per year [3, 4]. It is estimated that
3.1 million people in Europe today suffer from active epilepsy. Rates of epilepsy are 
elevated in young children and the elderly resulting in a characteristic U-shaped age 
specific incidence curve [3]. Societal costs for epilepsy are considerable as severe cases 
make up a substantial proportion of the epilepsy population.
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1.1.2 Introduction to epilepsy classification
Aetiologically epilepsy is heterogeneous and therefore difficult to classify. The world’s 
preeminent association of epilepsy physicians, the International League Against Epilepsy 
(ILAE) has in its mandate the task of classifying the epilepsies. The ILAE based its most 
recent classification of epilepsies on two major divisions -  seizure localisation and 
aetiology [5]. At the most basal level, epilepsy was classified according to seizure 
localisation - the origin of electrical seizure activity in the brain. This can be determined 
using an electroencephalograph (EEG) - a device that monitors electrical brain activity 
through a series of electrodes placed on the scalp. Seizures that arise from large cortical 
areas in both hemispheres of the brain were termed “generalised”. On the other hand, 
seizures that arise from a specific cortical area were termed “focal” in nature.
1.1.3 Classifying epilepsy according to seizure localisation
Generalised and focal epilepsies present with different seizure characteristics. Generalised 
seizures produce synchronous, high amplitude generalised spike-wave discharges on 
EEGs. These originate in both hemispheres of the brain and result, typically, but not 
always, in a tonic-clonic' seizure that produces the whole-body convulsions from which the 
historical term for epilepsy, “falling sickness”, originated. Patients suffering from 
generalised epilepsies may also present with typical absence seizures (characterised by a 
momentary loss of contact with the surroundings), atypical absences (more prolonged
' Tonic-clonic are the most common generalised seizure. The patient loses consciousness, the body stiffens 
and the patient falls to the floor. The patient then suffers jerking movements. In all the seizure lasts around 
two minutes.
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absences accompanied by myoclonic activity), or myoclonic seizures (characterised by 
localised twitching). Thirty percent of patients suffer from generalised epilepsy.
Focal epilepsy (also termed localisation-related or partial epilepsy) arises from a specific 
cortical area (often the hippocampus) and produces a characteristic ‘inter-ictal’ spike 
pattern on EEG. Focal seizures involve a discrete part of the body (e.g. a sudden speech 
arrest, a memory issue, jerking of the head or of a limb) and consciousness might be either 
preserved or impaired (in contrast to absence seizures where consciousness is always 
impaired). Seventy percent of patients suffer from focal epilepsy.
A second seizure closely following a first (status epilipticus) is potentially life threatening. 
This occurs in approximately 3% of all epilepsy patients, independently of whether the 
patient usually suffers from generalised or focal seizures. Patients can experience a focal 
epileptic seizure followed almost immediately by a generalised seizure, but it does not 
typically occur the other way around.
1.1.4 Classifying epilepsy according to seizure aetiology
The second major categorisation distinguishes epilepsies according to the underlying 
cause of the seizures. Epilepsy resulting from a known disorder of the central nervous 
system is termed ‘symptomatic’ epilepsy (or secondary epilepsy). ‘Idiopathic’ epilepsy (or 
primary epilepsy) has no apparent underlying cause but tends to have a strong family 
history.
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Not all epilepsies can be classified as either ‘symptomatic’ or ‘idiopathic’. A third category, 
‘cryptogenic’ epilepsy, was created to account for epilepsies presumed to be symptomatic, 
but without known aetiology. This category of cryptogenic epilepsies suffers from 
imprecision in the definition as it accounts for essentially all epilepsies that cannot be 
classified either as symptomatic or idiopathic.
The division of epilepsies according to aetiology best reflects the presumed degree of 
genetic contribution to the different types. For example, the idiopathic epilepsies are 
thought to be largely or exclusively caused by genetic factors while the symptomatic 
epilepsies are thought to be mostly non-genetic in origin. The degree to which this 
presumption has been tested however, is limited.
As our knowledge of the biology of epilepsy develops, it has become increasingly apparent 
that the current ILAE classification scheme falls well short of representing the underlying 
pathophysiology of the condition. However the ILAE scheme is informative about prognosis 
and treatment and is therefore clinically relevant. For example, although we know little 
about the underlying biology or genetics of the ILAE syndrome ‘juvenile myoclonic 
epilepsy’, we do know that patients diagnosed with this syndrome tend to respond well to 
treatment with Sodium Valproate. Although far from ideal, the ILAE classification scheme 
remains for the most part the standard used in clinical practice. The ILAE task force is 
constantly working to address shortcomings in the classification scheme and publishes 
modifications as consensus is reached.
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1.2 Control and treatment of epilepsy
1.2.1 Epilepsy in the community
Morbidity and increased mortality rates aside, epilepsy can be a major burden on the daily 
lives of sufferers. Epilepsy itself can result in serious social disadvantage and exclusion, for 
example through educational underachievement, unemployment or an inability to drive. 
Ignorance of the condition within a community can lead to stigmatisation and 
discrimination.
Although treatments for epilepsy are available, access is dependent on the localised 
perception of the condition. In some Third World regions for example epilepsy is thought of 
as a ‘supernatural ailment’ rather than a physical condition and is treated by traditional 
healers. The condition can be exacerbated if sufferers are denied access to medical help. 
Indeed, due to a combination of social and economic reasons, it has been estimated that 
over three-quarters of the 40 million sufferers worldwide are not medically treated. It is 
clear that for epilepsy to be addressed as effectively as possible the challenge is not only in 
the development of novel treatments but also in overcoming the common misconceptions 
surrounding the condition. It is only when epilepsy is recognised in a community as a 
treatable brain disorder that patients gain access to targeted care.
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1.2.2 The history of epilepsy treatment
One of the forefathers of epilepsy treatment, Sir Edward Henry Sieveking, commented in 
his 1861 book that ‘there is scarcely a substance in the world capable of passing through 
the gullet of man that has not at one time or other enjoyed the reputation of being an 
antiepileptic’ [6]. Although our knowledge of antiepileptic compounds has developed since 
Sieveking’s comment we still have a lot to learn about the treatment of epilepsy. The 
following is a brief description of the history of epilepsy care and management.
Perhaps the first true drug used to treat epilepsy was bromide, which was recognised to 
have antiepileptic properties in 1857. It was widely used across Europe and the United 
States through the late nineteenth and early twentieth centuries. With the birth of modern 
pharmaceuticals two drugs were quickly produced and became the principal treatments for 
epilepsy up to the 1950s: phenobarbital and diphenyhydantoin (marketed as Phenytoin).
In the 1920s the development of EEG by Hans Berger represented a major advance in 
understanding the aetiology of epilepsy. This novel tool not only revealed the presence of 
electrical discharges in the brain but, critically, also showed that different seizure types 
resulted in distinct patterns of brain-related electrical activity. Better diagnosis improved 
treatment as it became apparent that certain seizure types responded better to certain 
drugs. For example phenobarbital was highly effective against generalised tonic-clonic 
seizures, whilst patients suffering from partial or secondarily generalised seizures (a focal 
seizure that expands during the seizure to become generalised) responded well to 
diphenylhydantoin.
21
The FDA in the United States tightened drug licensing laws during the 1960s in an effort to 
ensure that drugs were not only safe but also effective, inadvertently stagnating epilepsy 
drug development: since antiepileptic drugs had a comparatively small sales volume few 
pharmaceutical companies invested in epilepsy as a treatable condition. Between 1960 
and 1974 only one new drug, diazepam (Valium), became available in the fight to treat 
epilepsy. The situation improved little through the late 1970s, although carbamazapine 
(Tegretol) and valproic acid, both effective antiepileptic drugs, were granted licences.
A major breakthrough came in the 1990s when the National Institute of Neurological 
Disorders and Stroke in the US announced its antiepileptic drug development program.
This unique partnership between government, academia and industry has resulted in the 
appearance of a new crop of antiepileptic drugs.
Although antiepileptic drugs have immeasurably improved the lives of many epilepsy 
sufferers, around 30% of patients are resistant to all currently available medication. Clearly 
one of the principal goals of epilepsy research must be to greatly reduce, or negate 
altogether, the size of this group.
Resective surgery, the removal of the epileptogenic region of the brain, is one option for 
refractory patients. Viewed as a ‘last resort’ treatment, success rates are reasonable with 
30-50% of patients achieving seizure freedom, and 50-90% reporting significant 
improvement in their condition after surgery [7, 8]. However, only 2-5% of individuals with 
medically refractory epilepsy are suitable for surgery as a number of criteria have to be 
considered -  for example the prognosis is improved if the patient is young, there must be
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minimal risk to memory or speech and, critically, there must be concordance between the 
epileptic lesion (the structural lesion associated with the development of seizures, 
measured by imaging such MRI) and the epileptic zone (the region of seizure onset and 
propagation, measured by EEG).
An alternative to drug treatment and resective surgery is the ‘ketogenic diet’. This diet, 
developed in the 1920s yet still poorly understood, is high in fat and low in carbohydrate 
and appears to force the body to undergo ketosis (the conversion of fats to ketones). 
Ketones are then used as an energy source in place of glucose. Although the diet has 
proven effective in some cases (indeed some clinicians regard it as the single most 
effective treatment of epilepsy) and has recently enjoyed an increase in popularity, it is 
unpleasant for the patient and can result in serious complications [9].
Although some degree of seizure control is achievable for the majority of epilepsy sufferers 
receiving medical treatment, there is still much room for improvement. With current practice 
it often takes long periods of time to find controlling doses and/or drug combinations. 
Adverse reactions to antiepileptic drugs are commonplace, making drug regimes 
uncomfortable for the patient. As with many other diseases, drugs for epilepsy have been 
designed without great knowledge of the underlying biology involved, often by simply 
testing compounds on animal models of the condition. Such ‘traditional’ drug design tends 
to result in treatments with unpleasant side effects that are exacerbated when drugs are 
used in combination, as is frequently the case. It is not acceptable that a patient be 
required to weigh up the benefits of seizure control against the drawbacks of drug-related 
side effects. The hope is that genetics can play a crucial role in improving patient care by
not only helping guide clinicians in dosing but also in highlighting novel biological pathways 
which might in turn lead to targeted drug design.
1.3 A genetic component to epilepsy? Evidence from Mendelian, 
monogenic cases of epilepsy
1.3.1 Mendelian forms of epilepsy
That genetics plays a role in at least a subset of epilepsies is beyond doubt given the 
existence of numerous families who exhibit a Mendelian-like inheritance of the condition. 
As with other Mendelian diseases, the advent of genetic linkage mapping techniques led 
to the discovery of a number of genes and mutations causal in these familial forms of 
epilepsy. It was six years after the discovery of CFTR and cystic fibrosis in 1989 that 
Steinlen and colleagues reported the first gene that harboured mutations causing epilepsy 
[10,11]. Since then, 16 additional Mendelian epilepsy genes have been mapped and 
shown to harbour hundreds of different disease causing mutations (see Table 1.1 below).
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Table 1.1 Genes known to harbour mutations causing epilepsy
Gene name and class Syndrome Location Year References
Voltage gated ion channels
Na channel
SCN2A
SCN1B
SCN1A
BFNIS (MIM 607745), 
GEFS+ (MIM 604233) 
GEFS+ (MIM 604233) 
GEFS+ (MIM 604233), 
SMEI (607208) ICEGTC
2q23-q24.3
19q13.1
2q24
2001/(020
1998
2000/(01)
[12] [13, 14]
[15-17]
[17-29] for 
review see [30]
Ca channel
CACNA1A FHM(MIM 141500), SCA6 19q 2001 [31-33]
(MIM 183086), IGE (MIM
600669)
CACNA1H CAE (MIM 607682) 16p13.3 2003 [34]
K channel
KCNQ2 BFNC1 (MIM 125370), 20q13.3 1998 [35-40]
BFNC/myokymia (MIM
606437)
KCNQ3 BFNC2 (MIM 121201) 8q24 1998 [37, 41,42]
Cl channel
CLCN2 CAE (MIM 607682), EGMA 3q26 2003 [43]
(MIM 607628)
Ligand gated ion channels
ACh receptor
CHRNA4 ADNFLE1 (MIM 6000513) 20q13.2- 1995 [10]
q13.3
CHRNB2 ADENFL3 (MIM 605375) 1p21 2000 [44, 45]
GABAA receptor
GABRA1 JME (MIM 606904) 5q34 2002 [46]
GABRG2 GEFS+ (MIM 604233), CAE 5q34 2001 [47, 48] [49, 50]
(MIM 607681)
GABRD GEFS+ (MIM 604233) 1p36.3 2004 [51]
Non-ion channel
LGI1 ADPEAF (MIM 600512) 10q24 2002 [52-54]
EFHC1 JME (MIM 254770) 6p12-p11 2004 [55]
ATP1A2 BFIC(MIM601764) 19p13 2003 [56]
MASS1 Febrile and afebrile seizures 5q14 2002 [57]
BFNIS, benign familial neonatal and infantile seizures; GEFS+, generalised epilepsy with febrile seizures plus; SMEI, 
severe myoclonic epilepsy of infancy; SCA6, spinocerebellar ataxia 6; IGE, idiopathic generalized epilepsy; CAE, 
childhood absence epilepsy; EA, episodic ataxia; FHM, familial hemiplegic migraine; BFNC, benign familial neonatal 
convulsions; EGMA, epilepsy with grand mal upon awakening; ADPEAF, autosomal dominant partial epilepsy with 
auditory features. ICEGTC, Intractable childhood epilepsy with generalised tonic-clonic seizures; ADNFLE, autosomal 
dominant nocturnal frontal lobe epilepsy; JME, juvenile myoclonic epilepsy; BFIC, benign familial infantile convulsions
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The focus of this thesis is complex forms of epilepsy and so discussion of Mendelian forms 
will be limited to salient points of relevance, of which there are several. The Mendelian 
genes (detailed in Table 1.1), for the most part (13 of 17) fall in to the category of either 
voltage, or ligand gated ion channels, an observation that has led to the epilepsies being 
proposed as a group of channelopathies. The ongoing discovery of Mendelian genes has 
led to numerous studies on the function and role of these genes in an attempt to further 
uncover the biology of the condition. Indeed the pathways illuminated by the Mendelian 
genes overlapped with known targets for many of the commonly prescribed 
anticonvulsants. But these discoveries have also shed light on other important traits of 
epilepsy, namely genetic and phenotypic heterogeneity. For example, we know of five 
different genes that harbour mutations causing GEFS+ whilst to date mutations in SCN1A 
are known to cause three clinically distinct types of epilepsy. The genetic architecture 
underlying even the hypothetically simply Mendelian epilepsies appears complex; the task 
of deciphering the more common forms is clearly testing.
While these discoveries have undoubtedly provided important new insights in to the 
pathogenesis of epilepsy, it should be noted that Mendelian epilepsies account for only a 
small minority (1-2%) of all human epilepsies [4, 58] with the vast majority being complex, 
multifactorial disorders. However it is reasonable to hypothesise that the biological 
pathways uncovered by the Mendelian successes will also play a role in more complex 
forms of the disease. As such the Mendelian list detailed in Table 1.1 is a good starting 
point from which to embark on the study of complex epilepsy. Finally, it should also be 
noted that several of the apparently Mendelian epilepsies exhibit incomplete penetrance
and variable expressivity within families, suggesting involvement of other genetic and 
environmental factors.
1.3.2 Evidence from twin and familial aggregation studies
Evidence of a significant genetic contribution to more common forms of epilepsy has been 
uncovered from familial aggregation and twin studies.
Twin studies provide an invaluable source of information on the relative importance of the 
contributions of genetic and environmental factors in complex disease [59]. The twin design 
can disentangle and quantify the contribution of genetics, shared environment and 
individual-specific environment to observed variation in complex traits. Under the 
assumption that there are limited differences in the environments experienced by members 
of monozygotic and dizygotic twin pairs (they both share the same uterus and 
developmental environment), higher concordance among monozygotic pairs would indicate 
that genetic factors play an important role in the disease or trait under study. Concordance 
is typically calculated as: 2C/(2C+D), where C is the number of concordant pairs and D is 
the number of discordant pairs.
Three major twin studies have been carried out to date on epilepsy [60-62]. All three 
studies were carried out in cohorts of European Caucasian origin and reached similar 
conclusions. Firstly, the concordance rate for epilepsy was higher in monozygotic (56 -  
62%), compared to dizygotic (14 -  21%) twins. This result provides strong evidence for a 
significant genetic component to complex forms of epilepsy. Secondly, concordance rates
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were higher in generalised epilepsies (monozygotes 65 -  82%, dizygotes 12-27%) 
compared to focal epilepsies (monozygotes 9- 36%, dizygotes 5-10%). Focal epilepsies of 
a cryptogenic nature showed a higher genetic component than those of a symptomatic 
nature. Thirdly, up to 94% of concordant monozygotic twins and up to 71% of concordant 
dizygotic twins presented with the same epileptic syndrome, suggesting the influence of 
syndrome specific alleles. Intermediate values were seen for febrile seizures (monozygotic 
21-58%, dizygotic 14-40%). While these results certainly provide not only evidence for a 
genetic contribution to epilepsy, but also a guide as to which forms of epilepsy are more 
‘genetic’ than others, they must be qualified by the likelihood that clinicians will be biased 
when diagnosing siblings known to be twins.
The proportion of the risk associated with developing a disease that can be explained by 
genetic factors, termed ‘heritability’, is often used as a guide in the study of complex 
disease. Kjeldsen et al [62] reported that 80% (Cl = 70-88%) of the liability to both seizures 
and epilepsy was found to be heritable with the remaining 20% attributable to environment- 
specific factors. However, this result must be qualified by the fact that it was carried out on 
a relatively small sample (214 twin pairs with seizures and/or epilepsy). It should also be 
noted that these values were calculated using “standard biometric assumptions” which 
included no epistasis and no gene-environment interaction. This is likely to be an 
oversimplified model, and as such the result should be regarded at best as a rough guide.
Studies examining the pattern of inheritance of epilepsy are an additional resource for 
questioning the genetic component of complex forms of epilepsy. Bianchi et al reported a 
comprehensive analysis on the pattern of inheritance of epilepsy in a large cohort of 11,000
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epilepsy patients, which, when considering first degree relatives included over 50,000 
individuals. The authors found 9.1% of epilepsy patients had a family history (affected first 
degree relative) of epilepsy.
Idiopathic epilepsies had the highest frequency of family history (15.3%) when compared 
against focal epilepsies of a cryptogenic (6.5%) or symptomatic (6.2%) nature. The 
prevalence of family history, defined as the ratio between the number of relatives with 
epilepsy and the total number of first degree relatives, is a useful measure of inheritance. 
Bianchi et al reported prevalence of family history values of 2.6% for all epilepsy cases, 
5.3% for IGE, 1.3% for focal symptomatic andl .8% for focal cryptogenic. Consistent with 
twin study data, probands with IGE were highly concordant with respect to their relatives’ 
epilepsy types.
Estimating concordance within families is an effective approach in separating shared from 
specific genetic effects. The procedure involves identifying families with two or more 
affected individuals and assessing whether the number of families concordant for seizure 
type exceeds that expected by chance. Through the application of this methodology, 
Winawer and colleagues showed evidence for distinct genetic effects on absence and 
myoclonic seizures [63]. The same authors replicated these results in an independent 
cohort of Australian families [64].
Together the twin and familial concordance as well as the familial aggregation study results 
support the notion that genetics plays a significant role in the development of common 
forms of epilepsy. Significantly, the results consistently order the principal epilepsy types in
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terms of a genetic contribution as: idiopathic generalised, focal cryptogenic, focal 
symptomatic and finally other focal epilepsies of unknown aetiology. In addition, the studies 
were generally in agreement that febrile seizures" carried a significant genetic component 
that appeared to lie somewhere between that for idiopathic and for focal cryptogenic 
epilepsies. Finally, the familial concordance studies in particular illustrate a distinct genetic 
effect on seizure type.
However, informative as these studies are in characterizing a genetic component, they do 
not explain the underlying architecture of that same component. Is the architecture 
complex involving many interacting factors of moderate effect or rather simple with a 
limited number of strong effect loci? As shall be discussed later, these issues are crucial in 
the design of studies that seek to elucidate the genetics of complex disease.
" A fever accompanied by a seizure observed in the first three months to three years of life. A history of febrile 
seizures increases the chances of developing epilepsy in later life
1.4 Tools available for mapping complex traits -  A vailing of both 
linkage and association
1.4.1 The task in hand
The field of epilepsy genetics is, in parallel with other disease fields, undergoing a 
transition that could not be more pronounced. Over the past 20 years or so human 
geneticists have identified more than 1200 genes causing Mendelian diseases, just over 
one percent of which cause epilepsy. With few exceptions the identifications have been 
unambiguous and uncontroversial. On the other hand we know next to nothing about the 
genetics of common forms of disease, including epilepsy, which are influenced by multiple 
genes in a complicated interaction with the environment. In fact, there are only about 20 
different polymorphisms that are generally accepted as risk factors for any form of so- 
called “complex” disease, none of which influence epilepsy [65-68].
Common disease genetics is clearly a different sort of research enterprise, yet the 
community of human geneticists has been moulded by its successes in studying Mendelian 
diseases. It is not clear that the prevailing perspectives and expectations resulting from this 
experience are relevant and useful in the study of complex traits such as predisposition to 
developing, and response to treatment for, common forms of epilepsy.
What little we do know about the genetics of common diseases, and of responses to their 
treatment, is that derived variants at a given gene can lead to increased or decreased
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susceptibility, or result in good or bad responses to a given medicine (e.g. SCN1a and 
required dose of carbamazapine and phenytoin [69]). More fundamentally, it seems likely 
that there is a continuum of effect sizes for variants that influence common diseases, 
ranging from moderate effects such as that of ApoE4 for Alzheimer’s, to apparently more 
marginal effects such as that of PPARy and Calpain-10 on Type II diabetes (odds ratios 
estimated at 3.3,1.23, and 1.19 respectively) [70-72]. Looked at this way, it is hard to see 
where one would draw the line to declare a particular gene a “susceptibility” gene for the 
condition; ApoE4 is certainly a risk factor for Alzheimer’s, though interestingly there are 
suggestions that it is deleterious only in certain environments [73]. But there is no reason to 
believe there is a small set of polymorphisms with clear and strong effects, like apoE4, and 
that the remainder of the polymorphisms have no effect. Rather it would appear more likely 
that there is a full continuum of effect sizes (and degrees of environmental dependency), 
and that whether a gene registers as a “susceptibility” gene will depend on the power of 
detection. Considering current sample sizes and study designs, it would seem that few 
genes carry polymorphisms of sufficiently strong effect to be consistently identified as risk 
factors [74]. For larger sample sizes, or designs that consider appropriate environmental 
interactions, it is probable that a much more sizable minority of the genes in the genome 
will have polymorphisms in or near them that have some effect on risk in some 
environments [72]. Currently, there is no way to guess how large this proportion might be.
It seems premature to cast the search as one for a small number of susceptibility genes for 
each condition. It may be more appropriately considered not a search for “disease” genes, 
but rather an assessment of how polymorphisms in the human genome influence disease 
risk and drug responses in specific environments and genetic backgrounds.
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Around 10 million of the approximately 3 billion bases in our genome are polymorphic in 
typical human populations (where polymorphic is defined as having a minor allele 
frequency greater than 1% [75]). Rather than focusing on identifying the few disease 
polymorphisms out of these 10 million, the challenge is to understand how these 10 million 
polymorphisms collectively moderate disease risk, and how they influence response to 
treatment, in their appropriate genetic and environmental backgrounds.
A focus on even this large set of sites assumes that the most important genetic 
contributions are due to sites that carry classical polymorphisms (i.e. minor allele frequency 
greater than 1%). Clearly these polymorphic sites contribute primarily to genetic differences 
among people on average, but there is considerable debate about their importance relative 
to less common variation in the genetics of common disease predisposition [76].
When the problem is cast this way it is apparent that very large scale and high quality 
genetic association studies, with all their problems [72], are indispensable in the effort to 
understand the genetics of common diseases and variable drug reactions.
1.4.2 Linkage as a tool for mapping complex disease
The best approach to decipher complex genetic disorders remains the subject of debate 
and is a rapidly evolving area in the field of molecular genetics. The traditional and highly 
successful approach for mapping monogenic traits is linkage analysis. The method focuses 
on the level of co-segregation between a disease locus and a battery of genetic markers, 
usually microsatellites. The level of co-segregation is measured using a LOD score, a
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representation of the logarithm of the odds of the phenotype in question and a given 
genetic marker being linked, versus the odds they are unlinked. Parametric linkage 
analysis requires a precise genetic model, specifying the mode of inheritance, gene 
frequency and penetrance of the genotype under study. Such parameters are typically 
calculable for Mendelian diseases, a key factor in the dramatic success of parametric 
linkage in mapping these disorders. However for common forms of epilepsy and indeed for 
complex disease in general, knowledge of these parameters is typically the exception 
rather than the rule.
Non-parametric linkage analysis, being model free, is theoretically more amenable to the 
scenario presented by epilepsy. Here the focus is on alleles or chromosomal segments that 
are shared by affected relatives (e.g. sibling pairs) more often than expected. Easing 
parametric requirements is obviously advantageous, but the method has some important 
limitations. The statistical power of this approach is reduced compared to parametric 
linkage and defined candidate regions are usually large. Furthermore, the method assumes 
that the susceptibility factor is necessary and sufficient to cause disease, rarely the case in 
complex diseases.
An additional complicating factor that compromises both parametric and non-parametric 
linkage is that common forms of epilepsy are thought to be caused by the additive effect of 
numerous alleles at several interacting loci. Any individual variant in itself would typically be 
insufficient to cause the phenotype in the absence of specific variations at other genetic 
loci and/or additional environmental factors. Whilst linkage is robust against allelic 
heterogeneity, it suffers against locus heterogeneity. Considering that the genetic
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component to epilepsy is likely to be complex with variants interacting at multiple loci, it is 
paramount that any mapping method is powered to detect weak to modest effects at any 
given locus.
Finally, use of linkage analysis for common forms of epilepsy is limited by the availability of 
large multiplex families. Although such families are more readily available for idiopathic 
generalised forms of epilepsy, they are very rare for the more difficult to treat focal 
epilepsies. Linkage strategies are therefore not ideally suited to common epilepsy 
syndromes; either the optimization of current linkage techniques or the development of 
alternative strategies are required.
1.4.3 Linkage results to date
Given the availability of suitable families, idiopathic generalised epilepsy has been the 
focus of linkage studies in epilepsy to date (see Table 1.2 for summary). Several risk loci 
have been proposed including the EJM2 region on chromosome 15q [77], 8q24 [78] 3q26, 
14q23 and 2q36 [79]. However these peaks were not always reproducible in follow up 
studies [80-83]. The most robust linkage peak, termed EJM1, was proposed by Greenberg 
and colleagues in 1988 [84] to contain a risk factor for JME. This finding was successfully 
replicated in several studies [80, 85-87], although many also failed to detect this peak [88- 
91]. The recently proposed causative variant at this locus is discussed in Chapter 4 [1].
In summary, linkage studies have identified over 10 potential susceptibility loci for IGE, 
although few of these have stood up to replication. The genes responsible for the reliable
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peaks remain to be characterised. An obvious strategy to identify the underlying genes is 
fine-mapping of the linked interval by means of association analysis. This approach has 
proven successful for identification of the BRD2 gene in JME [1] and has now become 
significantly simplified thanks to the tagging approach.
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Table 1.2 Summary of published linkage studies in complex forms of epilepsy
Study name Year Type # families LOD Phenotype Location Note
Tauerr92] 2005 Genome wide 60 4.3"' PPR 6p21 PPR at 6p21
Nakayama[93] 2004 Genome wide 59 3.68 FS 18p11.2 Proposed IMPA2 gene as causal
Pinto[94] 2005 Genome wide 16 3.47/2.44 PPR 7q32,16p13
Pintor90] 2004 6p11/21 replication 18 3.17 JME 6p11 Partial replication of [95]
Sander[82] 2003 8p12 replication 176 Negative IGE No evidence Failed replication of [95]
Robinson[96] 2002 scattered 33 5-15.1 CAE 16q12,15q11 Tested candidate genes
Sander[83] 2002 18q21 replication 130 Negative IGE No evidence Failed replication of [951
Windemuth [81] 2002 5p14 replication 99 Negative IGE No evidence Failed replication of [95]
Bai[97] 2002 6p12-11 31 4.21 JME Refined peak Mexican
Durner[95] 2001 Genome wide 91 1.9-5.2 IGE 6p?, 8p?, 18q21 Propose oliqoqenic model
Obach[89] 2000 6 7 Negative JME No evidence Spanish. Failed replication of [84]
Sander[79] 2000 Genome wide 130 4.19/3.28 IGE 3g26, 14q23 German No subtype analysis
Greenberg[87] 2000 6 85 4.2 JME 6p? US replication of [84]
Nakayama[98] 2000 Genome wide 40 4.59 FS 5q14 Japanese pop.
Durner[99] 1999 8 88 3.24 aolGE 8pcentromeric US. aolGE-JME
Sander[100] 1999 15q14 57 Negative JME/CAE No evidence German. Replication of [77]
Sander[101] 1998 8q24 38 Negative IGE/JME No evidence German. Failed replication of [14]
Elmslie[77] 1997 Various local 34 4.4 IGE/JME 15q14 UK
Sander[801 1997 6p25 29 3.27 IGE/JME 6p21 Partial replication of [84]
Sander[102] 1997 15q11 -15q13 94 1.4 Mixed IGE JME 15q11-15q13 German
Liu[911 1996 Genome wide 22 4.4 JME 6p12-p11 Belize Failed replication of [84]
Sander[103l 1996 5q32-5q35 63 Negative IGE No evidence German
Elmslie[104l 1996 6p 19 Negative JME No evidence UK
Sander[105] 1995 6p21 44 1.92 Mixed IGE JME 6p21 German. Partial replication of [841
Zarar781 1995 Genome wide 10 10.61,v IGE 8q24 US, failed to replicate [84]
Whitehouse[881 1993 6p 25 Negative JME No evidence UK, failed rep of [84]
Durner [851 1991 6p 21 4.1 JME 6p21 Refined EJM1 peak
Weissbecker[861 1991 HLA reqion 23 3.1 JME 6p21 Replicated[84]
Greenberg[841 1988 HLA region 68 3.11 JME 6p21 First report of EJM1 peak
PPR=Photoparoxysmal response, FS=febrile seizures, JME=juvenile myoclonic epilepsy, CAE=childhood absence epilepsy, IGE=ldiopathic generalised epilepsy, aolGE=adolescent onset IGE
nonparametric MOD linkage score. In a MOD score analysis, the LOD score is maximized not only over the genetic position of the disease locus, but 
also with respect to the penetrances of the disease gene genotypes and the disease allele frequency.
Iv This figure represents the chi2 value (p=0.0006) from an extended sib pair analysis in the 10 families studied
u>
1.4.4 Association as a tool for mapping complex disease
An alternative to linkage is the association study design. Association studies compare the 
frequency of specific alleles, hypothesised to be disease causing, in affected cases and 
unaffected controls. An allele is claimed to be ‘associated’ with the disease if its frequency 
differs between cases and controls by a margin greater than would be predicted by chance. 
Association studies assess allele frequencies in populations whilst linkage studies track the 
co-inheritance or otherwise of marker and disease alleles within families.
Association studies have several advantageous traits and has been viewed as strong 
where linkage is weak (note that the reverse is also the case). As association is population 
based, large multiplex families, rarely seen in most common forms of epilepsy, are not 
required and so sample collection is less restricted. Power of detection in association is 
directly related to the size of the populations under study. Generally speaking it is easier to 
identify and collect unrelated individuals for use in association studies rather than the deep 
multiplex pedigrees required for linkage. Cases and controls can be selected to match for 
environmental factors, such as age or lifestyle, which may also be important in the disease. 
The candidate region surrounding an associated variant is likely to be significantly smaller 
than a candidate gene region identified by linkage, as linkage looks at a few generations 
only, while association studies are based on historic recombination [106]. Finally, in an 
often cited paper, Rish and Merikangas argued association studies are likely to be more 
powerful than linkage for detection of weak susceptibility alleles [107]. They showed that
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for modest effect sizes affected sibling pair analyses, for example, would require 
unrealistically large sample sizes.
On the other hand association has some distinct disadvantages when compared to linkage. 
Population stratification can be a confounding factor in association studies. Stratification 
occurs when multiple genetically distinct subgroups exist in different proportions in cases 
and controls. The case and control populations are thus genetically mismatched. Similar to 
any other confounder, stratification may cause spurious associations (type-1 error) or may 
mask real associations (type-2 error). The problem increases with population sample size 
in that slight stratification can become statistically significant (thus driving a spurious 
association), a concern for the many large scale association studies currently under way. 
Various methods have been developed to correct for stratification although conservative 
correction results in reduced power of detection [108-111].
An alternative to having to correct for stratification within a population is to use non­
transmitted parental alleles as controls, which by definition cannot be stratified. The 
haplotype relative risk method [112] and transmission disequilibrium test (TDT) [113] are 
the commonly used examples of family based association that circumvent the stratification 
issue. Although these methods are valid and reliable, they have some practical drawbacks. 
Parents of affected individuals must be available, which may be a problem and as only 
heterozygous parents can be included for the TDT, some genotype information becomes 
redundant, resulting in a loss of statistical power to detect genuine allelic association.
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The association study design performs poorly in detecting rare disease causing alleles - a 
problem that is exacerbated when the causal variant is of modest or weak effect or under 
conditions of locus or allelic heterogeneity. Whilst, as mentioned previously, linkage is 
somewhat more robust to allelic heterogeneity, both approaches suffer in the face of locus 
heterogeneity.
Although all these potentially confounding issues must be considered in the design of any 
association study, the most problematic confounder is type-one error due to multiple 
testing. If multiple independent tests are assessed within the same experiment, a 
researcher is required to correct for the total number of tests undertaken. The temptation is 
for a researcher to test multiple hypotheses without correction but report only those tests 
that proved ‘significant’. Unfortunately this practice has led to a flood of false positive 
reports in the literature, an issue that has severely hindered progress not only the field of 
epilepsy genetics, but also in almost every other complex disease area.
The simplest and most conservative approach to correction for multiple testing is the 
Bonferroni method: P=<a/n where P is the experiment wide significance threshold, or is the 
significance value for each comparison (typically 0.05) and n equals the total number of 
tests undertaken in the experiment.
The conservative nature of the Bonferroni correction is such that the incidence of type-2 
error can increase, in particular when a large number of tests are undertaken. Furthermore, 
Bonferroni assumes that tests are independent of each other and does not factor in the 
relationship between genetic variants being tested (i.e. levels of linkage disequilibrium).
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Permutation testing considers the relationship between variants within a test (useful for 
haplotype analysis within a gene) but still does not address the problem of haplotype 
testing across a panel of genes that are essentially independent (i.e. there is little or no LD 
between the genes). The best method for correction is currently a matter of debate, but it is 
unlikely that any single statistical model can account for the variability in LD across the 
genome [106].
1.4.5 Association results in epilepsy to date
A summary of all association studies published to date for common forms of epilepsy is 
shown in Addendum Table 8.1. It is striking that although over sixty studies have been 
published, none have been clearly replicated. For example, take studies examining 111-b, a 
proinflamatory cytokine hypothesised to play a role in the development of febrile seizures7. 
Kanemoto et al [114] first reported an association with hippocampal sclerosis. Virta et al 
[115] then reported supportive evidence, but in patients with a history of febrile seizures 
rather than hippocampal sclerosis. A number of follow up studies failed to replicate either 
the original association with hippocampal sclerosis, nor that with febrile seizures although 
one report showed association with refractory partial epilepsy (a loosely related phenotype) 
[116-120]. The example of 111b also illustrates several other weaknesses that are relevant 
to other association studies listed in the table. Firstly, studies are all small in size 
(maximum 112 cases) which effectively restricted power of detection to only strong effects. 
Secondly, only one variant was considered despite the fact that numerous others (of
v See section 3.1.2 for discussion of the hypothesised link between febrile seizures and hippocampal 
sclerosis
41
functional and unknown significance) were known. Finally, the phenotypes used were often 
poorly defined (refractory partial epilepsy is a very loose diagnosis).
The consequence of this poor application of the association study design is that despite the 
large number of publications, the method has contributed little if anything to our 
understanding of epilepsy genetics.
Clearly neither the linkage nor association approach is ideally suited to the situation 
presented by common syndromes of epilepsy. The challenge presented to the field is to 
refine both methods bearing in mind what we understand of complex disease genetic 
architecture. In this way our knowledge of epilepsy genetics will expand. This thesis 
focuses on developing and applying association based methodology for use in epilepsy 
genetic studies.
1.5 The evolution of map based association
1.5.1 Sequence versus map based association
Traditionally association based approaches in complex disease genetics (and in particular 
in epilepsy) have focused on one or a small number of putatively functional variants, 
located in the coding or promoter region of a gene. Whilst this approach is perfectly valid in 
the micro sense of those variants being tested, very little if anything is learnt about other 
variants in the gene that may be contributing to the phenotype in question. With this in 
mind, the method has evolved along two basic routes: termed sequence based and map 
based.
42
Botstein and Risch [66] have recently argued for a sequence based approach which 
focuses on the identification of all variants in and near exons, and in core promoter regions 
of genes. They argue that the experience of Mendelian disease dictates these regions to 
be most important in terms of disease causing variation. All identified variants in these 
putatively functional genomic regions would then be genotyped in individuals of known 
phenotype, and correlations assessed in a case-control or related design.
The map based approach on the other hand, refrains from making any assumptions about 
the precise genomic location of causal variants. Instead, the aim is to identify a set of 
markers sufficient to represent all other variation in the gene region of interest.
Both approaches have strengths and weaknesses. The principal advantages of the map 
based approach are economy and the fact that it does not require strong assumptions 
about where the important variants lie. The principal weaknesses of the map based 
approach are reduced power of association for any one variant examined and difficulty in 
accurately representing variants with low minor allele frequency. For these reasons, both 
approaches could be viewed as more complementary than competing. What follows is a 
description of the development of map based approaches.
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1.5.2 LD mapping
Linkage disequilibrium gene mapping was first used successfully to fine localize Mendelian 
mutations within genomic regions implicated through linkage analyses, as for example in 
the cloning of the gene responsible for cystic fibrosis [11].
Two factors greatly increased interest in the application of LD mapping to common 
diseases. One was the previously mentioned demonstration of Risch and Merikangas [107] 
of the greater power of association mapping over linkage studies. The other was the rapidly 
developing understanding of the relationship between polymorphic markers spanning the 
human genome.
The potential application of LD mapping for common disease generated intense interest in 
deciphering actual patterns of LD in human populations. Until 2001 this work was 
predicated in many ways on expectations of gradual, though noisy, decay of LD with 
physical distance in the genome. It has long been appreciated that certain genes, such as 
the beta globin gene cluster [121,122] harboured hotspots of recombination -  regions of 
intense homologous recombination -  and also that LD decay was often poorly correlated 
with distance, either because of uneven recombination in some regions or because of the 
stochastic effects.
Nevertheless, many empirical studies looked at the average decay in LD with distance over 
different genomic regions, effectively ignoring the precise pattern of decay within a given 
region. In addition, models used to generate expectation of the pattern of LD assumed
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uniform recombination. In his influential report Leonid Kruglyak established a sort of null 
model for the expected extent of LD by assuming an idealized human demographic history 
and assuming homogeneous recombination rates [123]. Under these assumptions 
Kruglyak [123] showed that usable levels of LD (at that time set at d2>0.1, which 
corresponds to a ^<0.2, see below) would not extend further than about 3 kb in the human 
genome, implying that a genome wide map would require more than 1 million markers.
This conclusion was at odds however with empirical descriptions of LD, for example Reich 
et al [124], looking at multiple genomic regions, published conclusive evidence of much 
higher levels of LD extending over relatively long sequence tracts. The reasons for the 
discrepancy between early modelling and empirical patterns depend on both the ways in 
which human demographics differ from the models assumptions, and also the fact that 
recombination in the human genome is not uniform. The relative importance of these two 
factors in shaping patterns of human LD remains unclear.
The tendency to view LD decay with distance as gradual (although noisy) was dramatically 
changed by a set of papers published in the October 2001 issue of Nature Genetics. The 
challenge to the “gradual-decay” view had two components. Analysing 103 common SNPs 
(MAF>5%) across 500kb of chromosome 5q31, Daly et al [125] argued that the pattern 
was better viewed as discrete, with stretches of sequence showing little or no LD 
breakdown interspersed by regions of sharper LD breakdown. The stretches of limited 
haplotype diversity were called blocks, and within them up to 95% of the observed 
chromosomes were accounted for by 3 or 4 haplotypes [125]. Similar patterns were 
reported by Johnson et al, who observed a similar block-like pattern of LD among 122
SNPs across 135kb of 9 genes in European populations. Haplotype diversity within blocks 
was low with a maximum of 6 common haplotypes (frequency >5%) observed within any 
one block [126].
These publications led directly to the idea that blocks of LD, within which haplotype 
diversity is limited, is a prevailing characteristic of the genome. This is turn led to the 
concept that a set of SNPs could represent, or tag, each of the common haplotypes in a 
given region. These SNPs were first referred to as haplotype tagging SNPs (htSNPs). In an 
accompanying supplement to the Johnson et al study, David Clayton introduced an 
approach for selecting htSNPs that focused on the proportion of the haplotype diversity that 
could be explained by a set of tags [126].
1.5.3 The application of HapMap
The realisation that the tagging concept was indeed valid and applicable led to the 
development of the HapMap project. This multi-centre collaborative effort, funded by the 
NIH, was officially started in October 2002 with the aim of cataloguing human variation 
across global populations of European, Asian and African origin. Within three years the 
consortium managed to identify and genotype over four million SNPs (>1SNP per KB) in a 
total of 270 individuals representing the three populations. The completion of the HapMap 
project offers the opportunity to freely tag any gene or region across the genome in 
minutes, a task that was previously not only costly but also time consuming.
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The HapMap is by no means perfect. The project set out to represent common variation 
across the genome, a goal it has achieved in spectacular fashion. However, this has 
resulted in a heavy bias in SNP ascertainment towards common variation. If indeed much 
of the genetic component to complex traits is explained by the interaction of rare variants, 
the utility of HapMap will be severely limited. Similarly, it is not known how well other kinds 
of variants (for example, repetitive elements or insertions and deletions) might be 
represented by SNP tags. Another complexity not yet adequately addressed concerns how 
well the four population groups studied in the HapMap project represent variation in other 
human populations. Nonetheless, the availability of a near complete catalogue of human 
genetic differences among populations will be invaluable in addressing one of the key 
questions facing human geneticists today -  what role does common variation play in the 
development and treatment of common disease.
1.6 Conclusions and aims of this thesis
1.6.1 Conclusions
It is apparent that in many ways the field of epilepsy genetics is at a similar stage to other 
disease fields with the success of Mendelian work contrasting against the difficulties 
experienced in mapping more complex questions. A genetic component has clearly been 
illustrated by twin and family studies but deciphering this component is obviously more 
difficult than originally hoped. This difficulty is further complicated by the heterogeneity of 
epilepsy -  obvious at the phenotypic level and extremely likely at the genotypic (already 
partially illustrated through Mendelian experience). In addition, epilepsy suffers a distinct
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lack of intermediate phenotypes7' so abundantly available in for example cardiovascular or 
cancer related traits. The task ahead is clearly difficult. Pharmacogentic questions however 
tend to be much more straightforward in terms of biology and phenotype. Pathways of 
action and metabolism are known for the vast majority of epilepsy drugs. Intermediate 
phenotypes, for example drug plasma levels, are readily available.
Recent progress in both genetic mapping techniques and genotyping technology hold huge 
promise for epilepsy genetics. The challenge is to learn from past experiences and apply 
this knowledge to future project design.
1.6.2 Aims of this thesis
At the initiation of this thesis work in September 2003, the field of medical genetics was still 
high on the wave generated by Mendelian mapping successes. Epilepsy research groups 
seeking to translate this success to more common forms of the condition published 
numerous reports of association with hypothesised risk variation. At the same time, 
population geneticists were, through the illumination of LD patterning, developing novel 
methods of disease mapping. It was thus both an exciting and challenging time to begin 
this work. Exciting in that huge leaps were being made in mapping methods yet also 
challenging in how to interpret the published reports of association and apply the new 
mapping methods.
Vl In intermediate phenotype is one closely related to the gene (i.e protein level) as opposed to an end-point 
phenotype (e.g. the disease).
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In the first experimental chapter of this thesis seven previous reports of association 
between genetic variation and common forms of focal epilepsy are examined. The goal 
here was to solidify our knowledge of epilepsy genetics by critically examining for 
robustness, positive reports in the literature.
The second experimental chapter extends the theme of replication from focal to 
generalised epilepsy. This chapter examines the previously reported effect of variation in 
BRD2 on the development of juvenile myoclonic epilepsy [1]. Again the goal here was to 
critically assess this reported association with a view to making a statement on the 
robustness of the association.
In the third experimental chapter, focus shifts from predisposition to treatment. Here an 
assessment is made of the potential use of genetic variation in guiding the prescribing of 
an effective antiepileptic drug whose use is severely limited by a serious adverse drug 
reaction. In this chapter focus also shifts from sequence, to map based methods of 
association. Data from the HapMap project is used to select tagging SNPs for a panel of 
candidate genes.
Finally, in the fourth experimental chapter, a study design is presented that attempts to 
address many of the difficulties illustrated and discussed in the first three experimental 
chapters. This study design represents the first truly large scale study of epilepsy genetics 
both in terms of the number of genes and variants considered and the size of the study 
population.
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Chapter 2 Methods
2.1 Sample collection and storage
2.1.1 Patient recruitment
Patients were recruited from two independent epilepsy referral centers: the National 
Hospital for Neurology and Neurosurgery, Queen’s Square, London, United Kingdom 
(incorporating the National Society for Epilepsy at Chalfont, London) and the epilepsy clinic 
at Beaumont Hospital, Dublin, Ireland.
All patients with a diagnosis of a common, non-Mendelian form of epilepsy were eligible for 
inclusion in the study. Patients were provided with information on the project and those 
interested provided a blood sample for DNA extraction after signing the informed consent 
form.
The study protocol was approved by Joint Research Ethics Committee of the National 
Hospital for Neurology and Neurosurgery and Institute of Neurology (JREC 00/N081 and 
01/N088) and by the ethics panels of University College London and Dublin. As patient 
recruitment is ongoing, the number of DNA samples is continuously increasing. As of 
December 2005, the collection had passed 1800 samples. 90% of samples collected are of 
North Western European origin, the remaining 10% are from a variety of non-European 
ethnic groups.
50
During the course of the study, a patient panel of North Western European origin on which 
clinical data had been entered into a phenotype database at that time was assembled. The 
total number of samples in this panel was 673.
2.1.2 Patient phenotyping and databasing
Clinical details of participating patients were stored in two separate databases, stored at 
the Institute for Neurology, Queen’s Square, London, and at Beaumont Hospital, Dublin. 
These databases cover in detail a wide variety of clinical phenotypes including sydromic 
diagnosis (according to ILAE classification), seizure diagnosis, seizure frequency and 
antiepileptic drug history.
2.1.3 Control cohort
Controls for this study were assembled from the National Twin Research Unit at Guy’s and 
St Thomas’ Hospitals, London, United Kingdom. To be considered for the control cohort, 
individuals must have been of British ancestry and unrelated to any other member in the 
selected cohort. Only one member of each sibship was included.
The use of these samples as controls is covered by ethics approval held at the Twin 
Research Unit, Guy’s and St Thomas’ Hospitals, London, United Kingdom.
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2.1.4 DNA extraction from whole blood
DNA extraction from whole blood was carried using an Autogen extractor (AutoGenPrep® 
NA-2000).
Step 1: Obtain nuclei pellet:
Each blood sample (20ml) was split in to 2x50ml Falcon tubes (i.e. 10ml in each tube). To 
these tubes was added 30ml of a red blood cell lysis solution7". The samples were inverted 
several times and left at room temperature for 5 minutes. In order to obtain a nuclei pellet, 
the samples were then spun at 2,000 x g for 20 minutes. The supernatant was discarded. 
Step 2: Wash nuclei pellet:
The pellet was washed with 10ml PBSV" and centrifuged again at 2,000 x g for 10 minutes. 
The supernatant was discarded and the pellet resuspended in 5ml PBSvii. The samples 
were again spun at 2,000 x g for 10 minutes and the supernatant discarded.
Step 3: Digest/lyse pellet:
To digest protein and lyse the white blood cell nuclei 100ul (100ug/ml) proteinase K 
(Sigma-Aldrich P2308) and 1ml 10% SDS was added to each sample. The samples were 
then incubated overnight at 559C.
Step 4: Precipitate DNA:
On completion of digestion the samples were transferred to the Autogen machine which 
performed an automated phenol/choloroform extraction.
VN See Addenda for details of solutions
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Step 5: Wash DNA
The autogen 2000 uses 70% ethanol to wash the DNA pellet resulting from the 
phenol/choloroform extraction.
Step 6: Resuspend DNA
Extracted samples were resuspended in 500ul of TBE (Sigma-Alrich 93306) and stored at - 
70SC.
2.1.5 DNA quantitation and standardisation
Traditionally DNA is quantified by measuring absorbance at 260nm using a 
spectrophotometer. Although this method is highly accurate, it is not particularly sensitive 
and requires relatively large amounts of DNA for a read. Instead we availed of the 
Picogreen® method. Briefly, picogreen® is a fluorescent dye that undergoes a dramatic 
fluorescence enhancement upon binding with DNA. This fluorescence can be measure 
using a microplate fluorometer. The principal advantages of the picogreen® method are 
increased sensitivity (10,000 times more sensitive than ultra violet absorbance methods), 
the linear nature of the fluorescence over three orders of magnitude and robustness to 
protein contamination.
The “Quant-iT™ PicoGreen® dsDNA Assay Kit” from Molecular Probes (part # P7589) 
was used for DNA quantitation. Manufacturer’s instructions were followed.
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To 19.9ml TEviii solution was added 100 |jl of Picogreen®. A standard curve was set up as 
follows. To 45 pi of the TE/Picogreen® solution was added 5 pi of standard concentration 
DNA (100 pg/ pi, delivered with Quant-iT™ PicoGreen® kit). A standard curve was 
constructed by filling the first five wells of a 96 well plate with the following volumes of the 
TE/Picogreen mix (solution A in Table 2.1) and the TE/Picogreen/DNA mix (solution B in 
Table 2.1).
Table 2.1 Dilution factors for picogreen quantitation
Position Solution A (ul) Solution B (ul) Concentration (ng/ul)
A1 76 24 2.4
B1 88 12 1.2
C1 94 6 0.6
D1 97 3 0.3
E1 98.5 1.5 0.15
The remaining 91 wells on the plate were filled with 99ul of solution A. To each well was 
added 1 ul of DNA of unknown concentration. Each well was thoroughly mixed and allowed 
to stand for 5 minutes. The fluorescence of each well was measure using a fluorometer 
(FluoroCount™, Packard) and the concentration of each unknown sample calculated from 
the standard curve.
Once the concentration of each sample was known, it was possible to create 96 well 
“working” plates at a standardised concentration much lower than that of the stock tubes. In 
general we aimed to standardise working plates at a concentration of 10ng/ul.
VUI See Addenda for details of solutions
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2.2 DNA sequencing
2.2.1 PCR amplification
Amplification of genomic DNA by PCR was performed using Applied Biosystems 9700 
thermal cyclers. The standard reaction protocol is detailed below. Any changes from this 
protocol are detailed in the relevant chapters.
Standard PCR reaction mixture:
10ng DNA, 2.5 mM MgCI2) 0.5 uM of each primer, 0.2mM of each dNTP, 1.6ul 10X Qiagen 
PCR buffer and 0.25 units of Qiagen HotStartTaq polymerase. The mixture is made up to 
10pl using H20.
Standard PCR cycling conditions:
Initial denaturation at 95QC for 15minutes.
35 cycles of:
Denaturation at 94QC for 30 seconds,
Primer annealing at 60QC for 30 seconds,
Primer extension at 72QC for 30 seconds,
Final extension at 72QC for 10 minutes
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A negative control (H20  instead of DNA) was included in all experiments.
2.2.2 Agarose gel electrophoresis
Before proceeding to the PCR cleanup and sequencing stages, the outcome of the PCR 
reaction was determined by running products on agarose gels. One pi Orange G® loading 
buffer (Trevigen) was added to 2 pi of each PCR product. DNA fragments were loaded on 
a 1% agarose gel containing 2.5 pg/25 pi ethidium bromide. A 100bp Hyperladder® 
(Midwest Scientific) size marker was added alongside the samples to allow identification of 
DNA fragments size. The gels were cast in 1x TBE buffer and run at a constant voltage of 
100V. Gels were viewed over an UV light box.
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2.2.3 PCR clean up for sequencing reaction
In order to remove single stranded DNA (primers) and unincorporated dinulceotides from 
each reacted PCR making them suitable for a sequencing reaction, the following protocol 
was applied.
An equal volume of MicroClean® (Microzone Ltd.) was added to each cycled PCR 
reaction. The sample was left at room temperature for 15 minutes then spun at 3750 RPM 
for 60 minutes. The supernatant was discarded. 150pl of ethanol was added to each 
sample and the plate spun at 3750 RPM for 10 minutes and the supernatant discarded. 
The samples were allowed to air dry for 30 minutes and room temperature. Once drying 
was complete, 5pl of water was added to each well.
2.2.4 Sequencing Reaction
Sequencing was performed using the dye terminator cycle sequencing technology as 
incorporated in the Applied Biosystems BigDye™ reaction. Cycle sequencing utilizes 
successive rounds of denaturation, annealing and extension in a thermocycler to create a 
linear amplification of extension products. With dye terminator labelling, each of the four 
dideoxy terminators is tagged with a different fluorescent dye. The growing chain is 
simultaneously terminated and labelled with the dideoxy terminator dye that corresponds to 
the terminal base. All reactions are carried out in the same tube, all four colours are
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assessed within the same capillary and false stops go undetected because no dye is 
attached. The ABI Prism Terminator Reaction Kit® contains the following reagents: 
didexoynucleotide terminators, each based type labelled with different fluorescent dyes, 
deoxynucleotides, AmpliTaq DNA polymerase FS (with thermally stable pyrophosphatase), 
MgCI2 and Tris-HCI buffer.
Standard sequencing reaction mix:
1 pi cleaned PCR product, 1 pi Ready Reaction mix, 2 pi 5x buffer, 3.2 pM primer. The mix 
was made up to a volume of 10pl with distilled H20.
Standard sequencing cycling conditions:
Initial denaturation at 96SC for 10 seconds 
25 cycles of:
Primer annealing at 50QC for 5 seconds 
Primer extension at 60QC for 4 minutes
2.2.5 Sequencing reaction clean up
40pl of 75% ethanol was added to each sequencing reaction. The sample was mixed 
thoroughly and left at room temperature for 15 minutes. The plate was then centrifuged at 
3750 RPM for 60 minutes and the supernatant discarded. Each pellet was then washed
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with 150pl of 70% ethanol. The pellets were then allowed to air dry for 30 minutes at room 
temperature.
10pl of hi-dye formamide was added to each cleaned sequence reaction before loading on 
either an ABI Prism® 3100 or 3700 automated capillary electrophoresis DNA sequencer. 
The output traces were analyzed using the Sequencher® software.
2.3 Genotyping by TaqMan
Whilst genotyping by sequencing is reliable and accurate, it is labor intensive and costly, in 
particular when multiple SNPs are being genotyped in large cohorts. ABI TaqMan 
technology is an alternative to sequencing and a big improvement in terms of cost and 
labour. TaqMan is a PCR based system on quenching one of two allele specific fluorescent 
dyes (FAM and VIC). A TaqMan assays contains locus specific primers used to target a 
typical PCR reaction to the region containing the polymorphism of interest. However, the 
assay also contains two allele specific probes, each composed of a short stretch (ca. 20-25 
bases) of oligonucleotides labelled with a specific fluorescent dye (FAM for one allele, VIC 
for the other). On the 51 terminus of each probe is a reporter dye and on the 3' terminus is a 
quenching dye. When the probe is intact, energy transfer occurs between the two dyes and 
emission from the reporter is quenched by the quencher. During the extension phase of 
PCR, the probe is cleaved by 51 nuclease activity of Taq polymerase thereby releasing the 
reporter from the oligonucleotide-quencher and producing an increase in reporter emission 
intensity. Fluorescence is detected using a CCD camera. If only one allele is present (i.e.
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the individual is homozygous for the SNP in question) then only that allele specific probe 
fluoresces. If on the other hand the individual is heterozygous (i.e. a copy of each allele 
present) both probes will fluoresce. Fluorescence can be plotted in two dimensions, each 
axis representing a fluorescent dye (or allele). Measurement takes place directly in the well 
without post-PCR processing. This reduces the time of analyses, minimizes the risk of 
error, reduces the risk of cross-contamination and eliminates the labor and supply costs of 
post-PCR steps. Taqman assays were ordered directly from Applied Biosystems as either 
‘Assay-on-Demand’ or ‘Assay-by-Design’ assays depending on availability. All genotyping 
runs were checked for Hardy-Weinberg equilibrium (the author notes that violation of 
Hardy-Weinberg can sometimes be observed in cases). What follows is a description of the 
standard TaqMan sequencing protocol used for the work described in this thesis.
Standard TaqMan reaction mix:
1 pi (10ng) DNA, 0.125 pi TaqMan assay, 2.5 pi 2X TaqMan Universal Master Mix. The mix 
was made up to a volume of 5pl with distilled H20.
Standard cycling conditions:
Initial denaturation at 95QC for 10 seconds 
60 cycles of:
Denaturation at 92QC for 15 seconds 
Primer extension at 609C for 1 minute
The assays were run on an ABI Prism® 7900HT machine and scored with SDS sequence 
Detection System) software.
2.4 Genotyping by digestion using restriction enzymes
The restriction digest method was used to generate genotype data for rs1044396 a SNP 
discussed in section 3.2.7. The protocol is described below.
The following primers were used in conjunction with the standard PCR protocol described 
in section 2.2.1 to amplify the region containing rs1044396.
F 5’-3’ CCTGGCCTCTCGCAACAC
R’ 5’-3’ TTGGTGCTGCGGGTCTTG
The resulting PCR product was digested with Hha1 according to manufacturers directions 
(New England Biolabs, product number R0139S). Digested PCR products were analyzed 
on a 2% agarose gel by running at 100 volts for 45 minutes along size a 100bp size 
standard. Gels were scored on a UV light box. Genotype was scored according to product 
size (enzyme cuts with ‘C’ allele, does not with T ). Suspected heterozygotes of the PCR 
products were sequenced, for avoiding partial digestion mistaken for a heterozygote.
2.5 Genotyping of a variable number tandem repeat
The 68bp variable number tandem repeat in the promoter of the PDYN gene is discussed 
in section 3.2.3. The protocol used to genotype this locus is described below.
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10ng DNA was added to a PCR reaction mix consisting of 20 mM Tris-HCI (pH 8.8), 50 mM 
KCI, 1.5 mM MgCI2, deoxynucleotide triphosphates each at 0.4 mM, 50 pmol of each
i
primer (sequence described below), and 1.5 U of Taq polymerase. The total reaction 
volume was 30 pi.
Cycling conditions were as follows:
Initial denaturation at 94°C for 10 minutes,
30 cycles of
Denaturation at 94°C for 30 seconds,
Annealing at 62°C for 30 seconds 
Extension at 72°C for 45 seconds
Final extension at 72°C for 10 minutes
F 5'-3’ AGCAATCAGAGGTTGAAGTTGGCAGC 
R’ 5’-3’ GCACCAGGCGGTTAGGTAGAGTTGTC
The amplification products were resolved by running (alongside a 100bp size standard) for 
45 minutes at 100 volts on a 2.5% agarose gel stained with ethidium bromide. Products 
were scored by viewing under a light box. Four common alleles, representing one (386bp), 
two (454bp), three (522bp) or four (590bp) copies of the variable number tandem repeat 
exist in the general population. To allow comparison with previous studies we grouped
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alleles as low expression “L” (i.e., those with 1 or 2 repeats) and high expression “H” (i.e., 
those with 3 or 4 repeats).
2.6 Screening for variation across BRD2 promoter and UTR regions
The following primers pairs were reacted using standard protocol (described in section 
2.2.1) to produce template for sequencing. To increase the sensitivity of SNP discovery, 
forward and reverse primers were reacted using the standard sequencing protocol 
(described in section 2.2.4). The label of each primer pair corresponds to that used in 
figure 4.1)
Promo S1 F 5’-3’ TGCTACTAATGTAGGTATGGGTTCC 
Promo S1 R’ 5’-3’ AGAATAGAGGCCAGAATGTACCC 
Promo S2 F 5’-3’ AGGAACCTTTATGCTGTTTTCC 
Promo S2 R’ 5’-3’ CACAAATGGGATTACATCAAGC 
UTR1 F 5’-3’ CCAT GCT G AACTCGTAT GG A 
UTR1 R’ 5’-3’ TTGGTTAAGCACTTGACTGACA 
UTR2 S1 F’ 5’-3’ GGGCATGGGAACGTTAGAT 
UTR2 S1 R’ 5’-3’ AATTGGCTGAGCTGTGGTC 
UTR2 S2 F 5’-3’ CTTCCGCACCTCTTCCAAC 
UTR2 S2 R’ 5’-3’ CAGAATCCTCCAGCTCGTTC 
UTR3 F 5’-3’ CTTCCGCACCTCTTCCAAC 
UTR3 R’ 5’-3’ GATCTCAGACACCGTCGTCA
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2.7 Quantitative mRNA work
Quantitative mRNA analysis was carried out as part of BRD2 work described in section 
4.2.7.
2.7.1 Samples used in quantitative mRNA work
The experiment was carried out in two separate, fully anonymised cohorts. The first cohort 
consisted of samples of temporal neocortical brain tissue from anterior temporal 
lobectomies obtained at therapeutic surgery from 40 patients with drug-resistant epilepsy 
and hippocampal sclerosis. The brain tissue was frozen in liquid nitrogen soon after 
resection. The second cohort also consisted of temporal neocortical tissue, but collected 
from post mortem brain samples of 23 patients who had had Parkinson’s disease selected 
from a wider sample donated to the National Hospital for Neurology and Neurosurgery 
Parkinson’s disease brain bank, based on the candidate causal variant rs3918149 
genotype.
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2.7.2 Preparation of mRNA
All tissue was stored at -80°C until extraction. Genomic DNA for samples used in the 
mRNA analysis was extracted from approximately 25 mg of the same brain tissue used for 
mRNA analysis using the Wizard Genomic DNA Purification Kit (supplied by Promega, 
catalogue number A1120) according to the manufacturer’s conditions.
Total RNA was isolated from approximately 30 mg tissue using the RNeasy Lipid Tissue 
Purification Kit (supplied by Qiagen, catalogue number 74804), according to 
manufacturer’s conditions. The RNA was quantified spectrophotometrically at 260 nm, and 
1 jig RNA of each sample was reverse-transcribed to cDNA using the High Capacity cDNA 
Synthesis Kit (supplied by Applied Biosystems, catalogue number 4322171), according to 
manufacturer’s conditions.
2.7.3 Quantitation of mRNA
Quantitative PCR was carried out using an Applied Biosystems 7300 real-time PCR system 
on a volume of cDNA corresponding to 10 ng starting RNA, using Assay on Demand 
assays for gene expression (supplied by Applied Biosystems). Quantitation of mRNA 
expression was obtained using the standard curve method. Each sample was run in 
triplicate, and the signal for each gene was normalised over the endogenous control ACTB, 
as outlined in User Bulletin 2 (Applied Biosystems, Catalogue No. P/N4303859). ACTB
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was chosen as the endogenous control as it has been previously shown not to be 
upregulated in epileptogenic tissue [127]. The data for each sample were averaged over 
two independent replicates of the same experiment (from mRNA extraction onwards). The 
fit of the data to a normal distribution was assessed using a Kolmogorov-Smirnov (K-S) test 
for the composite hypothesis of normality. Correlation between different experiments was 
assessed using regression analysis. Association between mRNA expression and 
genotypes at the BRD2 candidate causal variant rs3918149 was evaluated using a 
Kruskal-Wallis (K-W) rank test. All analyses were implemented in the software package R 
[128].
2.8 Selection and assessment of tagging SNPs
2.8.1 Tagging methodology and related issues
The term “tagging” was introduced by Johnson and colleagues who suggested the method 
to capture the variance in commonly observed haplotypes across a gene or region [126]. 
But tagging common haplotypes is only one of many possible ways to select a subset of 
SNPs that retain as much information as possible about the other SNPs. Broadly speaking 
the approaches that have been evaluated can be divided into 2 groups [129], those based 
on maximising the haplotype diversity present in the tagging set compared to the tagged 
set (diversity based) and those based on establishing as high an association as possible 
between the ‘lagging” and ‘lagged” set (association based). To avoid the close
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identification with haplotype diversity in the selection of tags, some have suggested that 
tags be referred to as tSNPs as opposed to htSNPs (e.g. [129]).
The primary motivation for tSNP selection is their application in LD based gene mapping. 
For this reason, a tSNP selection criterion focused on the r2 measure of LD seems logical 
because it allows quantification of the loss of power in typing the tSNPs instead of all the 
SNPs. Pritchard and Prezeworski showed that for two biallelic loci, power scales with r2, 
such that typing the associated marker with n/r2 individuals would have approximately the 
same power as n individuals in which the causative variant itself was typed, where r2 is the 
association between the two variants [130]. This finding has been extended by Chapman et 
al [131] to include generalised r2, including haplotype r2 (see section 2.8.2 below).
2.8.2 Multi marker vs. pairwise approaches
There still remains the question of how to define the r2 value. Relying on pairwise 
measures is straightforward, but may be inefficient. This is because pairs of SNPs will only 
have high pairwise association when their minor allele frequencies are very closely 
matched, thus meaning that SNPs that exhibit a full range of frequencies will need to be 
selected as tags. This can be overcome if combinations of the tSNPs are used to predict 
the other SNPs. Two principal approaches have been discussed in the literature; the 
haplotype r2 method (Weale et al 2003; Goldstein et al 2003; Chapman et al 2003 and 
Clayton website: http://www-gene.cimr.cam. ac.uk/clayton/software) and the allelic r2
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method (Chapman 2003 and Clayton website: http://www-gene.cimr.cam. 
ac.uk/clayton/software).
Haplotype r2 is defined as the proportion of variance in a ‘lagged” SNP of interest that is 
explained by an Analysis of Variance based on the G haplotypes formed by the set of 
tSNPs. :
Yi = xi1b1 +xi2b2 + .... + xiGbG
Where V7is the predicted state of the tagged SNP of interest on the /th chromosome, 
x/f...x/Gare indicator variables for the G haplotypes and bi...bG are coefficients estimated 
by standard least squares from the observed data.
Allelic r2 only differs in that the tSNP alleles, as opposed to the haplotypes defined by the 
tSNPs as the indicator variables in the above regression equation. Although less efficient 
than haplotype r2, allelic r2 is attractive in that haplotype inference, a complicating factor 
when dealing with large genomic regions, is not required.
The combinatory approaches (haplotype and allelic r2) are clearly more efficient in the 
sense of requiring fewer tags because they rely on combinations of haplotypes or alleles 
generated by tagging SNPs to predict the state of tagged SNPs. These combinations are 
identified by selecting the appropriate coefficients in a linear regression. At the present 
time, it is hard to predict which approaches to tSNP selection will prove the most useful in 
practise although it is clear that the LD properties of the region in question will influence 
any decision.
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2.8.3 Block-based and block-free selection of tags
While the discovery of the block-like nature of LD and its effect on haplotype distribution 
inspired the idea of tags for given haplotypes (Johnson et al 2001), the use of tSNPs in no 
way depends on blocks of LD. Indeed, even if there is such a block structure, it is not 
apparent that tag selection should make reference to blocks. As noted in section 2.8.1 
above, the early suggestions for the definition of htSNPs did not address this issue directly. 
More recently, however, it has been argued that block based identification of tags will 
always be less efficient (sometimes considerably) than methods that select across block 
boundaries. This is because tagging within blocks limits the effective range of a set of 
tags, and means that cross-block associations cannot be exploited (Goldstein et al 2003). 
For this reason, we advocate the selection of tSNPs across large contiguous sequence 
stretches, independently of any underlying block structure in the region. Even so, some 
questions remain in this approach. For example, computational issues make it difficult to 
select across very large regions without some sort of subdivision. In addition, selecting 
across large regions may result in a set of tSNPs that are not optimised for specific 
subregions, as for example a candidate gene (Goldstein et al 2003). These are just some 
of the issues that will need to be addressed in order to develop appropriate, efficient 
strategies for genome-wide tSNP selection.
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2.8.4 Selecting tagging SNPs
All tags discussed in this thesis were selected using the haplotype r2 method (as described 
in section 2.8.2 above) applied to data from the HapMap project. The HapMap project 
website (www.haDmaD.org) offers a user-friendly interface allowing selection of any region 
of the genome of interest in manner similar to previously established genome browsers 
(UCSC, NCBI etc). Genotypic data is generated from 30 trios of a specific ethnic origin and 
can downloaded either as a large batch (i.e. all HapMap data or a chromosome), or for any 
defined region of the genome.
Haplotype inference is an essential prerequisite to tag selection using the haplotype r2 
method. The EM-related inference package PLEM (available from: 
http://www.people.fas.harvard.edu/~iunliu/plem/click.htmn is well equipped for this task. 
PLEM implements a partition-ligation approach (i.e. partitions the data in to subsets, infers 
haplotypes then ligates to neighbouring region etc) and is thus favoured over standard EM 
packages as it greatly helps in the analysis of larger datasets (i.e. haplotype inference 
across many SNPs), critically important as we move towards genome wide tags.
The TagIT package (available from
http://www.aenome.duke.edu/pressevents/lectures/pg2 050607). implemented in the 
Matlab programming environment was used for tag selection. TagIT allows tag selection 
using a wide range of variations of either diversity or association based methods 
(discussed briefly in section 2.8.2 and summarised in TagIT user guide). TagIT also offers
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functions allowing the calculation, and display, of various measures of LD that aid in 
judging the suitability of the technique for a give gene or region.
The haplotype r2 method focuses on the coefficient of determination (measured as 
haplotype r2 or Hr2) from a regression model involving the tagging and tagged SNPs. This 
provides a formal measure as to how well each individual SNP is being captured by the set 
of tSNPs. Increasing the number of tags improves performance. However, whilst 
improvement in tagging performance asymptotes, the cost of genotyping an increasing 
number of tags does not. A compromise is thus required and a consensus seems to be 
emerging that a Hr2 value above 0.8 is acceptable [129, 132]. This implies that increasing 
the sample size to n/O.Q, would be comparable to exhaustive typing of the hypothesised 
causal variant captured by a tag with a Hr2 of 0.8. With this in mind, a Hr2 value of 0.8 for 
any single observed SNP was set as the lower threshold for tSNP design in this thesis.
2.8.5 Evaluating the ability of tagging SNPs to detect unseen variation
The tagging method, when applied to incomplete data (such as that generated by the 
HapMap project), raises the inherent question of how well unknown variation is being 
captured. In order to address this crucial point the SNP dropping procedure was developed 
[133]. The approach entails taking the global set of known SNPs and for each SNP 7', 
dropping it from the analysis in turn. For each reduced set of N-1 SNPs new tags are 
selected, and their ability to represent the dropped SNP 7' is assessed (by Hr2). In this way, 
a table of Hr2 values for dropped SNPs is built, providing a statistical estimate of how well
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the tSNPs can represent SNPs that are not observed (for example SNPs which are not yet 
discovered) in the region.
The trade off between tagging performance and genotyping cost necessitates the definition 
of a threshold for SNP dropping performance. At present no consensus exists as to what 
this value should be. Indeed it is difficult to define as any threshold would depend on the 
context of the region. However, a value somewhere between 0.5-0.7 as the lower threshold 
would seem acceptable.
When dealing with incomplete data such as that provided by HapMap, dips in SNP 
dropping performance can indicate regions of insufficient SNP coverage. If however, the 
region indicated by the dip in SNP dropping performance does not correspond to a drop in 
LD, it then becomes very difficult to nominate a region in which to focus resequencing 
efforts as genealogically informative loci could be located anywhere across the LD block.
2.8.6 Example of tSNP design using SCN8a
Following is a detailed illustration of the tagging SNP methodology employed in this thesis 
using the SCN8A gene as an examplelx. The first step is to download and format the 
genotype data from the HapMap project website. An excel spreadsheet provides an 
efficient platform for data formatting, the principal steps being ordering samples as trios, 
and coding genotypes according to haplotype inference program used. Once haplotypes 
have been inferred, the researcher can proceed to tSNP selection.
“ See sections 2.8.4 and 2.8.5 for description of methodology
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As described in section 2.8.4, tagging a region requires the examination of Hr2 values for 
tSNP sets of increasing size in order that size that satisfies a Hr2 threshold of 0.8. The blue 
trace in Figures 2.1 and 2.2 illustrate the effect of increasing tSNP set size on SCN8a. 
Whilst three tags provide reasonable performance, an increase in the number of tags from 
three to six brings all loci above the threshold Hr2 of 0.8.
Figure 2.1 SCN8a tagged with three tSNPs
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Figure 2.2 SCN8a tagged with six tSNPs
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Legend for Figures 2.1. 
and 2.2
The X axis is Hr2 values. 
The Y axis is SNP
position. Solid black 
traces represent LD 
values calculated as a 
sliding window of D’ 
values from pairwise
comparisons between 3 
consecutive SNPs. Blue 
traces are Hr2 values. Hr2 
is the coefficient of 
determination value for 
that SNP in a linear
regression between 
haplotypes generated by 
tSNPs and the global 
SNP set (see section
2.8.4).
Red traces are SNP 
dropping Hr2 values. Each 
value represents the 
coefficient of
determination value for 
SNP n in a linear 
regression between 
haplotypes generated by 
tSNPs (designed on the 
global SNP set minus 
SNP n) and the global 
SNP set (see section
2.8.5).
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The result of SNP dropping procedures using three and six tags is illustrated by the red 
trace in figures 2.1 and 2.2. Dips in Hr2 values returned from SNP dropping id indicative of 
poor tag performance in predicting unknown variation. Given the poor performance of 
tagging with three tSNPs, it can be expected that SNP dropping would, in turn, perform 
poorly. Indeed this can be seen by comparing the red traces in figures 2.1 and 2.2. 
Increasing to six tSNPs returned an average Hr2 value of 0.95 from SNP dropping 
indicating a significant improvement in detection of unseen variation compared to three 
tSNPs.
In the example of SCN8a presented here, SNP dropping with six tSNPs returns a value of 
0.56 at SNP20 (see red trace in Figure 2.2). Significantly, this dip corresponds to a drop in 
LD values (indicated in the figure as solid black trace). Indeed, decay of LD generates 
haplotype diversity and as discussed previously decreases the performance of tagging. For 
this reason, localised regions of low LD typically correspond with dip in SNP dropping 
performance.
In summary, 6 tSNPs are sufficient for SCN8a to satisfy the selection criteria defined for 
this thesis. These variants capture the vast majority of common variation in the SCN8a 
gene and are ready for application in association studies.
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2.9 Statistical methods used In association analysis
2.9.1 Allelic and genotypic association
For single SNP analysis we assessed the significance of genotypic and allelic contingency 
tables using Pearson’s %2 distribution. For tables with insufficient cell counts (i.e. <5) we 
used an exact probability test as implemented in the program, RxC (available at 
http://bioweb.usu.edu/mDmbio/rxc.aspV
2.9.2 Haplotypic association
We assessed the distribution of haplotypes across case and control groups by calculating 
score statistics using the package haplo.score 18 in R 19. Briefly, this method uses 
generalised linear models to generate score statistics which can be used to examine the 
correlation between expectation-maximisation generated haplotypes and the trait of 
interest. We coded cases and controls as a binomial trait. When generating score statistics, 
we only considered haplotypes observed at a frequency of 1% or greater. The likelihood of 
spurious inference by the EM algorithm increases with lower frequency haplotypes.
2.9.3 Power calculations for association studies
What follows is a description of power calculations as applied in Chapters 3 and 4.
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In order to illustrate the expected power of replication in our cohort, we estimated power of 
detection using software available at http://stataen.iop.kcl.ac.uk/gpc/. To calculate power of 
detection at a 0.05 type-1 error rate level we used as parameter values: relative risk 
values, a disease prevalence of 0.1%, risk allele frequencies observed in our control 
population and the relevant case to control ratio. Direct positive replications are better 
estimators of genetic effect then original reports [Lohmueller etal. 2003]. However, as 
direct positive replications were not available, we used data from original reports to 
estimate relative risk and odds ratio values. We defined the risk allele as that conferring 
risk in the original report. We emphasise that we used the estimated relative risks, as 
opposed to the lower bounds on these relative risks. This means of course that we cannot 
rule out smaller effects for the variants even when our estimated power is high. Although 
TLE is the most common partial epilepsy, precise prevalence figures are not known. We 
view the use of a disease prevalence of 0.1 % as a conservative estimate for all types of 
TLE tested here.
2.10 Visual assessment for quantification of adverse reaction to 
Vigabatrin
This section refers to visual field measurements discussed in Chapter 5.
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2.10.1 Calculation of Goldmann perimetry values
Visual fields were recorded by an ophthalmologist using standard kinetic Goldmann 
perimetry. We calculated the mean radial degrees (MRD) for each eye by measuring the 
radial distance of the intact field in degrees from fixation at 12 points, 30 degrees apart and 
then taking the average of these values (as previously described [134]). We view this value 
as a quantitative measurement of vigabatrin-induced visual field constriction. The Ill4e and 
I4e isopters were used to calculate MRD values in cohorts “>4” and “B” respectively. The 
reason for this discrepancy was that the isopter routinely used in at one referral center was 
different to that used at the other. We felt justified in doing this because a) the two cohorts 
were analyzed separately and b) the aim of the study was to associate the development 
and severity of constriction with particular genotypes and not to compare values for 
constricted fields.
Catch trials were performed and fixation was carefully monitored during testing by direct 
visualization of the fixing eye. We excluded patients in whom fields were unreliable due to 
poor compliance, i.e. they did not maintain fixation, they were slow to react, or gave 
inconsistent responses to the light stimulus producing a wide variation in radii (so called 
'spiraling'). We also excluded patients with pre-existing eye disease, such as glaucoma, 
retinitis pigmentosa, optic nerve or macular degeneration or bilateral cataracts. We did not 
exclude patients with field defects due to previous intracranial surgery; however in such 
cases we did exclude the affected quadrant or hemifield from the calculation of the MRD. 
We used readings from the right eye in calculating MRD values unless local pathology,
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such as cataract, prohibited this. Where serial fields were available we selected the 
measurement that corresponded to the greatest drug exposure time.
2.10.2 Estimation of Goldmann perimetry values in a control populations
MRD values from epilepsy patients previously unexposed to vigabatrin were used as 
estimates of a normal, unaffected population. MRD values of 49.3 and 47.6 degrees were 
used as cut-off for normal visual fields in Cohorts A and B respectively [135, 136].
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Chapter 3 Attempted replication of previously reported 
genetic association studies with sporadic temporal lobe 
epilepsy. Lessons learnt for complex trait genetics
3.1 Introduction
Although major advances have been made in the field of Mendelian genetics, with the 
discovery of numerous genes underlying monogenic diseases, only a limited number of 
genetic susceptibility factors underlying common diseases have been convincingly 
identified [68]. This is mainly because common diseases arise from interaction of several 
genes, with additional environmental influences, and are therefore much more complex. 
Moreover, the best strategy to study such complex traits is a matter of ongoing debate [66].
3.1.1 The role of genetics in temporal lobe epilepsy
The study of genetic contributions to the aetiology of epilepsy exemplifies these issues. 
Temporal lobe epilepsy (TLE) is the most common form of partial epilepsy. According to 
the focus of seizure origin, TLE can be further subclassified into mesial TLE and lateral or 
neocortical TLE. Therefore, TLE is itself a heterogeneous condition with a wide range of 
possible underlying aetiologies. Although traditionally it was considered an acquired
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disorder, it is now becoming clear that genes play a role in at least a subset of cases. 
Evidence for this comes from both human and animal studies.
TLE rarely occurs in families as a monogenic trait. So far, the only known gene associated 
with a monogenic type of TLE is LGI1, mutations in which are responsible for some cases 
of familial lateral TLE manifesting as autosomal dominant partial epilepsy with auditory 
features [52]. Several families with autosomal dominant mesial TLE have also been 
reported, and linkage has been established in some of them [137-139]. In addition, 
individuals with a TLE phenotype have been reported in other multiplex familial epilepsies, 
such as generalized epilepsy with febrile seizure [17] familial partial epilepsy with variable
4
foci [140,141] and partial epilepsy with pericentral spikes [142]. Finally, genes have been 
identified in mice, mutations in which cause a phenotype reminiscent of TLE. Examples 
include Scn2a in the Q54 mouse [143], Jh8 in the jerky mouse[144] and Plc-(51[ 145].
These observations illustrate that there is good evidence for a genetic contribution to 
sporadic TLE.
3.1.2 A hypothesised link between febrile seizures and hippocampal sclerosis
Hippocampal sclerosis (HS) is the most common histopathology underlying sporadic forms 
of mesial TLE. In most cases, the cause of HS is not known. A long standing but 
controversial hypothesis links childhood febrile seizures (FS) with subsequent HS [146]; 
patients with TLE are more likely than patients with other focal epilepsies to have a history
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of FS [147]. The heritability of FS appears to be high [148, 149]. Taken together, these 
data imply a genetic component to HS and thus to many cases of mesial TLE.
3.1.3 Previous genetic associations studies involving temporal lobe epilepsy
Over the last four years several studies have reported associations between common 
variants in specific genes and sporadic TLE including mesial TLE. Significant association 
with TLE has been reported in four genes: 11-1 b [114], PDYN [150][Stogmann et al. 2002], 
GABBR1 [151] and PRNP [152]. One study has reported an association of APOE with age 
of onset of TLE [153]. In addition, variants in CHRNA4 [154] and GABRG2 [155] have 
been reported as risk factors for childhood FS. These associations, rightly or wrongly, have 
contributed to the growing view that TLE is at least partially genetic [156].
The well-accepted prevalence of false positive results in genetic association studies 
stresses the importance of replication to confirm or reject novel association results [106]. In 
fact, where follow-up studies have been reported (11-1 b [117] [120, 157] [116, 118,119]; 
PDYN [158, 159] APOE[160-162], CHRNA4 [163-167]) results have been conflicting, 
making it currently unclear whether any of the genes have important effects on the 
development of TLE or FS.
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3.1.4 Aims
In this chapter all seven claims of positive association (for TLE and FS) in the literature are 
examined by attempting to replicate them in an independent cohort of adult patients, which 
included subcohorts of 339 patients with a syndromic diagnosis of TLE and a partially 
overlapping subcohort of 107 patients with epilepsy of any type who had a definite previous 
history of FS.
Further, to make in total a cohort of 752 epilepsy patients, an additional 371 patients with 
forms of epilepsy other than TLE were added. This cohort was used to examine if the 
seven variants contribute to the development of any common type of epilepsy.
3.2 Results
3.2.1 Breakdown of patient cohort
The primary aim of this study was to re-test previous association studies involving various 
TLE phenotypes. We thus classified the 339 patients diagnosed with TLE in to relevant 
sub-categories as defined by the original studies reporting each association (see table 3.1). 
In this way we were able to re-test directly each of the claims for association. We note that 
these categories are not mutually exclusive, which is why the sum of the sub-categories is
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greater than the total number of patients with TLE examined. For each gene, we make 
clear which group of patients was used for the association.
Table 3.1 Breakdown of TLE patient cohort
TLE Classification* Number of patients
Hippocampal Sclerosis1 141
Familial non-lesional* 50
Non-lesionala 245
Refractory with Hippocampal Sclerosis4 121
Symptomatic Refractory5 181
* The categories of TLE defined here overlap. Thus their sum is greater then the total number of TLE patients.1 As used by Kanemoto et 
al [Kanemoto etal. 2000]. HS was diagnosed using high-resolution magnetic resonance imaging.2 As used by Stogmann et al 
[Stogmann etal. 2002]. Non-lesional TLE patients (HS allowed) with first or second degree relatives having a history of seizures.3 As 
used by Gambardella et al [Gambardella etal. 2003a]. Non-lesional TLE patients (HS allowed).4 As used by Walz et al [Walz etal. 
2003]. W e used criteria outlined in Siddiqui et al [Siddiqui etal. 2003] to define drug resistance.5 As used by Briellmann et al [Briellmann 
etal. 2000]. Patients with symptomatic, drug resistant (as defined in [Siddiqui etal. 2003]) TLE. Includes patients with HS.
In order to examine any effect of these variants on other classifications of epilepsy we have 
divided our overall cohort of 752 epilepsy patients as having idiopathic generalised 
epilepsy (IGE, n=96), cryptogenic (n=233) or symptomatic epilepsy (n=330). This scheme 
follows presumed gradations in the level of genetic contribution to aetiology and, for our 
patients, corresponds approximately, though not exactly, to the to the International League 
Against Epilepsy classification of epilepsies and epileptic syndromes [5]. Ninety-three 
individuals were unclassifiable according to these criteria. These patients therefore were 
only included in the association tests involving “all epilepsy”.
All patients and controls were of self-identified European ancestry. We used un-related 
individuals from a twin registry as controls [168].
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3.2.2 Results for U-1b
The 11-1 b -51 1 variant has been previously reported to associate with TLE and HS [169], 
FS [115,169], and refractory partial epilepsy [120]. The first of these reports [114] showed 
an association between 11-1 b - 511 genotype and development of TLE accompanied by HS 
in Japanese patients (p=0.0085; OR 3.29 (Cl 1.28-8.47)). Our results failed to replicate, or 
show a trend, in support of this association in our European cohort (see table 3.2). We 
estimated our cohort to have 68% power of detection for this association.
We also examined the reported association with FS in Finnish children [115] and in 
Japanese patients with HS [169]. We were unable to replicate the association with 
childhood FS in our cohort of 107 patients with all forms of epilepsy and antecedent FS 
(p=0.557 and 0.408 for genotype and allele)
Restricting our analysis to HS patients with a history of FS (n=50) similarly failed to show 
significance (p=0.886 and 0.865 for genotype and allele). We estimated our cohort to have 
90% power of detection for the febrile seizure association. We were unable to calculate 
power of detection for FS with HS as genotypic counts for these subgroups were not 
detailed in the original report.
Similarly, we found no association (p=0.780 and p=0.672 for genotype and allele) with 
refractory partial epilepsy in the 372 patients in our overall cohort who matched the
x 11-1 b -511 was genotyped by Taqman (see section 2.3). The method used to calculate power of detection is 
detailed in section 2.9.3.
phenotype reported in the original positive association study [120]. We estimated our 
cohort to have almost complete power of detection for this association.
Examination in other forms of epilepsy failed to show any contribution of this allele to 
development of other types of epilepsy. Results are shown in Table 3.2
Table 3.2 11-1 b -511 genotype counts and analysis results
TLE+HS'
n=141
All Patients Symptomatic Cryptogenic 
n=752 n=330 n=233
IGE
n=96
Controls
n=384
G/G 59(0.45) 309(0.45) 133(0.44) 98(0.46) 37(0.42) 161(0.44)
G/A 57(0.44) 306(0.44) 137(0.45) 94(0.44) 41(0.47) 162(0.45)
A/A 15(0.11) 74(0.11) 34(0.11) 21(0.10) 10(0.11) 41(0.11)
MAFf 0.33 0.33 0.34 0.32 0.35 0.34
Genotype p * 0.9808 ns ns ns ns
Allele p* 0.9272 ns ns ns ns
'TLE with hippocampal sclerosis as used by Kanemoto et al [Kanemoto etal. 2000].
*p values are uncorrected and calculated from x2 distribution generated from contingency tables.
“ns” = non significant. +Minor allele frequency. Genotype counts are those for successful typings only
3.2.3 Results for PDYN
Stogmann et al. reported an effect of a functional PDYN promoter variation on 
development of non-lesional TLE in patients of middle-European descent whose first 
and/or second degree relatives also had a history of seizures [150]. The authors reported 
an over representation of the low expression allele (“L”) in the patient cohort (p=0.0025; 
OR= 5.33(CI 1.94-14.65)). We failed to replicate this association in the 50 patients in our
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overall cohort matching this phenotype (see Table 3.3). Our cohort is predicted have 89% 
power of detection for this association*.
The same authors also reported that patients with TLE carrying the low expression PDYN 
allele had a significantly higher risk of developing frequent secondarily generalised tonic 
clonic seizures and status epilepticus. We were unable to replicate these associations as 
our patient numbers were too low in the case with frequent secondarily generalised 
seizures and we lacked reliable information that could confirm the absence of a history of 
status. However, of the 14 patients we identified with frequent secondarily generalised 
seizures (as defined in the original association), only one carried the low expression allele.
Analysis of the broader cohort suggests the possibility that PDYN may act as a general risk 
factor for epilepsy (p=0.035) and for idiopathic generalised epilepsy (p=0.038). Following 
the previous observation [150] that PDYN genotype effect was limited to familial cases of 
epilepsy we examined the variant in familial cases of IGE and found the association to 
strengthen (p=0.002). In light of the many tests we have conducted here, these results can 
be considered only as a modest trend. To clarify the role of PDYN in epilepsy further 
analyses is required in larger patient cohorts.
Xl The PDYN promoter repeat was genotyped as detailed in section 2.5. The method used to calculate power 
of detection is detailed in section 2.9.3.
Table 3.3 PDYN genotype counts and analysis results
TLE+FH' 
n=50
All Patients Symptomatic Cryptogenic 
n=752 n=330 n=233
IGE 
n= 96
IGE+FH"
n=32
Controls
at=384
H/H 17(0.36) 336(0.48) 152(0.49) 106(0.50) 33(0.36) 8(0.25) 175(0.48)
IVH 22(0.47) 270(0.39) 120(0.39) 80(0.38) 46(0.49) 16(0.50) 160(0.44)
LA 8(0.17) 92(0.13) 37(0.12) 27(0.13) 14(0.15) 8(0.25) 30(0.08)
MAFf 0.4 0.33 0.31 0.31 0.40 0.5 0.3
Genotype p * 0.0898 0.0348 ns ns 0.038 0.0021
Allele p* 0.0429 ns ns ns 0.012 0.0011
'Familial non-lesional TLE (history of seizures in first and/or second degree relatives) as used by Stogmann et al [Stogmann etal. 2002]. 
"Familial IGE (history of seizures in first and/or second degree relatives). *p values are uncorrected and calculated from %2 distribution 
generated from contingency tables. ”ns” = non significant.
MS/linor allele frequency. Genotype counts are those for successful typings only
3.2.4 Results for GABBR1
Gambardella et al. [151] reported the GABBR1 G1465A variant to have a major effect on 
the development of non-lesional forms of TLE in Italian patients (pt=<0.0001 OR= 37.95 (Cl 
8.84 -162.98)). In our cohort of patients with non-lesional TLE, however, we see no 
association (see table 3.4). We have 81% power of detection for this association501. 
However, this is a conservative estimate as we used the same relative risk value calculated 
for the heterozygote as an estimate for the homozygote risk genotype. This was required 
as it is impossible to calculate a relative risk value for the homozygote risk genotype as that 
genotype was not observed in the original control cohort.
We saw no effect of this variant on the development of other forms of epilepsy as classified 
here (see Table 3.4).
x“ GABBR1 G1465A was genotyped using Taqman as detailed in section 2.3. The method used to calculate 
power of detection is detailed in section 2.9.3.
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Table 3.4 GABBR1 G1465A genotype counts and analysis results
nl-TLE
n=245
All patients Symptomatic Cryptogenic 
n=752 n=330 n=233
IGE
n= 96
Controls
n=1089
G/G 218(0.99) 683(0.99) 302(0.99) 210 89(0.99) 1062(0.99)
G/A 2(0.01) 6(0.01) 4(0.01) 0 1(0.01) 8(0.01)
A/A 0 0 0 0 0 0(0.0)
MAFf 0.002 0.004 0.006 0 0.006 0.004
Genotype* 1 ns ns ns ns
Allele* 0.6823 ns ns ns ns
'Non-lesional TLE patients. Includes patients HS. As used by Gambardella et al [Gambardella etal. 2003a] 
*p values are uncorrected and generated using an exact probability test. ”ns” = non significant. 
fMinor allele frequency. Genotype counts are those for successful typings only
3.2.5 Results for PRNP
The non-synonymous PRNP variant Asn171Ser was reported by Walz et al [152] to 
contribute to the development of refractory TLE with HS in a Brazilian patient cohort which 
included patients of both European and African descent. The authors observed the variant 
in 23% of patients but were unable to detect it in controls suggesting the variant contributes 
greatly to disease development (p=<0.0001). We failed to replicate this association in our 
cohort of 121 patients with refractory TLE and HSX"‘ (see Table 3.5). In fact, we were 
unable to detect this variant in any of our refractory TLE patients. We observed the variant 
only twice, once in a patient with symptomatic epilepsy secondary to cerebrovascular 
disease and once in a control individual. As we could not estimate the genotypic relative 
risk of the variant in the original study (the variant was not observed in the control 
population), it was not possible to calculate power for this association.
XIH PRNP ASN171Ser was genotyped using Taqman as detailed in section 2.3.
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Table 3.5 PRNP Asn171 Ser genotype counts and analysis results
Refrac. HS1 All patients Symptomatic Cryptogenic 
n=121 n=752 n=330 n=233
IGE
n=96
Controls
n=384
Asn/Asn 109 718(0.99) 320(0.99) 219 93(0.99) 360(0.99)
Asn/Ser 0 1(0.01) 1(0.01) 0 0(0.01) 1(0.002)
Ser/Ser 0 0 0 0 0 0
MAFf 0 <0.001 <0.001 0 0 0.001
Genotype* 1 ns ns ns ns
Allele* 1 ns ns ns ns
'Refractory TLE with hippocampal sclerosis. As used by Walz et al [Walz etal. 2003]
*p values are uncorrected and generated using an exact probability test. ”ns” = non significant. 
tMinor allele frequency. Genotype counts are those for successful typings only
3.2.6 Results for APOE
Briellmann et al. [153] reported a significant association in Australian patients between the 
APOE s4 allele and age of onset of refractory TLE. Results indicated that the presence of 
the e4 allele correlated with a mean age of onset of 5 (+/- 5) years, whilst in the absence of 
the allele, mean age of onset was 15 (+/-10) years (Mann Whitley U test ptO.004). Our 
results, from 181 refractory temporal lobe epilepsy patients, do not support this association 
(Mann Whitley U test p=0.1808)xiv. Mean age of seizure onset in patients carrying at least 
one copy of the £4 allele (30 of 181 patients) was 13.7 (+/-10) years. Patients not carrying 
a copy of the £4 allele had a mean age of seizure onset of 16.7 (+/-11) years.
We further examined the distribution of the APOE haplotypes across refractory TLE and 
other sub groups of epilepsy (see table 3.6). We note a modest trend in haplotype 
distribution for the IGE (p=0.031) group and £4 allele frequency for refractory TLE. In both 
cases the trend seems to be generated by an under representation of the hypothesised risk
XIV APOE £4 was genotyped using Taqman as detailed in section 2.3.
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allele (z4). We feel this association is likely the result of multiple testing and thus would 
view it as tentative at best. As such, confirmatory testing in an independent cohort is 
required.
Table 3.6 APOE genotype counts and analysis results
Refrac. TLE' 
/7=181
All patients 
n=752
Symptomatic Cryptogenic 
n=330 n=233
IGE 
n=96
Controls
n=384
s3t 230(0.80) 926(0.79) 406(0.78) 285(0.8) 125(0.83) 469(0.74)
£4* 36(0.13) 156(0.13) 72(0.14) 46(0.13) 14(0.09) 108(0.17)
£2* 20(0.07) 92(0.08) 44(0.08) 24(0.07) 11(0.07) 57(0.09)
£4 freq* 0.13 0.13 0.14 0.13 0.09 0.17
Hap p" 0.205 Ns ns ns 0.031
^  A III£4 P 0.078 Ns ns ns ns
'Symptomatic refractory TLE patients. As used by Briellman et al [Briellmann etal. 2000]
"Uncorrected significance value for haplotype distribution. Detailed in methods section.
"'Uncorrected significance value for 2x2 %2 distribution between presence and absence of e4 allele.
”ns” = non significant. tHaplotype counts are those inferred from successful genotyping at both loci only. 
^Frequency of e4 allele
3.2.7 Results for CHRNA4
Chou et al reported, in a cohort of Taiwanese children, association of a synonymous SNP 
variant Ser543Ser with childhood FS (p= 0.001; OR= 2.84 (Cl 0.87-9.28)) [154]. Our results, 
from the 107 epilepsy patients with a history of FS in our cohort, failed to replicate this 
association. However, we do note our study is estimated to have only 17% power of 
detection for this association™.
Analysis across different subgroups of epilepsy failed to support a role for this variant in 
disease predisposition for the subtypes of epilepsy tested here (see Table 3.7).
w CHRNA4 Ser543Ser was genotyped using Taqman as detailed in section 2.3. The method used to 
calculate power of detection is detailed in section 2.9.3.
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Table 3.7 CHRNA4 Ser543Ser genotype counts and analysis results
Feb. Con.1 
n=107
All patients Symptomatic Cryptogenic 
n=752 n=330 n=233
IGE
n=96
Controls
n=384
TIT 36(0.36) 241(0.36) 119(0.40) 70(0.33) 26(0.29) 120(0.32)
C/T 48(0.48) 301(0.45) 122(0.41) 97(0.46) 45(0.51) 200(0.52)
C/C 15(0.15) 131(0.19) 53(0.18) 44(0.21) 18(0.2) 61(0.16)
MAF 0.39 0.42 0.39 0.44 0.46 0.42
Genotype* 0.6525 ns ns ns ns
Allele* 0.4665 ns ns ns ns
'Epilepsy patients with a history of childhood febrile seizures. *p  values are uncorrected and generated 
using an exact probability test. ”ns" = non significant. fMinor allele frequency 
Genotype counts are those for successful typings only
3.2.8 Results for GABRG2
Chou et al reported a synonymous variant in the GABRG2 gene (rs211037) to associate 
with FS in a cohort of 104 Taiwanese children (p=0.017, OR= 2.56 (Cl 1.01 -6.50)[155]. Our 
results in a cohort of 107 patients with a history of FS failed to support this association. 
Again, we note a lack of power, with our cohort estimated to have only 8% power of 
detection for this association™.
Analysis of the GABRG2 variant in the broader epilepsy cohort fails to support a role for 
this variant in the development of other forms of epilepsy tested here (see Table 3.8).
XVI GABRG2 rs211037 was genotyped using restriction digestion as detailed in section 2.4. The method used 
to calculate power of detection is detailed in section 2.9.3.
Table 3.8 GABRG2 rs211037 genotype counts and analysis results
Feb. Con.' 
n=107
All Patients Symptomatic Cryptogenic 
n=752 n=330 n=233
IGE 
n= 96
Controls
n=384
C/C 54(0.53) 391(0.60) 174(0.58) 126(0.64) 48(0.61) 203(0.61)
CfT 43(0.43) 213(0.33) 96(0.32) 62(0.31) 24(0.31) 114(0.35)
T/T 4(0.04) 45(0.07) 28(0.09) 10(0.05) 6(0.08) 13(0.04)
MAFf 0.25 0.23 0.26 0.21 0.23 0.21
Genotype p * 0.3188 ns ns ns ns
Allele p* 0.2269 ns ns ns ns
'Epilepsy patients with a history of childhood febrile seizures. *p values are uncorrected and generated using 
an exact probability test. ”ns” = non significant. fMinor allele frequency. Genotype counts are those for 
successful typings only
3.3 Discussion
This study has examined all positive genetic associations reported thus far on sporadic 
forms of TLE, and two associations on FS, in a single patient cohort of greater size than 
used in any of the original reports. We also tested whether the variants might predispose 
to the development of other forms of epilepsy.
Replication studies have previously been published on five of the seven variants examined 
here™1. In the case of APOE, data from other European populations published prior to the 
positive association [160,161], strongly suggest the reported effect on age of onset [153, 
162] to be a false positive association. The /L7/3-511 association with HS was similarly not 
replicated in European populations, though samples sizes were small [117,118,157]. It is
XVH Note that at the time this work was published, replication had only been attempted on four of seven original 
reports. In fact numerous additional replication attempts have been published since our paper was published 
-  all were negative, in agreement with our conclusions
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possible that this association is due to a population-specific effect in terms of functionality 
or patterning of linkage disequilibrium (LD), but this would appear unlikely since there was 
also a failed replication in a Chinese population [119]. Previous re-testing of the PDYN 
polymorphism in a population of European origin failed to clearly replicate the original result 
[158, 159]. Similarly, replication attempts of GABBR1 have also proved negative [156,
163, 165, 166]
Examination of the CHRNA4 association in an Australian population failed to replicate the 
original association [164]. However, both the Australian and our study lack power of 
detection for the CHRNA4 association. Similarly, we lacked power to replicate the 
GABRG2 association. Further research for both of these associations is required, 
particularly in Asian populations.
Our own results are consistent with these failed replication efforts. In particular, APOE 
results fail to show an effect in the same direction as the original report either in our study 
or in the other replication efforts. The results for PDYN are more ambiguous. We do not 
see association with “familial” non-lesional TLE, as originally reported. However, our results 
suggest a possible role for PDYN as a risk factor for epilepsy. In particular we note a trend 
of association with IGE, which is enhanced in “familial” IGE patients (following the definition 
of familial as used in original report). We encourage examination of this variant across 
large, well-phenotyped cohorts in order to further examine this putative role.
For PPA/PAsn171Ser, where there were no previous attempts at replication, our results 
suggest the original association to be likely false positive. In contrast to the original report,
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we see no evidence for even a marginal effect of this variant in the European population 
tested here. We cannot, however, rule out the possibility that this variant may be disease- 
causing or in LD with disease-causing variants that are specific to one or more population 
groups. We thus encourage replication attempts in the respective population. However, a 
more likely explanation is that the original association is due, at least in part, to population 
stratification; the cases and controls were drawn from a genetically heterogeneous base 
population and no formal test for stratification was undertaken.
The results presented here suggest that most or all of the reported associations for TLE 
are not reproducible in the European population. When these results are considered with 
previous replication attempts the fact remains that not one of these associations has been 
accurately replicated in a population of similar or other ancestry. On the weight of current 
evidence it appears likely that most or all of the reported associations for TLE were false 
positives. Our data certainly do not rule out the presence of risk factors in any of the genes 
studied. But given that our sample sizes were always at least as big as the previous 
reports and usually bigger, it seems fair to conclude that the genes studied here are at best 
neutral in not having any more supporting evidence than any other part of the genome. It 
would therefore appear that at present we know little about the genetic basis of sporadic 
TLE. Even worse than our ignorance, however, is the fact that false associations can lead 
to a waste of effort in trying to understand the biological bases of the involvement of genes 
which are not in fact involved in the disease, in this case sporadic TLE. How can this 
situation be improved?
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In agreement with recent recommendations [156], we believe methodological weaknesses 
in study design contribute to the variable results. For example, studies that fail to consider 
stratification in the context of an ethnically-mixed patient and control population (see [152]) 
should no longer be published. All seven of the variants tested here have been selected 
using a sequence-based approach, focusing on functional, or putatively functional, 
variation. Whilst this approach has obvious advantages, future studies should seek to 
merge a sequence- based approach with methods that systematically represent variation in 
candidate genes. Map-based approaches such as the tagging SNP method address this 
issue by taking advantage of LD to allow examination of most variation by typing only a 
small number of tagging SNPs [66, 170]. The publicly available HapMap resource, in 
conjunction with rapidly-developing tagging SNP selection techniques [132], makes this 
approach feasible even with only modest laboratory resource. In addition, for an 
association to be considered replicated, it should be replicated exactly. A follow up study 
that shows association with another polymorphism in a gene, or a somewhat different 
phenotype may be of interest, but should not be considered a replication. These sorts of 
“replications” must be treated with particular care because of the possibility of explored 
populations, polymorphisms, and phenotypes until something is found in a given gene that 
can be called a replication. Neale and Sham [170] have proposed a gene-based definition 
of replication that overcomes some of these issues.
These methodological issues deserve more serious attention than they have sometimes 
received, but we believe the central difficulty is more innate, and less easy to rectify.
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The most fundamental problem with current efforts is the relatively low sample size in most 
studies, resulting in limited power to either detect, or to definitively rule out, association. 
Few investigators working on epilepsy genetics have large cohorts for any particular type of 
epilepsy, including our own current and previous efforts. It does not appear to us that in the 
near future individual investigators will be able to increase their own sample sizes to levels 
sufficient to carry out highly powered association studies within the various forms of 
epilepsy. For example, our own collection comes from one of the biggest referral centres in 
Europe and although our own total phenotyped collection is sizeable, the numbers of 
patients with any given subtype of epilepsy is still small. Our previous study of refractory 
epilepsy, for example, included only 200 refractory patients, reporting a modest association 
with a putatively functional variant in the ABCB1 (MDR1) gene [171]. This association was 
not replicated in an exact replication attempt [172], but was reported as “replicated” for a 
similar but not identical definition of pharmacoresistance [173].
We therefore see two central lessons from our failure to replicate the TLE associations. 
First, the field must concentrate more seriously on efforts to determine which 
polymorphisms have real effects, as opposed to always racing to publish a new 
association. False positives are clearly exacerbated by the publication of multiple small 
studies and the practice of data exploration to identify subgroups that show associations. 
This fact must be recognised and addressed. Second, and most fundamentally, we believe 
it is critical for different research groups to increase substantially the size of their patient 
cohorts. Given that this will take time, we feel that in the near term, groups should combine 
their epilepsy samples, and attempt to replicate one another’s results in a population of 
similar ethnicity before publication. Although collaboration to such a level could be viewed
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as controversial from a scientific point of view, we feel that the trade off here is justified. It 
is only with such steps that the epilepsy community, like other disease areas, will be able to 
arrive at a reasonable false to true discovery ratio in reported associations.
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Chapter 4 Confirmation of BRD2 as a risk factor for juvenile 
myoclonic epilepsy in populations of European, but not Indian 
origin.
4.1 Introduction
4.1.1 Juvenile myoclonic epilepsy
Juvenile myoclonic epilepsy accounts for 26% of all IGE and is characterised by 
adolescent-onset myoclonic jerks (especially matinal), generalized tonic-clonic and/or 
absence seizures and, a characteristic interictal electroencephalogram in untreated 
patients and occasionally, in asymptomatic relatives [174]. Although single gene mutations 
that cause Mendelian forms of idiopathic epilepsy, including familial forms of JME, have 
been identified in a number of families (EFHC1[55], GABRA1[46], CACNB4{M5] and 
CLCN2[43]), the vast majority of idiopathic epilepsies follow a more complex mode of 
inheritance.
4.1.2 The genetics of complex forms of juvenile myoclonic epilepsy
Progress in understanding the genetic bases of common, more genetically-complicated 
forms of IGE has been much slower. Greenberg et al.[87] proposed an oligogenic model in 
which no single locus is either sufficient or necessary to cause IGE but rather a number of 
loci interact to produce specific subtypes of IGE. In the case of JME, disease manifestation
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may be due to interaction between variation at a locus linked specifically with JME termed 
EJM1, and susceptibility loci common to all IGE. Support for a role of the EJM1 peak 
comes from independent linkage studies [80, 85, 86, 95].
Recently it has been suggested that variation in BRD2 is responsible for the EJM1 linkage 
peak. Association analysis in 20 probands implicated two promoter SNPs (rs3918149 and 
rs206787) located in the BRD2 (RING3) as risk factors for JME. Both SNPs associated 
individually, although rs3918149 was slightly more significant than rs206787 (odds ratio, 
OR, 2.80 (Cl 1.19-6.64) and 2.21 (Cl 1.08-4.52) respectively). When considered together, 
the two SNPs formed an at-risk haplotype that confers an odds ratio of 4.37 (Cl 1.67 -  
11.45) for developing JME [1 ].
4.1.3 Aims
We sought to replicate the role of BRD2 in JME for two principal reasons. Firstly, both 
linkage and especially association studies have a high incidence of false positive results. 
We wished to determine whether putative risk allele did indeed confer increased risk. 
Secondly, estimation of the odds ratio in samples in which linkage has been identified is 
known to systematically overestimate effects. We wished to calculate a more accurate 
estimate of the true effect. We sought to replicate the role of BRD2 in JME by analyses of 
three independent cohorts of differing ethnicity to determine if the effect was consistent 
across populations.
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Our results support a role for BRD2 (or a nearby gene) in the development of JME in 
European population samples. The variant does not, however, appear to confer a risk in a 
patient population of Southern Indian ancestry suggesting heterogeneity of disease 
causation, differing patterns of linkage disequilibrium (LD), or that the Europeans 
associations are false positives (though this seems unlikely). We were also unable to show 
any effect of the promoter variant on BRD2 mRNA levels and so are unable to identify the 
causal variant.
4.2 Results
4.2.1 Replication in London cohort
The first stage of this study was to attempt replication of the association between BRD2 
promoter variation and JME as reported by Pal et al. [1]. We thus genotyped the two 
candidate causal promoter variants proposed by Pal et al. (rs3918149 and rs206787) in the 
34 JME patients from our London cohort.
Rs3918149 showed a significant level of association at both an allelic (p=0.001) and 
genotypic (p=0.001) level, with the derived allele (A) conferring increased risk. The derived 
homozygous genotype of rs3918149 (“AA”) conferred an OR of 29.1 (2.89-293.03). We 
consider this a clear replication of the Pal et al. association. The second candidate causal 
variant, rs206787 did not associate significantly with JME. Results are shown in Table 4.1.
100
Pal et al. also reported the haplotype defined by the derived state of the two candidate 
causal promoter variants (“AA’) to confer an increased risk of JME (OR=4.37 (1.67-11.45)). 
We assessed the frequency of this haplotype across cases and controls (haplotype 3 in 
Table 4.2) and found it conferred an OR of 2.49 (1.29-4.81), comparable with the original 
report. We also assessed the distribution of all two-locus haplotypes defined by the two 
promoter SNPs across cases and controls using the log-likelihood ratio test and found it to 
be significant (p=0.012). Results are shown in Table 4.2.
Pal et al. reported a five-locus risk haplotype consisting of four SNPs and one microsatellite 
spanning a 2.3kb region of BRD2 to confer an OR of 6.45 (2.36-17.58) (see orange 
coloured SNPs in Figure 4.1 for location in gene). We were unable to identify this haplotype 
in our patient populationxvlM.
Given that rs206787 was the less significant of the two candidate causal variants proposed 
by Pal et al., and that it does not associate with JME here, we no longer considered this 
SNP as candidate causal. The fact that rs3918149 and rs206787 are in high LD (D’=1, 
^=0.117) would suggest the association of rs206787 with JME reported by Pal et al. was 
likely driven by LD with rs3918149.
XVI" The original authors (i.e. Pal et al) did not provide sufficient information in their paper to identify the five 
locus haplotype. Despite acknowledging this via email, they have not provided the required information.
Table 4.1 Association analysis of BRD2 promoter variation in London JME patients and controls.
rs3918149 Patients
n=34
Controls
n=256
OR8
(95% Cl)
p Value RS206787 Patients
n=34
Controls
n=256
OR8
(95% Cl)
p Value
Genotype Genotype
GG 20(0.59) 194(0.78) 1 TT 8(0.24) 86(0.36) 1
GA 11(0.32) 54(0.22) 1.98(0.89-4.38) 0.001" AT 20(0.59) 120(0.50) 1.79(0.75-4.26) 0.375'
AA 3(0.09) 1(0.00) 29.1 (2.89-293.03) AA 6(0.18) 35(0.14) 1.84(0.60-5.70)
Allele Allele
G 51(0.75) 442(0.89) 1 0.001"' T 36(0.53) 292(0.61) 1 0.229'
A 17(0.25) 56(0.11) 2.63 (1.42 to 4.87) A 32(0.47) 190(0.39) 1.36(0.82-2.27)
lumbers are those in which successful genotypes were obtained aOdds ratio 'p value from x2test using 2 degrees of freedom." Empirical p value 
based on 25,000 replicates.'"p value from x2test using 1 degree of freedom."3 Non applicable.
Table 4.2 Haplotype association of promoter variants in London JME patients
ID Rs206787 RS3918149 Freq Cases Freq Controls
1 T G 0.510 0.623
2 A G 0.240 0.264
3 A A 0.231 0.113
4 T A 0.019 0.00
Likelihood ratio test: %2= 10.96, df=3, p=0.0119.
Odds ratio for haplotype “AA” against haplotype “TG” = 2.493 (Cl 1.292 to 4.813)
4.2.2 Screen of BRD2 to identify novel candidate causal variants.
Although rs3918149 associates strongly with JME both here and in the Pal et al. 
study, it is possible that the variant is not itself causal but associating through LD 
with an unidentified causal variant lying elsewhere in the gene. Pal et al., before 
proposing the promoter SNPs as candidate causal, screened all coding exons of 
BRD2 and surrounding genes [1]. However, they did not screen the 2.1 kb of 
untranslated exonic regions, located in three segments upstream and 
downstream of the BRD2 coding region, nor a section of the promoter (see 
Figure 4.1).
Figure 4.1 Graphical representation of variation across BRD2
Figure 4.1 legend: A
graphical representation of 
variation across a 28kb 
region containing BRD2 
considered in this study. 
The BRD2 gene is 
indicated by the arrow. 
Green fill represents 
coding exons, orange fill 
UTR. Solid black horizontal 
lines represent regions 
screened for variation in 
this study. These regions 
were not screened by Pal 
et al. [1]. Blue vertical lines 
indicate variation. Coloured 
variation labels represent 
the following: Blue = 
Hapmap SNP, Red = 
Candidate causal from Pal 
et al.[1], Green = Detected 
here as a result of UTR 
and promoter screen, 
Orange = Variants that 
make up Pal et al. 5 locus 
risk haplotype [1 ]
IVS2+1444
IVS2+450 
IS1049278 \
is11908
rs3918149
>8206784
is3135034
Promo S1 UTR3
Promo S2
UTR1 UTR2 S I UTR S3UTR2 S2
28 kb
In an attempt to identify novel candidate causal variants, we screened these 
regions in 16 unrelated CEPH individualsxlx. The screen resulted in the detection 
of 14 SNPs, eight of which were previously unreported (see Table 4.3 for SNP 
details).
Inference of haplotypes generated by variation across BRD2 allows 
characterisation of the relationship between SNPs in the region. This information 
can be used as a guide to select novel candidate causal variation.
4.2.3 Using the haplotypic structure of BRD2 to identify novel candidate 
causal variants.
We genotyped the 14 SNPs discovered in the screen, the two candidate causal 
promoter SNPs and four SNPs from the Pal et al. five-locus risk haplotype in the 
same European American samples used in the HapMap project. This allowed 
genotypes from these 20 SNPs to be merged with genotypes from HapMap (five 
SNPs in BRD2), thus creating a dataset of 25 SNPs spanning the BRD2 gene 
(i.e. all SNPs named in Figure 4.1).
The haplotypes inferred from these data, and the resulting network constructed 
from these haplotypes, are shown in Table 4.4 and Figure 4.2 respectively.
XIX See section 2.6 for details of protocol used in this screen.
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Table 4.3 SNPs discovered in BRD2 screen
SNP name Location Sequence context /[CEPH EU]
I VS 1+95 5‘ UTR ggcccccttg[l/D]ccccttggcgc 0.04
IVS2+450 5‘ UTR ccgcggagag[G/A]tgttccttccc 0.02
IVS2+870 5' UTR ctcggagtct[G/A]tccaccccctc 0.04
IVS2+1183 5' UTR tttgtcgcct[G/C]gaggcccaaga 0.06
IVS2+1437 Int 2 gcgcgctgct[G/C]ttgcggcgcag 0.04
IVS2+1444 Int 2 gctgttgcgg[C/T]gcagctgtcg 0.01
IVS14+117 3' UTR gacaaaacaa[C/T]attgaattccc 0.04
I VS 14+226 3‘ UTR ggagtgatct[C/G]ttggacacaga 0.05
/[CEPH EU] -  Minor allele frequency in CEPH Europeans, UTR=untranslated region. lnt=lntron
Table 4.4 BRD2 haplotypes inferred in CEPH American Europeans
ID F 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
HP1 0.27 T T T T G G T N T G T G G G C T T C T G T c C T T
HP2 0.11 T C T A G G T N T G T G G G C G C T del G C c c T T
HP3 0.11 T C T T G G T N T G T G G G C G T C T G T c c T T
HP4 0.09 T c C A G G C N T G T G G G c G C T del C C c c T C
HP5 0.07 T c T T G G T N T G T G G G c G T C T G C c c T T
HP6 0.06 A c T A G G T N T G G G G G c G C T del G c c c C T
HP7 0.06 T T T T G G T N T G T G G G c G T C T G T c c T T
HP8 0.05 T c T A A G T N T G T G G G c G C T del G c c G T T
HP9 0.02 T T T T G G T N T G T G G G c G T C T G c c C T T
HP10 0.02 T C T T G C T I/D T G T A G C c G T C del G c T C T T
HP11 0.02 T T T T G G T N T A T G C G c T T c T G T c C T T
HP12 0.02 T C T A A G T N T G T G G G c G C T del G c c C T T
HP13 0.02 T C T A G G T N T G T G C G c G C T del G c c c T T
HP14 0.01 T T T T G G T N T G T G C G c G T C T G T c c T T
HP15 0.01 A C T A G G T N T G G G G G c T C T del G c c c C T
HP16 0.01 A C T A G G T N T G G G G G c G C T del G c c c T T
HP17 0.01 A c T T G G T N C G G G G G c G T C T G c c c C T
HP18 0.01 T c T T G C T I/D T G T A C C c T T C del G c T c T T
HP19 0.01 T T T T G C T I/D T G T A G C c G T c del G c T c T T
HP20 0.01 T T T T G G T N T G T G C G T G T c del G c c c T T
HP21 0.01 T C T T G G T N T G T G C G T G T c del G c c c T T
f=  frequency HP=HaplotypeSNP coding: 1=rs313 5 4 0 4 ,2=rs206784,3=rs1367727, 4=rs206787, 5=rs3918149, 
6=rs3918150, 7=rs9276935, 8=IVS1+95, 9=rs1049278 ,10=IVS2+450,11=rs974357,12=IVS2+870,13=IVS2+1183, 
14=IVS2+1437, 15=IVS2+1444, 16=rs620202,17=rs516535,18=rs635688,19= rs2066741, 20=rs15912, 21=rs11908, 
22=IVS14+117, 23=IVS14+226, 24=rs1049526, 25=rs3135034
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Figure 4.2 Network of BRD2 haplotypes
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Figure 4.2 legend: A reduced median joining network illustrating haplotypes of BRD2. Coloured 
variation labels represent the following: Blue = HapMap SNP, Red = Candidate causal from Pal 
et al., Green = Detected here as a result of UTR and promoter screen, Orange = Variants that 
make up Pal et al. 5 locus risk haplotype. Filled yellow circles represent haplotypes. The size of 
the circle is directly proportional to the frequency of the haplotype as observed in CEPH 
American Europeans.
The network depicts the genealogical relationship between haplotypes of BRD2. 
SNPs found on the same branch of the genealogy are in complete LD (r2=1). 
Haplotype HP12 represents the risk haplotype defined by the derived state of the 
candidate causal variant rs3918149. We calculated r2 values between each SNP 
and rs3918149 in order to quantify the relationship between the candidate causal 
variant and other SNPs. Any variants in high r2 values with rs3918149 can be 
considered as novel candidate causal variants and thus warrant examination for 
association in the patients and controls.
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In this context, the SNP IVS14+226 is of particular interest. This previously 
unreported variant lies in the same region of the genealogy as, and is in high LD 
(D’=1, ^=0.7) with, rs3918149. The derived form of the variant defines haplotype 
HP08 (see Figure 4.2). Analysis of this variant in the London JME cohort showed 
the variant associated significantly (see Table 4.5). However this association was 
likely due to LD with rs3918149 as the association was not as strong as that 
between rs3918149 and JME.
Table 4.5 Association analysis of IVS14+226 in London JME patients and 
controls.
IVS14+226 Patients
n=34
Controls
n=256
OR8
(95% Cl)
p Value
Genotype
CC 26(0.76) 217(0.90) 1
CG 8(0.24) 23(0.10) 2.9(1.78-7.15) 0.062'
GG 0(0.0) 1(0.0) na
Allele
C 60(0.88) 457(0.95) 1 0.032"
G 8(0.12) 25(0.05) 2.44(1.05-5.65)
Numbers are those in which successful genotypes were obtained. 
aOdds ratio ‘p value from x2test using 2 degrees of freedom.
“ Empirical p  value based on 25,000 replicates.
"'p value from x2test using 1 degree of freedom'*8 Non applicable.
SNPs defining the branches representing haplotypes HP04, 06 and 13 are all in 
low r2 with rs3918149 (r2<0.007). It is thus highly unlikely that the causal variant 
lies on any of these haplotypes. Haplotype HP02, defined by rs206787, shows 
borderline association in the report of Pal et al., and no association here, and 
thus is not considered as candidate causal. Variants lying on branches of the
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genealogy defined by the ancestral allele of rs206787 (i.e. haplotypes 
HP1,3,5,7,9-11 and 14) are all in low r2 (<0.096) with rs3918149 and thus 
similarly highly unlikely to harbour the causal variant.
4.2.4 Replication of rs3918149 in a population of Irish ancestry.
To further rule out the possibility of a false positive, we examined the role of 
rs3918149 in an independent cohort of Irish ancestry. The association was 
borderline significant (genotype p=0.077, allele p=0.043). Unlike the London 
cohort it did not show a clear replication. Results are shown in Table 4.6.
Table 4.6 Association analysis of rs3918149 in Irish JME patients and 
controls
rs3918149 Patients Controls OR p Value
n=57 n=227 (95% Cl)
Genotype
GG 43(0.75) 196(0.86) 1
GA 13(0.23) 29(0.13) 2.04 (0.98-4.25) 0.077'
AA 1(0.02) 2(0.01) 2.28 (0.20-25.71)
Allele
G 64(0.87) 421(0.93) 1 0.043"
A 8(0.13) 33(0.07) 1.93(1.01-3.70)
Numbers are those in which successful genotypes were obtained. 
aOdds ratio 'p  value from x2 test using 2 degrees of freedom.
“'Empirical p value based on 25,000 replicates."'p value from x2test using 1 degree of freedom 
na Non applicable.
4.2.5 The role of rs3918149 in the development of other common forms of 
epilepsy.
We next wished to examine if the rs3918149 plays a role in the development of 
other forms of epilepsy. We therefore assessed this variant in our full panel of 
678 patients with epilepsy from the London cohort. We tested for association with 
a) all forms of epilepsy, b) IGE excluding JME, c) focal cryptogenic epilepsy, and 
d) focal symptomatic epilepsy. Considering that we are testing one polymorphism 
across four forms of epilepsy, we applied a significance threshold of 0.0125xx. 
Using this threshold there are no significant associations. We do note however, 
a trend with cryptogenic epilepsy (p=0.068). Results are shown in Table 4.7.
Table 4.7 Association analysis of rs3918149 with other forms
of epilepsy in London cohort.
Rs3918149 Controls
n=256
All Epi
n=678
IGE-JME
n=61
FC
n=200
FS
n=269
Genotype
GG 194(0.78) 457(0.76) 43(0.75) 134(0.76) 184(0.78)
GA 54(0.21) 131(0.22) 13(0.23) 36(0.21) 50(0.21)
AA 1(0.004) 12(0.02)
0.239'
1(0.02) 6(0.03) 1(0.004)
P 0.395" 0.068" 1"
Allele
G 442(0.89) 1045(0.87) 99(0.87) 304(0.86) 418(0.89)
A 56(0.11) 155(0.13)
0.341'
15(0.13) 48(0.14) 52(0.11)
P 0.56' 0.29' 0.928'
Numbers are those in which successful genotypes were obtained
'p  value from x2 test between case and control group using 2 degrees of freedom.
" Empirical p value between case and control group based on 25,000 replicates
** Bonferroni correction used here. The method is described in section 1.4.4.
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4.2.6 Is rs3918149 a risk factor JME in India?
We next sought to identify a third population in which to test the association with 
JME detected in the London and Irish cohorts. In doing so, we wished to identify 
a population that would maximise the likelihood of replication, should the 
association indeed be real.
Knowledge of risk allele frequency helps identify populations with substantially 
greater power of detection. We thus assessed the frequency of the risk variant 
(rs3918149) in healthy individuals across a global panel of populations. Results 
illustrated in Figure 4.3 indicate that populations of Asian ancestry appear to 
carry the risk allele at a higher frequency and therefore may be better powered to 
replicate the association™.
XXI Power calculations are detailed in section 2.9.3. Note that as direct positive replications are 
better estimators of genetic effect than original reports, we used, to calculate power of detection, 
relative risk values as determined from the London cohort presented here.
Figure 4.3 The frequency of rs3918149 across 8 global populations
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Figure 4.3 legend: A diagram 
illustrating the frequency of the 
risk variant rs3918149 across 8 
global populations. Each 
population is represented by a 
bar chart indicating the 
frequency of the variant in black 
and the power of detection in 
grey. Parameters used in power 
of detection calculation are 
detailed in materials and 
methods section 2.9.3. IRL = 
Ireland, NOR = Norway, ITA = 
Italy, CAM = Cameroon, ETH = 
Ethiopia, S. IND = South India, 
CHN = China, PNG = Papua 
New Guinea
Given these results, we tested the association in a population of JME patients 
collected in Southern India. The variants failed to show significant association 
with JME, or even any trend in that direction. Results are shown in Table 4.8.
Table 4.8 Association analysis of rs3918149 in
Southern Indian JME patients and controls.
rs3918149 Patients Controls ORa p Value
n=48 n=144 (95% Cl)
Genotype
GG 27(0.56) 82(0.57) 1
GA 16(0.34) 46(0.32) 1.05 (0.52-2.16) 0.980'
AA 5(0.10) 16(0.11) 0.95 (0.32-2.83)
Allele
G 70(0.73) 210(0.73) 1 1'
A 26(0.27) 78(0.27) 1 (0.59-1.68)
Numbers are those in which successful genotypes were obtained. aOdds ratio ' p  value 
from x2test using 2 degrees of freedom. "Empirical p  value based on 25,000 replicates, 
"p  value from x2 test using 1 degree of freedom.na Non applicable.
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4.2.7 A functional assessment of rs3819149
Finally, we wished to assess the functionality of rs3918149. Given the location of 
the variant in the promoter of the gene, we hypothesised the variant plays a role 
in influencing mRNA expression. To examine this, we carried out quantitative RT- 
PCR analysis on 40 samples of temporal neocortex from patients who had 
undergone resective surgery for refractory temporal lobe epilepsy™1. Genotyping 
of these samples at the candidate causal variant, rs3918149, revealed 29 
(72.5%) of the patients to be “GG” and 11 (27.5%) to be “GA”. No homozygote 
patients for the risk allele “AA” genotype were observed.
The mRNA values were normalised over ACTB and shown to be normally 
distributed (K-S test P-value >0.05). The median expression levels for “GG” and 
“AG” genotypes were 1.39 ± 0.57 and 1.21 ± 0.32 respectively. The resulting 
ratio of mRNA expression for “AG” relative to “GG” genotype was 0.87. This 
result is non significant at the 5% level (K-W test, x2=0.64, df=1, p=0.42). Results 
are shown in panel “A” of Figure 4.4.
xx" See section 2.7 for methodology
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Figure 4.4 A plot of the relative BRD2 mRNA levels in neocortical 
temporal lobe brain tissue categorised according to rs3918149 genotype
A) Temporallobotomy. Drug-re sis taut epilepsy
K-Wjp® 0.64, df = 1,p-value = 0.4237
B) Post-mortem Parkinson’s disease
i "
K-Wx^= 0.3478, df= 2,_p-value = 0.8404
Figure 4.4 legend: A diagram indicating expression levels of BRD2 mRNA categorised 
according to rs3918149 genotype. In the case of both plots, the X axis represents rs3918149 
genotype, the Y axis mRNA expression levels. The mean, range and 95% confidence intervals of 
mRNA expression for each genotype category are indicated. Results in plot “A” are from temporal 
neocortical brain tissue from temporal lobe epilepsy patients having gone anterior temporal 
lobectomies. Results in plot “B” are from temporal neocortex brain tissue samples from a 
Parkinson’s disease brain bank.
Given that we were limited to brain tissue from 40 from epilepsy patients, none of 
which carried the risk “AA” genotype at rs3918149, we assessed mRNA levels in 
a separate cohort of temporal neocortex brain tissue samples from a Parkinson’s 
disease brain bank selected based on rs3918149 genotype (10 x “GG”, 10 x 
“GA”, 3 x “AA”). The median expression levels for “GG”, “AG” and “AA” 
genotypes were 4.16 ± 1.98, 3.42 ± 2.6 and 3.52 ± 1.28 (see Figure 5). The 
resulting ratios of mRNA expression relative to “GG” genotype were 0.82 for “AG” 
and 0.85 for “AA”. These results are not significant at the 5% level (K-W test, 
%2=0.35, df=2, p=0.84). Results are shown in panel “B” of Figure 4.
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Our conclusion from mRNA analysis was that the rs3918149 variant does not 
appear to play a role in influencing expression levels of BRD2 mRNA, at least not 
in the developed adult brain.
4.3 Discussion
When assessing the contribution of genetic variation to complex disease follow- 
up studies are essential in order to distinguish false positives from true 
associations. Whilst variation in several genes has been linked to common forms 
of IGE (OPRM1[ 176], SLC4A3[ 177], ACP1[178], LGI4 [53], CACNA1A [32], 
GABRB3{ 179], GRIK1[ 180] and /CCA/J3[181]), few follow-up replication studies 
have been reported. In cases where they have, results have been conflicting (i.e. 
CACNA1A [182] and <3R//(7[183], for review see [156]).
Taking this into account, the set of variants that have been reliably associated 
with complex, common diseases is still small, although growing [68]. Currently 
there are no examples for epilepsy among the set that appears to have broad 
acceptance.
We have shown a clear replication of the BRD2 association in the London cohort 
and a borderline replication in the Irish population. We would consider the Irish 
result a very encouraging trend supporting the notion that the association is likely 
real. When considered in context with previous reports, these results support the
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notion that variation in BRD2 acts as a marker of increased risk for JME. Further, 
these results propose this association to be the most robust example to date of 
common variation predisposing to a form of epilepsy.
Power calculations showed a strong sensitivity to minor allele frequency. The 
weakened effect observed in the Irish sample may be a consequence of the 
slightly lower risk allele frequency compared to the London sample. Given the 
observation of increased risk allele frequency in Asian populations, we sought to 
replicate the association in a population of Southern Indian origin. Surprisingly, 
although we had considerably higher power of detection in the Southern Indian 
population (88% compared to 32% in Ireland), we found no association. Our 
results therefore showed the effect to be robust in populations of European 
origin, but apparently absent in the one Asian population studied here.
One explanation for this discrepancy is that the European results may be false 
positives. Isolated cases of replication do not always indicate a real effect [74], 
and it must be kept in mind that our sample sizes have been low. However, since 
three associations in populations of European ancestry have been significant, the 
weight of evidence would seem to favor a role for BRD2 as a marker for JME. 
Should this indeed be the case, we see three possible explanations for the lack 
of association in the Indian cohort.
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Firstly, it is possible that rs3918149 is not itself causal but rather a marker, 
associating through LD with the causal variant. The lack of association in the 
Southern Indian population would be explained by different patterns of LD 
between the marker and causal variant in European and Asian populations. If so, 
the extensive efforts in screening BRD2Xo date would suggest it more likely that 
the causal variant lies in a region outside of BRD2. Indeed, LD levels are high 
across the 150kb region containing BRD2, HLA-DMA, HLA-DMB and HLA-DOA. 
Although Pal et al. screened coding regions of these genes, it is not impossible 
the causal variant was missed. For example, we calculated that a SNP 
genotyped as par* of the HapMap project, the non-synonymous variant 
rs1063478 lying in exon 2 of HLA-DMA, is in near complete LD with rs3918149 
(D’=1, ^=0.86) in Europeans.
The second explanation is genetic heterogeneity with different genes and/or 
alleles contributing to disease in different populations. Indeed, evidence for 
genetic heterogeneity exists from a previous linkage study where it was noted 
that linkage was based almost entirely on families of European origin [80, 87]. 
Families of non-European origin did not show evidence for linkage to EJM1 
markers. Related to this, the functionality of BRD2 variation in JME may be 
dependent on interactions with population-specific environmental factors. 
Promoter variation is arguably more likely to respond to environmental changes 
than other, typically functional variation (e.g. coding). As such, rs3918149 as a 
causal variant would fit with this theory. Recent research on the population
116
specificity of genetic variation functional in diseases would suggest population- 
specific functionality unlikely [68]. It must be noted, however, that this conclusion 
emerges from a lack of evidence for differences among populations rather than 
positive evidence that effects were the same [184].
The third explanation is that variation interacts in a trans-like manner to cause 
JME. That is, a general IGE risk locus interacts with a JME specific locus leading 
to disease development. Should the suspected general IGE risk locus be at a low 
frequency in a given population, then the apparent contribution of BRD2 to the 
development of JME in that population would be negligible. Indeed there is 
support in the literature for such a scenario. Comparison of LOD peaks 
generated from linkage studies involving heterogeneous cohorts of IGE led to the 
proposal of an oligogenic model whereby variation at general risk loci interacts 
with variation across specific loci to produce characteristic forms of IGE such as 
JME, juvenile absence epilepsy and epilepsy with generalised tonic clonic 
seizures only ([1, 87, 95]). The EJM1 locus has been shown independently to be 
the site of a strong LOD peak for linkage analysis in JME samples, but the peak 
disappears when non-JME IGE samples are examined [85, 95, 105, 185]. The 
fact that we observed the association only for JME, and not other forms of IGE, is 
consistent with the hypothesis that EJM1 /BRD2 represents a risk locus specific 
to JME. Should the oligogenic model hold, it is possible that the variant with 
which BRD2 interacts to confer risk in Europe is absent or rare in India. The 
nature of the data presented here, however, is such that we cannot confirm both
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aspects of the oligogenic model, in particular the presence of general risk loci as 
suggested by linkage mapping [95] and follow-up association [186]. We do note, 
however, that we were unable to replicate the Malic enzyme 2 result (data not 
shown). It is now important to try and find such a variant to further understand the 
role of BRD2. In the absence of such identification or other explanation of the 
discrepancy, we must still consider the heterogeneity scenario as hypothetical.
The results of mRNA analysis presented here show no evidence that rs3918149 
influences BRD2 expression. However, our analysis was limited to post-mortem 
tissue from fully developed temporal lobe of adult brain. The effect of the agonal 
period on mRNA expression levels is unclear but likely substantial. In addition, 
when considered in the context of JME, neither refractory focal epilepsy or 
Parkinson’s disease patients are ideal for studying the role of mRNA expression 
in JME. As such it is possible the variant is in fact functional, but that our assay 
was unable to detect an effect.
Although the results shed some light on the issue, the role of BRD2 in JME 
remains unresolved. Further replication in populations of European origin would 
provide a solid foundation for a wider mapping project that seeks to examine, in 
detail, variation in surrounding genes. Indeed, follow-up mapping studies would 
need to be extensive as the low frequency of the risk variant would allow LD to 
extend for long distances both upstream and downstream of BRD2.
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These findings suggest that association analysis in a genomic region identified 
(and preferably replicated) in linkage studies may be a successful approach to 
identify susceptibility genes for common forms of epilepsy. These results 
motivate the use of this strategy in other known candidate regions for IGE in 
which no gene has been identified yet [78, 79, 95, 187].
Chapter 5 A pharmacogenetic exploration of 
vigabatrin-induced Visual Field Constriction
5.1 Introduction
5.1.1 Vigabatrin
Vigabatrin is an effective anti epileptic drug (AED) licensed for use as an add-on 
therapy for partial epilepsy. Although its efficacy is similar to that other AEDs, it is 
particularly useful for treating infantile spasms where its efficacy appears to 
outweigh that of any other AED [188, 189]. Indeed Vigabatrin has been reported 
to be as effective as hormonal treatment for both controlling spasms and 
preventing neurodevelopmental decline in this otherwise very disabling condition 
[190]. In fact, it is widely known that in regions where the drug is unlicensed due 
to the side-effect profile, physicians regularly import Vigabatrin on a named- 
patient basis.
5.1.2 Vigabatrin induced irreversible visual field constriction
The use of Vigabatrin is severely limited by the development of retinopathy 
causing irreversible visual field constriction. This adverse reaction to the drug 
was first reported in 1997 [191] and is estimated to occur in approximately 40% 
of patients, although estimates of prevalence vary widely [135, 136, 192-197].
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The natural history of the adverse drug reaction (ADR) is poorly understood, but 
there are a number of features that suggest the response to be idiosyncratic. 
Firstly, clinical experience shows that some patients, despite taking large doses 
of Vigabatrin over prolonged periods, fail to develop the ADR, while in others 
quite severe constriction appears to develop relatively rapidly. The extent of 
constriction can also vary markedly between affected individuals despite 
comparable dosing. Secondly, although most of the available data are 
retrospective, the findings with regard to dose-relationship are inconsistent, with 
a number of studies reporting the development of visual constriction to be 
unrelated to the daily or cumulative dose of the drug or the duration of therapy 
[135,198,199]. We wished to consider whether genetic variation in genes 
thought to play a role in the development and severity of Vigabatrin retinopathy 
could be used as a guide for predicting the severity of the ADR. Discovery of 
such variants may allow for safe individualized prescribing of Vigabatrin, similar 
to the use of mercaptopurine in chemotherapy [200], and thus the resurrection of 
an essentially orphaned drug.
5.1.3 The pharmacology of Vigabatrin
The pharmacology of Vigabatrin is relatively well understood, making it a good 
candidate drug for pharmacogenetic research. The drug works by irreversibly 
inhibiting GABA transaminase, the enzyme that metabolizes gamma- 
aminobutyric acid (GABA) the principal inhibitory neurotransmitter in the brain.
121
After oral intake of Vigabatrin, about 10% of the drug crosses the blood-brain 
barrier [188]. However, in animal models the drug has been shown to accumulate 
in the retina at concentrations up to 18.5 times that of brain [201, 202]. The 
precise mode of transport into the brain and retina is unclear but data suggest it 
is via one of the high affinity GABA transporters (GAT 1-4) [203-205]. In animal 
models, the drug appears to be taken up in the retina principally by the amacrine 
cells, expressing GAT-1 [205]. Vigabatrin-induced increased intracellular 
concentration of GABA reverses plasma membrane-expressed GABA transporter 
function causing GABA to be transported out of the cell resulting in a large rise in 
ambient GABA concentration [206]. This rise in ambient GABA increases tonic 
inhibition via its action on post-synaptic GABA receptors, including GABAa and 
GABAc receptors GABAc receptors are a specialized type of GABA receptor 
located almost exclusively in the retina [207]. The highest concentration of these 
receptors is on axon terminals of rod bipolar cells, the predominant neuron in the 
peripheral retina, the region principally affected by Vigabatrin toxicity, as 
evidenced by the loss of peripheral vision. Elevated concentration of GABA can 
reverse chloride currents at GABA receptors, causing depolarization of the cell 
leading to a potentially cytotoxic calcium influx [208]. Although speculative, the 
drug may cause retinal toxicity in this manner.
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5.1.4 Selection of candidate genes
Selection of our candidate genes focused on presumed transporters of Vigabatrin 
into the retina, its target enzyme GABA transaminase, and the GABAC receptor. 
We selected the following candidate genes: GABA transporters GAT1-3 
(SLC6A1, SLC6A13, SCL6A11), GABA transaminase (ABAT), and the rho 
subunits of the GABAC receptor (GABRR1 and GABRR2). An overview of the 
selection of candidate genes is shown in figure 5.1
Figure 5.1 Diagram of the retina showing sites relevant to 
pharmacogenetic study of vigabatrin toxicity
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transporters 
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3. Effect of 
high dose 
GABA => 
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receptor
Figure 5.1 legend: (1) Vigabatrin enters the retina via GABA transporters. (2) Within amacrine 
cells, Vigabatrin targets the enzyme GABA transaminase. (3) The resultant high ambient GA 
BA concentrations may result in toxicity through its effect on GABAc receptors located at the terminal 
of bipolar cells.
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5.1.5 Aims
We wished to test the hypothesis that common, functional variation in these 
candidate genes increases the risk of developing this ADR. Specifically, we are 
interested in detecting variants of strong, clinically relevant effect; variation that 
would be beneficial in guiding clinicians in prescribing Vigabatrin. We thus 
examined the correlation between variation in selected candidate genes and the 
amount of Vigabatrin-induced visual constriction. To ensure a thorough analysis, 
we have availed of recently made available HapMap data allowing the application 
of the tagging single nucleotide polymorphism (tSNP) method [209]. We have 
performed the study in two independent cohorts of sporadic epilepsy patients, 
allowing more robust conclusions to be made from the results.
5.2 Methods
Details of tag SNP selection, genotyping and visual field assessment are 
described in the methods chapter sections 2.8.4, 2.3 and 2.10 respectively
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5.2.1 Subjects
The first cohort, termed the Dublin cohort, consisted of 73 patients recruited at 
the epilepsy clinic at Beaumont Hospital, Dublin, Ireland. The second cohort, 
termed the London cohort, consisted of 58 cases recruited at the epilepsy referral 
centre at the National Hospital for Neurology and Neurosurgery, London, United 
Kingdom. Patients were selected based on a history of current or prior exposure 
to Vigabatrin without prior knowledge of the results of visual field testing. To be 
included in the study patients must have been exposed to Vigabatrin for at least 
one year. For each patient we recorded age, sex, epilepsy diagnosis, duration of 
Vigabatrin therapy, cumulative dose and exposure to other medications. We 
included patients who were not currently taking Vigabatrin as the general 
consensus in the literature is that, with the exception of isolated case reports, the 
development of visual constriction is irreversible [210, 211]. Patient 
characteristics for the two groups are shown in Table 5.1.
Table 5.1 Summary of patient dosing data for Dublin and London 
cohorts
Dublin (n=73) London (n=58)
#Male/#Female 
Mean Age (years)
Mean VGB Daily Dose(mg) 
Mean VGB Duration (years) 
Mean VGB Cumulative Dose (g)
38/35 33/25 
36.7 38.1 
2060.4 2663.8 
7.2 6.1 
5380.8 6502.2
VGB - Vigabatrin
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5.2.2 Study design
We applied, using HapMap data, a tagging SNP strategy that seeks to represent 
most, or all, common variation across the candidate genes. Data generated by 
the HapMap project allow the quantification of linkage disequilibrium (LD) 
between variants and hence the selection of tSNPs for any gene or region across 
the genome.
In the Dublin cohort we examined the correlation between tSNPs and Vigabatrin- 
induced visual constriction. In the London cohort we attempted replication of any 
significant associations found in the Dublin cohort. We considered for replication 
any variant or haplotype associating significantly with the ADR in the Dublin 
before correction for multiple testing™1. We then corrected in the London cohort, 
but only for the number of tests undertaken in that same cohort. This 
methodology simultaneously reduces the incidence of type-1 and type-2 errors.
5.2.3 Statistical analysis
Association was examined at both the single SNP and haplotype level. We 
assessed the correlation between single SNPs and MRD using multiple linear
XX1" Using Bonferroni method
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regression. We modeled considering both additive and dominant effects for each 
tSNP. We assessed the correlation of haplotypes generated by tSNPs with MRD 
values by calculating score statistics using the package haplo.score in 'R' [128, 
212]. Briefly, this method uses generalized linear models to generate score 
statistics that can be used to examine the correlation between expectation- 
maximization (EM) generated haplotypes and the trait of interest. When 
generating score statistics, we only considered haplotypes observed at a 
frequency of 1% or greater. The likelihood of spurious inference by the EM 
algorithm increases with lower frequency haplotypes. MRD values were 
normalized where required.
Given that we intended to replicate any association detected in the Dublin cohort, 
we did not correct for multiple testing in that cohort and applied a significance 
threshold of 0.05. We considered as significant in the London cohort, only those 
associations that remained significant after Bonferroni correction for the relevant 
number of tests in the London cohort.
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5.3 Results
5.3.1 Summary of clinical data
Demographic and drug-exposure data for both cohorts are shown in Table 5.1. In 
The Dublin cohort, 64 of the 73 patients were taking Vigabatrin at the time of 
their initial assessment. Using the estimated unaffected population cut-off of 
49.3 degrees, 39 of the 73 patients in the Dublin cohort (53%) were considered 
as having constricted fields. In the London cohort, 45 of the 58 patients were 
taking Vigabatrin at the time of their initial assessment. Using the estimated 
unaffected population cut-off of 47.6 degrees, 45 of the patients in the London 
cohort (76%) could be considered as having constricted fields. The distribution of 
MRD values in both populations is shown in Figures 5.2 and 5.3™w.
XXIV Note that as a different isopter was used in each cohort, direct comparison of figures 5.2 and 
5.3 is not possible
Figure 5.2 Distribution of mean radial degrees as measured by Ill4e
isopter from Goldman field tests in the Dublin cohort
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MRD -  Mean radial degrees. The MRD value represents the level of visual field constriction. The lower the MRD value, 
the more constricted the visual field. (The technique for calculating MRD is described in section 2.10.1).
Figure 5.3 Distribution of mean radial degrees as measured by I4e isopter
in the London cohort
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MRD -  Mean radial degrees. The MRD value represents the level of visual field constriction. The lower the MRD value, 
the more constricted the visual field. (The technique for calculating MRD is described in section 2.10.1).
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5.3.2 tSNP selection
In total, we found 32 tSNPs to be sufficient to satisfy our tagging criteria. These 
tSNPs therefore represent, with minimal loss of power, the vast majority of 
common variation across the six genes included in this study. We found it more 
efficient, due to long range LD, to consider genes located adjacent to each other 
(i.e. GABBR1/GABBR2 and GAT1/GAT3) as single entities for tagging purposes. 
As such, these four genes are considered as two pairs in association analysis. 
Details of selected tSNPs are shown in Table 5.2
Table 5.2 Details of tSNP selection
tSNP# GABRR1/2 ABAT GAT2 GAT1/3
1 rs2297309 rs1345300 rs495360 rs1485142
2 rs1796740 rs3095512 rs2289954 rs1881354
3 rs282123 rs4984996 rs124440 rs746278
4 rs6902106 rs1640989 rs555044 rs2601126
5 rs9294426 rs1731017 rs10774021 rs1710891
6 rs2273508 rs3815508 rs525797 rs1062246
7 rs2148174 rs1641021 rs520932 rs971930
8 rs1570932 rs12049 rs2304725
9 rs3777514
~r2 0.92 0.88 0.98 0.90
haplotypes defined by tSNPs and the tagged SNPs. This is a direct measure of tSNP 
performance.
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5.3.3 Single SNP association analysis
Single SNP regression analysis in The Dublin cohort resulted in the detection of 
three significant associations between single tSNPs and MRD values 
(GABRR1/2tSNP6, GAT1/3XSNP7 and GA72tSNP6).
In the case of GABRR1/2tSNP6, an intronic variant, the minor allele (“A”) was 
associated with an increased risk of developing visual field constriction 
(p=0.027). The average MRD value for the ten individuals carrying the 
heterozygote genotype was 37.7 degrees compared to 45.8 degrees for the 
major allele homozygote. Although the sole individual carrying the homozygote 
risk genotype (“AA”) did not show constriction (MRD = 57 degrees), it is 
impossible to make conclusions based on this one observation. A plot of MRD 
values against GABRR1/2tSNP 6 genotype is shown in Figure 5.4
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Figure 5.4 Distribution of mean radial degree values with GABRR1/2 tSNP 6
genotype in the Dublin cohort.
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MRD -  Mean radial degrees. Values in brackets represent mean MRD value for that genotype.
In the case of GAT1/3 tSNP7 (intronic), the major allele (“A”) was associated with 
increased risk of developing the ADR (p=0.047). Homozygote carriers of the risk 
genotype (“AA”) had an average MRD of 40 degrees compared to 45.8 degrees 
for carriers of the homozygote protective “CC”. A plot of MRD values against 
GAT1/3 tSNP7 genotype is shown in Figure 5.5.
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Figure 5.5 Distribution of MRD values with GAT1/3 tSNP 7 genotype in
the Dublin cohort
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MRD -  Mean radial degrees. Values in brackets represent mean MRD value for that genotype.
Finally, the minor allele (“T”) of GAT2tSNP6 (intronic) was associated increased 
risk with heterozygote carriers having an average MRD value of 38.6 degrees 
(p=0.05). No individuals homozygote for the risk allele were observed in The 
Dublin cohort. A plot of MRD values against GA72tSNP6 genotype is shown in 
Figure 5.6.
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Figure 5.6 Distribution of MRD values with GAT2 tSNP 6 genotype in the
Dublin cohort.
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MRD -  Mean radial degrees. Values in brackets represent mean MRD value for that genotype.
5.3.4 Haplotype association analysis
At the haplotype level, the global statistic generated by GAT2 haplotypes showed 
a significant correlation with MRD values (p=0.012). This result would suggest 
that either a single haplotype or a combination of haplotypes is correlating with 
MRD values. Indeed, one haplotype of GAT2 showed a significant correlation, 
with carriers of this haplotype having a lower MRD reading than the Vigabatrin- 
exposed population average (p=0.039). Haplotypes generated by other tSNPs 
failed to show significant correlation with MRD values.
5.3.5 Attempted replication in the London cohort
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We carried forward these five significant results for replication in the London 
cohort. However, we failed to replicate or show any trends towards significance 
for any of the single SNP or haplotype associations detected in the Dublin cohort.
5.4 Discussion
We have tested the hypothesis that common variation of strong, clinically 
relevant effect, exists in the selected candidate genes. Detection of such 
clinically relevant variation might allow the safe prescribing of this drug to a 
subset of patients. In the Dublin cohort, we detected three single SNP variants, 
and two haplotypes that showed significant association with the extent of 
Vigabatrin-induced visual field constriction. However, we were unable to 
reproduce these results in the London cohort suggesting that the initial findings 
are likely to represent false positive results. As such, our results do not the 
support the notion of clinically relevant variation residing in these genes.
Although we feel that the marginally significant associations detected in the 
Dublin cohort are likely to be false positives, we have not definitively ruled out an 
effect for these variants. It is entirely possible that these variants are indeed 
functional, or perhaps more likely tag functional variants of small to medium 
effect that influence the development of Vigabatrin-induced visual field 
constriction. Should this be the case, our study is clearly underpowered.
Similarly, as the tagging method is known to perform poorly in capturing low
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frequency variation, we have not ruled out the presence of rare functional 
variation in these six genes. A large patient population would help address the 
issue of power but such a collection is difficult to collect, given that few 
individuals are currently exposed to, or initiated on Vigabatrin.
Natural selection dictates that it is extremely rare for disease causing variation of 
strong effect to be observed at a high frequency in a population. Variants 
associated with altered drug pharmacology, on the other hand, may be 
evolutionarily silent in the absence of a substrate (in this case the drug 
Vigabatrin) and thus variants of strong effect may drift to high frequency in the 
population, as is evident from pharmacogenetic studies of chemotherapeutic 
agents [213-215].
Other confounding factors must also be considered as a potential explanation for 
our failure to detect any clear associations. Although every effort was made to 
exclude unreliable Goldmann fields, the subjective nature of the test introduces 
unavoidable variation to the measurement. For example, the rate at which the 
test object is moved, and the promptness with which the subject reports its 
appearance are not always consistent. This is especially true for patients where 
only one test was recorded. Even in subjects without retinal defects, repeat 
testing has shown that visual fields may vary by up to 14% in individuals [216].
Further, although prospective data on the natural history of the retinopathy are 
lacking, case reports do exist that suggest, at least in some cases, substantial
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recovery of vision after discontinuation of the drug [217, 218]. If this were the 
case, any genetic signal would be obscured under our current study design. 
These isolated cases may have resulted from erroneous recording of either the 
initial or follow-up result, but one cannot out rule the possibility that a small 
subset of patients exist in whom real improvement does occur.
We felt that our gene selection represents the most appropriate front-line 
candidates based on what is understood of Vigabatrin pharmacology, but it is 
entirely possible that variation in other genes is responsible for the ADR. There is 
some evidence from mice models to suggest that the GAT-4 (BGT-1) transporter 
may be responsible for GABA (and thus possibly Vigabatrin) transport across the 
blood-brain barrier [203]. GABAa receptors are also present in the retina and 
variation within one of the many subunits of this receptor may influence toxicity. 
Mutations in the ornithine decarboxylase gene are known to cause rare cases of 
retinal degeneration and Vigabatrin is known to weakly inhibit this enzyme [188]. 
Indeed a previous study examined, in a small number of patients, the relationship 
between a limited number of variants in this gene and Vigabatrin-induced visual 
field defects [219] but no effect was reported.
Finally, its possible that, despite that apparent idiosyncrasy of the reaction, 
genetic factors do not play a major role and that some other unidentified factor 
such as a drug interaction or environmental agent, or perhaps a combination of 
factors predispose to the development of toxicity. Identification of either genetic
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or environmental predisposing factors may allow for safe prescribing of 
effective antiepileptic medication in selected individuals.
Chapter 6 Project design of a large scale map based 
association study
6.1 Introduction
In previous chapters I have highlighted some of the critical issues facing the field 
of epilepsy genetics such the need to increase sample sizes and incorporate 
map based association in to study design. In this chapter I will describe the initial 
stages of a project that seeks to integrate these lessons in to a large scale 
association study. The result should be a massive improvement over previous 
efforts in terms of overall study power and scope of variation examined.
6.1.1 Concept and overall study design
Our goal was to assemble the largest collection of epilepsy samples to date in an 
effort to identify variation across a panel of candidate genes that might predict 
the development or guide in the treatment of common forms of epilepsy. 
Coinciding with efforts to assemble this cohort came the release of phase one of 
the HapMap data which effectively opened the door to tagging any gene or 
region in the human genome. Similarly, recent technological advances have 
resulted in great reductions in the cost and time required for genotyping.
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We wished to tag all common variation across a list of candidate genes but also 
directly examine known functional variation. Our approach was to a) assemble 
the list of candidate genes, b) use bioinformatics techniques to identify functional 
variation in each of the candidate genes, c) use the HapMap data to select 
tSNPs for each candidate genes but where possible, forcing functional variation 
identified in step ‘b’ as tags and finally d) genotype and analyse the data.
Since the concept of tagging SNPs was first proposed in late 2001, a diverse 
range of tagging SNP selection strategies have been developed [126, 129, 220]. 
Much work has been carried out in an effort to quantify the different methods in 
terms of efficiency to predict tagged variants. However, the critical issue for 
association work is not how well variants are predicted but rather what is the 
overall power of the selected tSNP set to detect association driven by an 
unknown (or invisible) functional variant. Given that little work had been carried 
out to evaluate the question of power of a given tag set, a number of experiments 
were run with the aim of selecting the optimum tagging method for the situation 
presented by this study.
There are a range of questions we would ideally like to address using genotype 
data generated from this study. The first and perhaps most straightforward in 
terms of phenotype collection is the question of predisposition to seizure and 
syndrome type. Extracting high quality phenotypes for pharmacogenetic 
questions tends to be more difficult as the phenotype must be defined in a
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manner that maximises any potential genetic effect. Oftentimes the definition that 
is settled on for a given pharmacogenetic question is not in line with that stored in 
current phenotype databases. To further complicate matters, even if the 
phenotype were available at one collection centre, it is often not from another. 
These issues are certainly surmountable; it just takes a longer period of time to 
assemble the phenotype than for the predisposition question.
6.2 Methods
6.2.1 Selection of candidate genes
Candidate gene selection was based on current biological knowledge of epilepsy. 
This largely stems from Mendelian genes identified by positional cloning. As 
discussed in the introduction to this thesis (see section 1.3.1 and Table 1.1), 
positional cloning has identified a number of genes that have in turn highlighted 
key biological pathways involved in epilepsy. For example, many epilepsy 
causing mutations are located in genes that form subsets of the voltage gates ion 
channels, critical in the generation and propagation of action potentials. Included 
in the candidate gene list therefore, are all the voltage gated sodium (11), 
calcium (26) and chloride (11) channels as well as a subset of the large 
potassium channel family (22). Due to restrictions in space, the potassium 
channel genes were limited to those coding for subunits of types A,C,D,Q,AB and 
BK. Also included were key members of the calcium regulated potassium
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channel, the inwardly rectifying channel and the hyperpolarization activated- 
cyclic nucleotide gated potassium channel.
The Mendelian genes listed in Table 1.1 also confirmed the importance of 
several key neurotransmitters in epilepsy such as acetylcholine, GABA and 
glutamate. Included in the candidate gene list are the principal metabolisers and 
transporters as well as key receptors for each of these neurotransmitters.
Apoptosis is receiving increasing attention in epilepsy and there is a growing 
suspicion that it plays an important role in epileptogenesis [221]. Key genes from 
the rapamycin signalling pathway, the related PI3K/PTEN/AKT pathway, the 
JAKs and STATS pathways were included in the candidate gene list. These 
pathways have been shown, through animal models to play a role in 
epileptogenesis [222].
All the principal metaboliser and transporters of the principal anti-epileptic drugs 
were included with a view to pharmacogenetic studies. We paid particular 
attention to leviteracetam (commonly known as Keppra).
6.2.2 Population sample
To date, over 3400 patient samples have been contributed from 7 collection 
centres across the globe. In order to reduce stratification, we have targeted 
samples of Caucasian origin. However, we have recruited additional
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collaborators who have assembled cohorts of non-Caucasian origin that would 
allow testing of suspected functional (in terms of predisposition and treatment) 
variation in different ethnic groups.
Table 6.1 Summary of DNA sample contributions
Name Ethnicity # Patients # Controls
UC London, UK UK 833
British 1958 birth cohort, UK UK 2112
Beaumont Hospital, Dublin, Ireland IRL 835 719
University of Anderlecht BEL 234
University of Antwerp BEL 91
University of Melbourne AUS 220
University of Melbourne AUS 423
GSK (Glaxo S K) FIN 490 490
Total 3126 3321
UK -  United Kingdom, IRL -  Ireland, BEL -  Belgium, AUS -  Australia, FIN -  Finland 
Note that non-Caucasian populations have been omitted from this table
6.2.3 Retrieving the genomic location of each gene
In order to access the relevant data for functional and tagging SNP selection, it is 
first necessary to define the genomic region of each gene. In defining the 
genomic region, we wished to include rare isoforms of each gene. The ‘ref seq’ 
track from UCSC defines known protein gene locations by aligning mRNAfrom 
reference sequence collections. As ‘ref seq’ defines genomic locations using 
mRNA as opposed to protein alignment, rare isoforms are also represented. 
Additionally, as there can be several different ‘refseq’ entries for a given gene, 
the minimum of the start column to the maximum of the end column was taken as 
the actual genomic location. This is illustrated in Table 6.2 using the example of 
OPRM1 below which was assigned the location: chromosome 6: 154,391,433 -
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154,598,991.
Table 6.2 Assigning genomic location from ref seq data
GENE ACC# CHR Tx Len Start End
OPRM1 NM 0010085 chr6 52,275 154,391,433 154,443,708
OPRM1 NM 0010085 chr6 54,213 154,391,433 154,445,646
0PRM1 NM 000914 chr6 79,864 154,391,433 154,471,297
OPRM1 NM 0010085 chr6 202,358 154,396,633 154,598,991
OPRM1 na ch6 207,558 154,391,433 154,598,991
Acc# - NCBI accession number. CHR -  Chromosome. Tx Len = Transcript length. Start = transcript start point (NCBI build 
34). END = transcript stop point (NCBI build 34)
Using this methodology, the genomic address of each gene was recorded and 
used for both functional analysis and tSNP selection (described below in sections
6.2.2 and 6.2.5)
6.2.4 Selection of functional SNPs
Functional SNPs were identified and assembled using the bioinformatics tool 
TAMAL, developed at University of Chapel Hill, North Carolina [223]. The tool 
collects all SNPs from a number of publicly available databases then reduces the 
list to a set of functional variants (sometimes putative, sometimes biologically 
proven) according to user defined criteria.
The tool first collects all SNPs from the following freely accessible SNP 
databases HapMap (www.hapmap.org), Perlegen (www.genome.perlegen.com). 
This inclusive list is reduced to a set of functional SNPs for genotyping if there is 
evidence that the SNP is a) polymorphic in Caucasians and b) if the SNP is
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functional according to the criteria defined by the user. The latter criterion refers 
to SNPs that: i) lead to non-synonymous or synonymous amino acid changes 
augmented with in silico prediction of functionality [224] or alteration of a splice 
site; ii) are in a promoter region (in silico prediction, but with biological 
validation)[225]; iii) are in regions with conservation scores =99th percentile 
genome wide for human-chimp-rat-mouse-chicken alignment via a hidden 
Markov model [226], iv)predicted regulatory potential [227], or v) a transfactor 
binding site [228]. An explanation of each of these functional criteria follows.
Coding variation (i.e. synonymous and non-synonymous) was accessed from the 
LS-SNP database (www.alto.compbio.ucsf.edu/ls-snp/). This database consists 
of all known coding variation supplemented with a prediction of functionality. The 
curators of the database have implanted a three module computational pipeline. 
In the first module they independently create a database of coding variation by 
extracting the genomic locations of all dbSNP variation (validated and non­
validated) and map this on to human protein sequences in the Swissprot and 
TrEMBL databases. In the second module a database of high resolution protein 
structural information is created. The difficulty here is that only around 8% of all 
known proteins have been extensively studied using methods that define high 
resolution protein structure such as x-ray crytallography or nuclear magnetic 
resonance spectroscopy [229]. The curators attempt to address this issue by 
inferring the structure of a poorly studied protein from the structure of a putatively 
homologous protein solved by the previously mentioned experimental methods.
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In the third module the curators use the outputs of the first two modules to 
compute a variety of annotations for each SNP examined including whether the 
SNP is near a ligand or a domain-domain interface as well as whether the SNP is 
putatively destabilizing. The database is updated twice a year.
Variation in promoter regions was defined by mapping SNP target sequence to 
promoter sequence at the Stanford promoters website (http://www- 
shgc.stanford.edu/). This database contains bioinformatically inferred promoter 
sequence (likely containing basal and upstream regulatory elements) from over 
10,000 genes [225]. The database has been shown, through in-vitro 
confirmation, to be 91% accurate in predicting core promoter elements.
Variation lying in conserved sequence regions was determined by aligning SNP 
target sequence against the ‘Evolutionary Conserved Elements’ database at 
(http://www.soe.ucsc.edu/~acs/conservation/). This database consists of over 
1.31 million elements conserved across human, mouse, rat, chicken and fugu 
rubripes.
Polymorphisms lying in the critical regions transcription factor binding sites were 
identified using the TRANSFAC database (http://www.gene-regulation.com/).
This database contains sequence information on bioinformatically inferred cis- 
acting DNA elements and trans-acting factors.
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Selected SNPs genotyped by the HapMap consortium and observed with a 
frequency greater than 5% were set aside to be forced as tagging SNPs (see 
section 6.2.5 below). All other variants (i.e. those not genotyped by HapMap and 
those with a minor allele frequency less than 5%) were to be genotyped ‘on the 
side’ of tagging SNPs.
6.2.5 Selection of tagging SNPs
Tagging SNPs were selected using the allelic r2 (or locus scoring r2) method as 
detailed by Chapman et al [131]. This method is similar to the haplotype r2 
method in that it employs logistic regression. However, the regression model is 
fitted not to haplotype groups but to each tSNP entered as separate additive 
terms. The principal advantages of allelic, over the haplotype r2 method are i) the 
abolishment of haplotype inference, ii) fewer predictor variables in the regression 
modal (thus less chance of over-fitting) and iii) fewer degrees of freedom in the 
association test. As allelic r2 is, similar to haplotype r2, a multimarker test, it would 
perform better than single locus methods such as pairwise- r2 in predicting 
unknown variation.
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6.2.6 Selection and filtering of HapMap data
The relevant SNP data was first extracted from HapMap data using the gene 
coordinate details as defined in section 6.2.3 and illustrated in Table 6.2. From 
this dataset was removed the following: SNPs with a minor allele frequency less 
than 5%, SNPs with greater than 10% missing data, SNPs that violated 
Mendelian inheritance in one or more trio units and SNPs which violated Hardy- 
Weinberg equilibrium with a significance values greater than p=0.01. In order to 
reduce computational burden large genes were broken down in to sub-regions 
containing a maximum of 52 SNPs.
6.2.7 Criteria used for tSNP selection
The following criteria had to be satisfied for tSNP set selection: any variation 
defined as functional in our bioinformatics screen and genotyped by HapMap 
was to be forced as a tSNP, every tagged SNP to be captured with a minimum 
allelic r2 of 0.8 (that is, the coefficient of determination returned by the regression 
model must be greater than 0.8 for all tagged variants), a maximum average 
allelic r2 of 0.3 between the selected tSNP set and a panel of unlinked variants 
(this test controls against over-fitting of the model).
6.2.8 Selection of neutral SNPs
Populations for this study although of Caucasian ancestry, have been assembled 
from five different geographic locations (see Table 6.1). Cryptic stratification
148
within a population can adversely affect results of an association study driving 
either false positive or false negative results depending on the nature of the 
substructure. Clearly some degree of stratification will exist between the five 
populations. Indeed stratification within any one of the populations is also a 
possibility. Knowledge of underlying structure is best estimated using a panel of 
neutral markers. We have thus included a panel of 100 neutral markers chosen 
as follows:
a) A panel of 300 SNPs were selected independent of Fst values from the 
HapMap dataset. SNPs were required to be at least 50kb from any known genes 
and have a minor allele frequency greater than 5%.
b) Of this panel of 300 SNPs, 100 SNPs, spread evenly across chromosomes 1- 
22 were selected for genotyping.
Estimation of population substructure is possible using the program 
STRUCTURE [230]. This information could be used as a guide in grouping or 
dividing populations for association analysis. The degree of structure within any 
one population can be estimated and used to correct association statistics. A 
brief discussion of relevant methodology is covered in section 1.4.4.
6.3 Results
6.3.1 Candidate gene selection
Four hundred and fifty eight candidate genes were selected. For each gene, 
genomic coordinates on NCBI build 34 were extracted from the UCSC database
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and ten kibobases of upstream and downstream sequence added in order to 
capture regulatory regions. In total, these genes represent 54.4mb of sequence, 
an average of 119kb per gene. A small number of genes were not suitable as 
they had not been annotated on NCBI build 54. This set represents the vast 
majority of the majority of biologically plausible candidate genes for 
predisposition to, or treatment of, common forms of epilepsy. Details of selected 
genes and coordinates are shown in Table 8.2.
6.3.2 Functional analysis
Bioinformatic screening for functional variation across the 458 candidate genes 
resulted in the identification of 1650 putatively functional SNPs. On average, four 
functional variants were selected for each gene. Eight hundered and seven of the 
1650 functional variants were genotyped by HapMap and thus forced as tags in 
SNP selection. Details of selected variants are shown in Table 6.3.
6.3.3 Tagging analysis
A total of 5447 tags, an average of 12 SNPs per gene, were found to be sufficient 
to represent variation across the 458 candidate genes. Forced functional variants 
accounted for 15% of all tagging SNPs. This level of efficiency, when 
extrapolated to a genome wide level (estimated at 3.07x109 at NCBI build 35), 
would predict approximately 308,000 tags to cover the entire genome. Genome-
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wide tagging, but of genic regions only is an alternative to exhaustively tagging 
the entire genome. The UCSC genome browser has annotated 39,368 genes 
accounting for 2.33x109 (equivalent to 75% of the genome) base pairs of 
sequence. However, many genes overlap or are nested within each other which 
reduces the actual amount of genic sequence considerably. In fact, it has been 
estimated that genic regions cover only 25% of the genome [231]. By 
extrapolating using a figure of 25%, 77,000 tags would be sufficient to tag all 
known .genes in the human genome
Table 6.3 Summary of functional SNP analysis
SNP class SNP count HM*
Protein 459 201
Coding 292 147
Promoter 319 190
TFBS 230 105
Regulatory 92 38
Conserved 258 126
Total 1650 807
’All functional variants detected, functional variants also genotyped by HapMap 
Protein = alters amino acid or protein stability. Coding = Located in an exon 
Promoter = Located in inferred promoter region 
TFBS = Located in inferred transcription factor binding site 
Regulatory = Located in inferred regulatory region.
Conserved = Located in a region conserved at the 95 percentile across human-chimp-rat-mouse chicken
6.4 Discussion
The set of 6289 tagging and functional variants identified here represent a 
comprehensive assessment of variation across 489 candidate genes for 
epilepsy. The method described merges a sequence based, direct assessment 
with an indirect map based tagging SNP approach thus examining directly
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putatively functional variation whilst at the same time capturing variation of 
unknown significance.
The broad approach taken to selection of putatively functional variation covers 
the principal functional groups identified to date; coding, promoter, regulatory and 
conserved. However, as information on SNP frequency in a Caucasian 
population was an inclusion criterion, the screen was limited to variation 
deposited in the two suitably annotated SNP databases -  HapMap and Perlegen. 
Although these databases represent a major component of human variation, they 
are not complete. The alternative of including all functional variation ran the risk 
of inflating the proportion of non-variable SNPs.
There are numerous methods of tagging and each method has advantages and 
disadvantages. We chose allelic r2 for three principal reasons, all related to the 
multi-marker nature of the method. Firstly the method is efficient in that it allows 
tags to work in combination to predict tagged variation. Secondly, it is powerful in 
detecting association as the number of degrees of freedom in the model is 
reduced when compared to other multimarker methods (for example haplotype 
r2). Thirdly the method tends to behave better in capturing unknown variation 
than single marker methods. This is particularly important as we used Phase 1 
HapMap data to run these experiments. Capturing unknown variation is less of 
an issue as SNP density is increased (HapMap consider Phase 2 to cover all 
common coding variation and the vast majority of non-genic variation). In
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addition, haplotype inference is not an essential component of the allelic r2 
method. This greatly simplifies issues as haplotype inference can become 
unreliable across regions of complex LD structure.
Association studies are becoming increasingly large scale. The additional power 
and scope of such studies should begin to identify numerous loci across the 
genome that are contributing to the development and treatment of common 
disease. There currently are two approaches to large scale studies -  candidate 
gene or genome wide. Whilst genome wide studies obviously have a larger 
scope, it would seem logical to first run large scale candidate gene studies as 
power of detection for the specific regions examined would be greater than the 
same regions by genome wide study. The correct execution of a candidate gene 
study should solidify current knowledge thus paving the way for examination or 
previously ‘unsuspected’ regions by genome wide association.
Indeed, considering the current extent of our knowledge, a third approach might 
be considered, one that examines, using a framework similar to that described 
here, all known genes across the genome. The advantage of this method is that 
whilst all coding regions are examined, power of detection is focused on coding 
regions as opposed to diluting it by including the 75% of the genome that does 
not contain any known genes. Such an approach raises interesting questions. 
Although the amount of sequence covered by genes is equivalent to 75% of the 
genome (2x109bp), the fact that some genes overlap reduces the actual size of
153
the region covered to 25% (7.5x108bp). The region could be reduced further by 
restricting the amount of intronic sequence examined.
The integration of Bayes theory to genome wide studies might allow the 
researcher to factor in biological knowledge a priori. Such an approach would 
allow known functional variation as well as key regions of the genome to be 
weighted thus maximising power of detection.
In a sense the candidate gene approach described seems logical as a first large 
scale study not only in that it clarifies what we currently suspect of disease 
pathways but also because the performance of current genome wide genotyping 
assays is not well understood. For example, most groups currently running 
genome wide studies avail of the Affymetrix chip systems. Whilst the number of 
variants examined is obviously impressive, the performance of those variants 
against a carefully chose tagging set is unknown. In the near future more 
carefully designed chips will become available that address many or all of these 
concerns.
154
Chapter 7 Discussion and conclusions
A pubmed search using the keywords ‘epilepsy’, ‘association study’, ‘genetic’ 
returns 136 listed publications, yet the field is little better off now than when it first 
embarked on mapping genetic variation for common forms of epilepsy. We know 
from heritability studies that genetics explains a significant proportion of the risk 
of developing epilepsy, the question we are attempting to address is thus 
fundamentally valid. The challenge now is to implement lessons learned from 
past difficulties to future study designs.
In epilepsy, as with many other disease fields, the so called ‘low hanging fruit’ 
(common variants of large effect) have not been identified. The apparent lack of 
such variation does not necessarily contradict the observation from heritability 
studies that a large component of epilepsy is genetic, in that the heritability of a 
trait explains nothing of the underlying genetic architecture. Indeed it is becoming 
more apparent that for complex disease the underlying architecture is seemingly 
characterised to a large extent by interaction between numerous small and 
medium effect variations. The effect of any single variant is thus marginal, 
making detection difficult.
With this in mind it would seem reasonable to view past epilepsy studies as 
exploratory. Although we have advanced our biological knowledge little, we have 
learnt the key lesson that power of detection must be increased through the
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refinement of study design. Deciphering this complicated genetic signal will 
require developments on three fronts, all focused on maximising power of 
detection: a) increasing study cohort sizes; b) refining phenotype definition and c) 
improving genetic mapping techniques.
7.1.1 Increasing study cohort sizes
The broad phenotypic heterogeneity of epilepsy is such that any one phenotypic 
group represents a small proportion of the overall cohort size from a typical 
referral centre. For example, the cohort at the Institute of Neurology in London 
contains over 2000 individuals, a figure that initially appears substantial. However 
this figure must be contextualised by the underlying characteristics of the genetic 
component to epilepsy. Broad genetic risk factors (i.e. something that 
predisposes to epilepsy in general) probably do not exist, rather it is thought that 
genes play a role in developing specific syndrome or seizure types. When viewed 
in this way a ‘large’ cohort quickly becomes subdivided in to smaller groups in an 
effort to homogenise the genetic signal. For example only around 15% of patients 
in the London cohort fall in to what is regarded as a clearly definable genetic 
group such as IGE. An expansion of collection efforts is clearly required if any 
one subgroup within a cohort is going to reach a reasonable size to detect 
moderate and rare effect variants. Within a study centre this translates to greater 
investment in patient collection, databasing (fast and easy access to data of a 
specific nature) and, crucially, phenotyping.
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7.1.2 Refining phenotype definition
Genotype and phenotype data play equally important roles in disease mapping, 
yet often the focus of attention is biased towards the former. As mentioned 
previously, one of the major difficulties with epilepsy genetics is the lack of 
intermediate phenotypes. This emphasises more the end-point phenotype of 
seizure or syndrome type. A key challenge facing the field is to align the end­
point phenotype with the underlying genetic component. Correct alignment will 
maximise power. Any discrepancy in this alignment reduces power of detection 
considerably. For example, around 40% of TLE are caused by sclerosis in the 
hippocampus. Should TLE be considered as two independent groups - those with 
and those without sclerosis of the hippocampus - or should they instead be kept 
as a single group as has traditionally been the case? Genetic effect may well 
cross currently defined ILAE syndrome and seizure types, possibly leading to a 
realignment of current categories.
7.1.3 Improving genetic mapping techniques
The fruition of HapMap has made map based studies technically and financially 
feasible for a growing number of research groups. But the tagging methodology 
has yet to be fully optimised, a fact reflected by the numerous diverse methods
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detailed in the literature. Further studies are required to compare and contrast 
the relative power of each method under different models (single functional locus, 
multiple interacting loci, different frequencies of functional loci etc.). Although this 
should be viewed as a natural maturation process, care must be taken in 
ensuring the optimal method is chosen for the study in question. Neither should 
the tagging methodology be used blindly. It should always be assumed that even 
under a best case scenario, the actual performance of tagging SNPs will not 
achieve the level predicted from the tag selection analysis due to differing 
patterns of LD in HapMap and test populations.
Regardless of the attention the HapMap project has generated, linkage mapping 
should continue to play a central in role epilepsy genetics. Indeed despite its 
limitations, linkage has been far more productive than association in terms of 
generating positive genetic knowledge’00'. However, for reasons described 
previously (see section 1.4.2), linkage in the form applied to epilepsy to date is 
poorly suited to the complex nature of the trait. Linkage needs to be refined and 
applied to carefully selected populations with deep pedigrees and homozygous 
environments. Homozygosity mapping is an alternative map based technique 
that has been under-examined in epilepsy. The application of the method in deep 
consanguineous pedigrees could yield candidate regions in the near term.
xxw Although linkage success stories have been largely restricted to cases of Medelian epilepsy.
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7.1.4 Collaboration in epilepsy genetics
There are few if any research groups that can adequately tackle all three issues 
raised here, by increasing study cohort sizes, refining phenotype definition and 
improving genetic mapping techniques. It is clear that future epilepsy genetics 
teams will require the careful integration of clinicians, statistical geneticists and 
medical biologists. Collaboration is therefore key.
Despite the difficulties, epilepsy genetics is in the advantageous position of 
being, relative to other disease fields, in its infancy. In addition to having the 
luxury of learning from the experience of other more established disease fields 
an emerging field can develop large scale collaborative efforts at an early stage. 
Establishing an efficient system across groups greatly speeds research efforts. 
For example, streamlining phenotype databasing (a critical component of disease 
mapping) across collaborating centres allows an exact phenotype to be quickly 
and efficiently extracted at numerous centres simultaneously. Pooling of cohorts 
through collaborative efforts allows, in the near term, a significant increase in 
overall cohort size. Given the heterogeneous nature of the epilepsy phenotype 
pooling of cohorts appears to be the only way to achieve reasonable cohort sizes 
in the near term.
Collaboration must be built on a global scale. Large, ethnically homogenous, 
cohorts aid initial detection of functional variation, but access to patient cohorts of
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different ethnicity is critical to determining the functionality of those variants 
across ethnic groups. Only through collaboration can this be carried out quickly 
and efficiently.
There are obvious disadvantages to large scale collaborative efforts, and care 
should be taken to avoid them. Diversity in how a question is tackled must be 
conserved. If the community is dominated by the thoughts of one or two key 
figures the development of alternative strategies might be hampered. However, 
for reasons discussed above, the system of research groups working in complete 
independence will compromise progress, at least in the short term.
The community must also think through the implications of the obviously complex 
nature of epilepsy genetics. The relevance of detecting variation of small to 
medium effects in known candidate genes is unclear. Deciphering interactions 
between such variants in order to explain a larger component of the risk would be 
beneficial in identifying high risk individuals who have not yet experienced a 
seizure. Perhaps of greater relevance to the management of epilepsy is the 
identification of novel, or confirmation of suspected, candidate genes, which 
would aid in the development of novel anti-epileptic drugs. Studies seeking to 
explain variability in dosing and efficacy of current anti-epileptic drugs are much 
required.
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7.1.5 Pharmacogenetics in epilepsy
The community has recently focussed heavily on predisposition when the 
question of treatment might be more fruitful. The development of any new drug 
typically results in the identification of metabolisers, transporters and targets of 
the drug, thus immediately presenting a list of well motivated candidate genes for 
a pharmacogenetic study. Critically, these genes (in particular the drug 
metabolisers) have been extensively screened for variation, and furthermore, 
much of this variation has been tested for functionality. Intermediate phenotypes 
are often available (for example plasma levels of a drug). This allows known 
functional variants to be tested against drug related phenotypes, a strategy that 
has proven successful in epilepsy and other disease fields. For example variation 
in CYP2C9 has been shown to affect plasma levels of Phenytoin [232]. In a more 
extensive study, part of the variability in dose of Phenytoin and Carbamazapine 
was shown to be explained by SCN1a genotype [69]. Although the proportion of 
the variation in dose explained is low (3-5%), it seems reasonable to predict that 
the addition of other weak to moderate effect variants would bring this above the 
threshold of clinical relevance.
The argument has been made that much of the genetic variation relevant to 
pharmacogenetics may be under positive and/or balancing selection to a much 
greater extent than disease causing variation. It is also possible that some 
variants may have been evolutionarily neutral until becoming functional on
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exposure to previously unseen drug compounds. Under either scenario, 
‘functional’ variants might drift to a relatively high frequency which would greatly 
increase not only the genetic power of detection but also the clinical relevance of 
the variant in question.
But there are still many challenges connected with pharmacogenetics in epilepsy 
As most patient recruitment takes place at tertiary referral centres, patients tend 
to be on a cocktail of multiple drugs. The interaction of different drugs is poorly 
understood but likely to introduce a significant confounder effect. The type and 
severity of epilepsy also plays a role in drug response. Ideally study cohorts 
should be controlled with this in mind -  for example a large cohort of JME 
patients might be better matched to a Valproate study than a cross-section of all 
epilepsy types. All these factors could and probably do play a role in determining 
the relative contribution of specific genetic variants to the efficacy of the drug.
7.1.6 Concluding thoughts
Epilepsy is clearly behind other common diseases fields such as diabetes and 
cardiovascular disease which have been subjected to large-scale studies 
comprising thousands of patients. As of 2005 the biggest association study in 
epilepsy considered one genetic variant in 563 cases and 660 controls. The 
execution of the study described in chapter six of this thesis looks set to change 
this picture and move epilepsy closer to the fore of complex disease genetics.
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Epilepsy research could in principal emerge centre stage in genomics, alongside 
cancer research, because of the availability of affected tissue. This factor has 
allowed cancer studies to race ahead in a number of ways, yet the availability of 
affected tissue has been under-exploited in epilepsy. What is required is an 
integrated approach that correlates germline genetics with genomic patterns of 
protein related traits available from tissues (expression levels, alternative 
splicing, proteomics). This could not only further our understanding of epilepsy, 
but would also be a useful model for studying mechanisms such as apoptosis 
and the factors affecting long term potentiation.
Inherent potential and promise are insufficient alone if research funding bodies 
are to continue supporting a concept. Clear progress is required. Genomics 
research has been long promising to translate practically to the clinic; the time 
has come to deliver or the window of opportunity will be lost.
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Addenda
Solutions:
-PBS (phosphate buffered saline)
For 11: 2 PBS tablets (Sigma-Aldrich P08057) added to 11 of H20
2 tablets in 1L of water yields in 0.01 M phosphate buffer, 0.0027 M KCI, 0.14 M 
NaCI, 0.05% Tween, pH 7.4
- Red blood cell lysis solution
320mM sucrose, 5mM MgCI2, 10mM Tris/HCI, 1% Triton X-100.
For 11
104.9g sucrose 
1.02g MgCI2.6H20 
10ml 1M Tris pH 8.0 
10ml Triton-X-100 
Make up to 11 with H20
-TE
For 11
10ml 1M Tris-HCI (pH 8.0)
400pl 0.25 M EDTA 
Make up to 11 with H20
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Table 8.1 Summary of published association studies in complex forms of epilepsy
Study Variant #cases/#controls Phenotype Result P value Comment
Studies on focal epilepsies -  initial positive report with or without replication attempts
111-b
Kanemotori14] -511 50/112 TLE+HS Significant 0.0085 Japanese
Virtari15l -511 35/400 FS Significant 0.03 Finnish
Kanemoto[169] -511 66/163 TLE+HS, FS Significant 0.0022 Japanese
Tilgen -511 99/126 FS Negative na Failed replication of [115], Germans
Peltola[ 120] -511 38/400 RPE Significant 0.0023 Finnish
Heils[117] -511 50/112 TLE+HS Negative na Failed replication of [114],German
Buono[157] -511 61/119 TLE+HS Negative na Failed replication of [114], USA
Haspolat [118] -511 73/152 FS Negative na Failed replication of [114], Turkish
Jin [119] -511 112/115 TLE+/-HS Negative Na Failed replication of [114], Chinese
11-1 Ra
Tsai [233] 1410 51/83 FS Positive 0.03 Taiwan
Haspolat [118] 1410 73/152 FS Negative na Failed replication of [233], Turkish
PDYN
Stogmann[150] promo 155/202 Fam nl-TLE Significant 0.0025 German
Tilgen[158] promo 182/205 nl-TLE Negative na Failed replication of [150], German
Gambardella[159] promo 60/259 Fam nl-TLE Negative na Italian
GABBR1
Gambardella[151] G 1465A 141/372 nl-TLE Significant <0.0001 Italian
Ma[165] G1465A 120/118 nl-TLE Negative na Failed replication of [151], USA
Ren [1631 G 1465A 112/124 nl-TLE Negative na Failed replication of [151], Chinese
Salzmann [166] G 1465A 134/145 nl/l TLE Negative na Failed replication of [151], French
Tan [234] G1465A 234/164 nl-TLE Negative na Failed replication of [151], 
Australian
PRNP
Walz[152l Asn171Ser 100/180 rf TLE+HS Significant <0.0001 Brazilian
Table 8.1 continued... Summary of published association studies in complex forms of epilepsy
APOE
Briellmann[153] e4 43 AoE TLE Significant 0.004 Australian
Blumkef160] e4 125 AoE TLE Negative na German
Gambardella[161] e4 63/220 AoE TLE Negative na Italian
Yeni [162] e4 47/62 mTLE+HS Negative na Turkish
CHRNA4
Chou[154] Ser543Ser 102/80 FS Significant 0.001 Taiwanese
Mulley(164] Ser543Ser 49/93 FS Negative na Failed replication of [154], Australia
GABRG2
Chouri55] rs211037 104/83 FS Significant 0.009 Taiwanese
Nakayama [167] rs211037 94/106 FS Negative ns Japanese (mutation screen)
Kananura [49] rs211037 135/154 FS/CAE Negative ns German (mutation screen)
CSNK1G2
Yinan [2351 IVS2-33, A2241G 60/101 FS Significant 0.009 Chinese
Studies on idiopathic generalised epilepsies -  initial positive report with or without replication attempts
OPRM1
Sander [236] Asn40Asp 72/340 IAE Significant 0.019 German
Wilkie [176] Asn40Asp 230/234 Mixed IGE Significant 0.00026 UK (retracted)
CACNA1A
Chioza [32] ‘SNP8’ 188/200 Mixed IGE Significant 0.00033 UK
Sander [182] ‘SNP8’ 354/186 Mixed IGE Negative na Failed replication of [32], German
CHRNA4
Steinlein [237] Cfolbp594 103/92 Mixed IGE Significant 0.0394 German
Chioza [238] Cfolbp594 182/178 Mixed IGE Negative na Failed replication of [237] UK
GRIK1
Sander D80] AGAT rep 20 familiesxxvl JAE Significant 0.004 German
Izzi [183] various 2 g X X V II JAE Negative na German (mutation screen)
KCNQ3
_ Vijai [239] D8S558 119probandsxxvl" JME Significant 0.008 South Indian
Hauq [2401 D8S448, D8S1835 71 families’00* Mixed IGE Negative na German
KCNJ10
Buono [241] Arg271Cys 407/284 Mixed epilepsy Significant US/German
Lenzen [242] Arg271Cys 563/660 Mixed IGE Significant 0.03 Positive replication of [241], German
xxv' Family based analysis using HHRR statistic.
xxv" This study consisted of a screen in 25 patients. There was no case/control analysis. 
xxv'" Family based analysis using TDT statistic. 
xx,x Family based analysis using TDT statistic.
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AE3
Sander Ala867Asp 366/183 Mixed IGE Significant 0.021 German
KCNJ3
Chioza ri81] T1038C 187/198 Mixed IGE Significant 0.0097 UK, strongest in absence
DAT
Sander [243] 3’UTR repeat 133/223 Mixed IGE Significant 0.005 German, strongest IAE
CACNA1H
Chen [244] Mutation screen 118/230 CAE na na Han Chinese
LGI4
Gu [245] 1914GC 42/110 CAE Significant 0.01 German
BRD2
Pal [1] Various n/n JME Significant nn USA, mapping after linkage
ME2
Greenberg [186] 7 locus haplotype 156/126 Mixed IGE Significant <0.0001 USA, mapping after linkage
Lenzen [246] 7 locus haplotype 660/666 Mixed IGE Negative na Negative replication of [186], German
CX36
Mas [247] C588T 29/123 JME Significant 0.017 European
Negative association studies involving genes for which no previous positive report existed in the literature.
5HT2c
Samochowiec [248] Cys23Ser 119/242 Mixed IGE Negative na German
ARC
Hauq [249] C498 143/n Mixed IGE Negative na German, mutation screen
EAAT2/SERT
Sander [243] G603/promo 133/223 Mixed IGE Negative na German
GABBR1
Sander r250] Various 118/130 JME/IAE Negative na German
Lu [251] Various 96/96 CAE Negative na Han Chinese, mutation screen
GABRD
Lenzen [252] C659G 462/664 Mixed IGE Negative Na German
GLRA3/GLRB
Sobetzko [2531 Various 104/141 Mixed IGE Negative na German, mutation screen
mGluR7/R8
Goodwin [254] Tyr433Phe/C2756T n/n Mixed IGE Negative na UK
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GRIM4
Izzi [255] C1455T 144/144 JME Negative na German, mutation screen
KCNQ2
Steinlein [2561 Thr752Asn n/n? Mixed IGE Negative na German, mutation screen
ChouJ257] ? paper not available ? FS Negative na Taiwan
hKCa3
Sander [258] CAG repeat 126/290 Mixed IGE Negative na German
TASK-3
Kananura [259] C636T 65/ IAE Negative na German, mutation screen
SCN2a
Haug [260] Various 46/ Mixed IGE Negative na German, mutation screen
Nakayama R19K 93/100 FS Negative na Japanese
MAO-A
Haug [261] Promo variant 248/248 JME/IAE Negative na German
PAX6
Sander [262] Promo variant 125/354 JME/IAE Negative na German
II-4
Tsai [263] Intron 3 repreat 94/83 FS/mixed IGE Negative na Taiwan
Drug response stud ies
MRD1
Siddiqui [171] C3435T 200/115 Any epilepsy Significant 0.006 UK
Zimprich [173] Various inc. C3435T 210/228 TLE Significant 0.009 German
Tan [1721 C3435T 401/208* Any epilepsy Negative na UK
Sills [2641 C3435T 230/170* Any epilepsy Negative na UK
APOE
Sporis [265] £4 30/30* Refractory/non Positive 0.002 Croation
DBH
Depondt C1021T 675/1087 Epi/controls Negative na UK
* refractory/sensitive to drug treatment
Table 8.2 Summary of candidate genes and SNP selection for large scale epilepsy project
P1 Gene Gene coordinate Size* Gene Descriptions
#func
non
HMXXX
#func HM #tags
Voltage-Gated Sodium Channels
1 SCN1A chr2:167038217-167142693 104476 Na channel, voltage-gated, type I, alpha 1 2 4
2 SCN2A2 chr2:166343136-166459083 115947 Na channel, voltage-gated, type II, alpha 2 3 2 5
3 SCN3A chr2:166136584-166273097 136513 Na channel, voltage-gated, type III, alpha 0 1 9
4 SCN4A chii 7:62479285-62533649 54364 Na channel, voltage-gated, type IV, alpha 0 1 9
5 SCN5A chr3:38540211 -38661744 121533 Na channel, voltage-gated, type V, alpha 3 2 20
6 SCN8A chrl 2:50261287-50498365 237078 Na channel, voltage gated, type VIII, alpha 0 0 11
7 SCN9A chr2:167247353-167380858 133505 Na channel, voltage-gated, type IX, alpha 2 4 11
8 SCN1B chii 9:40203565-40227014 23449 Na channel, voltage-gated, type I, beta 0 1 2
9 SCN2B chrl 1:117563856-117594966 31110 Na channel, voltage-gated, type II, beta 1 1 6
10 SCN3B chrl 1:123027549-123072607 45058 voltage-gated Na channel beta-3 0 2 13
11 SCN4B chrl 1:117531744-117571187 39443 Na channel, voltage-gated, type IV, beta 4 1 6
Voltage-Gated Calcium Channels
12 CACNA1A chr19:13169088-13488274 319186 Ca channel, voltage-dependent, P/Q type, 1A 3 0 39
13 CACNA1B chr9:135980855-136245245 264390 Ca channel, voltage-dependent, L type, 4 2 14
14 CACNA1C chrl 2:2084680-2681584 596904 Ca channel, voltage-dependent, L type, a 1C 8 13 61
15 CACNA1D chr3:53476031 -53813420 337389 Ca channel, voltage-dependent, L type, 2 1 31
16 CACNA1S chrl :198286899-198379951 93052 Ca channel, voltage-dependent, a 1S subunit 6 3 15
17 CACNA1F chrX:48077757-48126067 48310 Ca channel, voltage-dependent, a 1F subunit 0 2 4
18 CACNA1E chrl :178682262-179017473 335211 Ca channel, voltage-dependent, a 1E subunit 6 3 28
19 CACNA1G chii 7:49103459-49189264 85805 voltage-dependent Ca channel a 1G subunit 2 3 15
20 CACNA1H chrl 6:1133242-1221583 88341 Ca channel, voltage-dependent, a 1H subunit 6 4 11
21 CACNA1I chr22:38199797-38338774 138977 voltage-dependent T-type Ca channel 0 2 18
22 CACNA2D1 chr7:81181469-81694856 513387 Ca channel, voltage-dependent, a subunit 3 4 46
23 CACNA2D2 chr3:50351109-50509866 158757 Ca channel, voltage-dependent, a subunit 2 4 9
24 CACNA2D3 chr3:54104040-55075929 971889 Ca channel, voltage-dependent, a subunit 10 4 98
25 CACNA2D4 chrl 2:1761392-1908131 146739 voltage-gated Ca channel a(2)delta-4 4 3 20
26 CACNB1 chrl 7:37694669-37738864 44195 Ca channel, voltage-dependent, beta 1 0 5 12
27 CACNB2 chrl 0:18423611 -18844043 420432 Ca channel, voltage-dependent, beta 2 6 4 52
xxx HM = HapMap
Table 8.2 continued... Summary of candidate genes and SNP selection for large scale epilepsy project
P2 Gene Gene coordinate Size* Gene Descriptions #func non HM #func HM #tags
COo ge-Gated Calcium Channels -  continued.
28 CACNB3 chrl 2:47488781 -47518991 30210 Ca channel, voltage-dependent, beta 3 0 2 4
29 CACNB4 chr2:152887685-153168048 280363 Ca channel, voltage-dependent, beta 4 2 2 16
30 CACNG1 chrl 7:65580807-65613010 32203 voltage-dependent Ca channel gamma-1 2 0 5
31 CACNG2 chr22:35193437-35351660 158223 voltage-dependent Ca channel gamma-2 2 1 22
32 CACNG3 chrl 6:24224277-24350278 126001 voltage-dependent Ca channel gamma-3 2 1 19
33 CACNG4 chrl 7:65501127-65589611 88484 voltage-dependent Ca channel gamma-4 2 0 10
34 CACNG5 chrl 7:65413552-65441458 27906 voltage-dependent Ca channel gamma-5 0 1 8
35 CACNG6 chii 9:59177354-59217730 40376 voltage-dependent Ca channel gamma-6 1 0 5
36 CACNG7 chii 9:59097898-59147359 49461 voltage-dependent Ca channel gamma-7 1 0 6
37 CACNG8 chrl 9:59148102-59187915 39813 voltage-dependent Ca channel gamma-8 0 0 5
Voltage gates Chloride Channels
38 CLCN1 chr7:142474149-142530027 55878 Cl channel 1, skeletal muscle (Thomsen 0 3 11
39 CLCN2 chr3:185375307-185410180 34873 Cl channel 2 0 0 5
40 CLCN3 chr4:171227689-171348047 120358 Cl channel 3 isoform e 0 0 8
41 CLCN4 chrX:9527833-9625025 97192 Cl channel 4 3 4 18
42 CLCN5 chrX:48741496-48784861 43365 Cl channel 5 0 0 1
43 CLCN6 chr1:11565814-11622731 56917 Cl channel 6 isoform CIC-6a 9 6 9
44 CLCN7 chrl 6:1425346-1475013 49667 Cl channel 7 1 2 12
45 CLCNKA chr1:15701802-15732900 31098 Cl channel Ka 2 3 5
46 CLCNKB ch ii: 15723056-15756160 33104 Cl channel Kb 1 3 7
47 SLC12A5 chr20:45333412-45384205 50793 solute carrier family 12 member 5 2 4 11
48 BSND chrl:54824535-54854379 29844 barttin 2 0 4
Voltage-Gated Potassium Channels
49 KCNQ1 chrl 1:2420530-2844530 424000 K voltage-gated channel, KQT-like 5 8 60
50 KCNQ2 chr20:62747915-62840206 92291 K voltage-gated channel KQT-like protein 4 5 15
51 KCNQ3 chr8:133087845-133459227 371382 K voltage-gated channel KQT-like protein 7 5 57
52 KCNQ4 chrl:40652978-40727654 74676 K voltage-gated channel KQT-like protein 2 2 15
53 KCNQ5 chr6:73317621 -73911178 593557 K voltage-gated channel, KQT-like 9 1 45
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P3 Gene Gene coordinate Size* Gene Descriptions #func non HM
#func
HM #tags
Voltage-Gated Potassium Channels -  continued.
54 KCNAB1 chr3:157149261 -157587247 437986 K voltage-gated channel, shaker-related 5 3 32
55 KCNAB2 chrl .5800142-5880069 79927 K voltage-gated channel, shaker-related 0 5 13
56 KCNAB3 chrl 7:8016986-8043319 26333 K voltage-gated channel, shaker-related 0 2 4
57 KCNMB1 chr5:169776062-169807292 31230 K large conductance Ca-activated 2 2 9
58 KCNMB2 chr3:179587401 -179893129 305728 Ca-activated K channel beta 2 3 1 26
59 KCNMB3 chr3:180271478-180300316 28838 Ca-activated K channel beta 3 0 4 7
60 KCNMB4 chrl 2:69036446-69121065 84619 Ca-activated K channel beta 4 1 3 12
61 KCNA1 chrl 2:4880806-4902293 21487 K voltage-gated channel, shaker-related 0 1 4
62 KCNA2 chrl: 110434632-110456131 21499 K voltage-gated channel, shaker-related 1 0 2
63 KCNA3 chr1:110503807-110526105 22298 K voltage-gated channel, shaker-related, 3 0 0 2
64 KCNA4 chrl 1:29986307-30012797 26490 K voltage-gated channel, shaker-related 0 2 3
65 KCNA5 chrl 2:5013346-5036208 22862 K voltage-gated channel, shaker-related 2 2 7
66 KCNA6 chrl 2:4778603-4802839 24236 K voltage-gated channel, shaker-related, 6 1 2 7
67 KCNA7 chrl 9:54252487-54278010 25523 K voltage-gated channel, shaker-related 1 3 6
68 KCNA10 chrl: 110348566-110370524 21958 K voltage-gated channel, shaker-related 2 0 5
69 KCNN1 chrl 9:17913111-17980800 67689 K intermediate/small conductance 1 3 12
70 KCNN2 chr5:113764232-113918405 154173 small conductance Ca-activated K 2 0 16
71 KCNN3 chrl: 151886705-152069546 182841 small conductance Ca-activated K 3 2 42
72 KCNN4 chii 9:48952527-48987249 34722 intermediate conductance Ca-activated 2 0 7
73 KCNJ6 chr21:37907185-38219058 311873 K inwardly-rectifying channel J6 1 1 37
74 KCNJ10 chrl: 157217130-157266830 49700 K inwardly-rectifying channel J10 1 1 6
75 KCNC1 chii 1:17711846-17768486 56640 Shaw-related voltage-gated K channel 1 3 11
76 KCND2 chr7:119458225-119954890 496665 K voltage-gated channel, Shal-related 3 2 22
77 HCN1 chr5:45297474-45751721 454247 hyperpolarization activated cyclic 1 1 14
78 HCN2 chrl 9:530893-578157 47264 hyperpolarization activated cyclic 1 2 10
79 HCN3 chii :152454166-152485053 30887 hyperpolarization activated cyclic 0 3 ^ 4
80 HCN4 chii 5:71319752-71386994 67242 hyperpolarization activated cyclic 0 2 11
Acetylcholine metabolism
81 CHAT chii 0:50156686-50227753 71067 acetylcholine acetyltransferase isoform 2 4 3 14
82 ACHE chr7:100089015-100113406 24391 acetylcholinesterase isoform E4-E5 precursor 5 1 2
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Acetylcholine receptors
83 CHRNA1 Chr2:175805151-175841714 36563 cholinergic receptor, nicotinic, a 1 2 5
84 CHRNA2 chr8:27330175-27368668 38493 cholinergic receptor, nicotinic, a 2 (neuronal) 4 3 8
85 CHRNA3 chrl 5:76593471 -76639141 45670 cholinergic receptor, nicotinic, a 2 2 2
86 CHRNA4 chr20:62692799-62729096 36297 cholinergic receptor, nicotinic, a polypeptide 4 2 0 7
87 CHRNA5 chrl 5:76563725-76612277 48552 cholinergic receptor, nicotinic, a 2 2 3
88 CHRNA6 chr8:42615150-42650987 35837 cholinergic receptor, nicotinic, a 0 0 3
89 CHRNA7 chrl 5:30028757-30187178 158421 cholinergic receptor, nicotinic, a polypeptide 7 0 1 13
90 CHRNA9 chr4:40243011 -40282515 39504 cholinergic receptor, nicotinic, a 0 1 3
91 CHRNA10 chrl 1:3641126-3666923 25797 cholinergic receptor, nicotinic, a 1 1 3
92 CHRNB1 chrl 7:7538983-7571455 32472 nicotinic acetylcholine receptor beta subunit 0 2 5
93 CHRNB2 chrl: 151747049-151775875 28826 cholinergic receptor, nicotinic, beta 1 0 4
94 CHRNB3 chr8:42559964-42619577 59613 cholinergic receptor, nicotinic, beta 3 2 3
95 CHRNB4 chrl 5:76622455-76659406 36951 cholinergic receptor, nicotinic, beta 1 0 5
96 CHRM1 chrl 1:62441512-62474372 32860 cholinergic receptor, muscarinic 1 0 1 7
97 CHRM2 chr7:136105655-136127055 21400 cholinergic receptor, muscarinic 2 isoform a 3 3 9
98 CHRM3 chrl :237101901 -237123589 21688 cholinergic receptor, muscarinic 3 2 1 4
99 CHRM4 chrl 1:46360977-46382416 21439 cholinergic receptor, muscarinic 4 1 1 1
100 CHRM5 chrl 5:32016484-32082987 66503 cholinergic receptor, muscarinic 5 0 1 4
GABA-B Receptors
101 GABRA1 chr5:161246464-161317306 70842 GABA A receptor, a 0 0 5
102 GABRA2 chr4:46157248-46317487 160239 GABA A receptor, a 2 3 2 9
103 GABRA3 chrX:149944145-150247438 303293 GABA A receptor, a 3 0 0 14
104 GABRA4 chr4:46835784-46920997 85213 GABA A receptor, a 4 6 1 9
105 GABRA5 chrl 5:24712714-24767114 54400 GABA A receptor, a 5 0 0 2
106 GABRA6 chr5:161083865-161120014 36149 GABA A receptor, a 6 0 1 2
107 GABRG1 chr4:45947787-46051559 103772 GABA A receptor, gamma 1 1 1 4
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GABA-B Receptors - continued
108 GABRG2 chr5:161465724-161573421 107697 GABA A receptor, gamma 2 1 1 10
109 GABRG3 chrl 5:25318155-25390486 72331 GABA A receptor, gamma 3 2 1 9
110 GABRE chrX: 149729210-149770764 41554 GABA A receptor, 0 1 11
111 GABRP chr5:170181660-170231943 50283 GABA A receptor, pi 3 2 6
112 GABRB1 chr4:46939133-47353987 414854 GABA A receptor, beta 4 4 28
113 GABRB2 chr5:160691766-160966025 274259 GABA A receptor, beta 2 2 17
114 GABRB3 chrl 5:24328824-24575550 246726 GABA A receptor, beta 5 2 26
115 GABRQ chrX: 150414250-150449438 35188 GABA receptor, theta 0 2 5
116 GABRR1 chr6:89873568-89932656 59088 GABA receptor, rho 1 4 0 10
117 GABRR2 chr6:89952835-90030550 77715 GABA receptor, rho 2 3 3 20
118 GABBR1 chr6:29677897-29708753 30856 GABA B receptor 1 10 0 3
119 GPR51 chr9:96420204-96861317 441113 G protein-coupled receptor 51 4 9 67
GABA transporters
120 SLC32A1 chr20:38028533-38053443 24910 solute carrier family 32, member 1 0 0 5
121 SLC6A1 chr3:11022354-11063906 41552 solute carrier family 6 (neurotransmitter 1 1 11
122 SLC6A13 chrl 2:190052-252263 62211 solute carrier family 6 (neurotransmitter 2 1 9
123 SLC6A11 chr3:10822917-10965146 142229 solute carrier family 6 (neurotransmitter 3 2 18
124 SLC6A12 chrl 2:159513-202759 43246 solute carrier family 6 (neurotransmitter 0 0 6
GABA-Glut metabolism/synthesis
125 GLS chr2:191938140-192042808 104668 glutaminase C 1 1 4
126 GLS2 chrl 2:55141003-55178447 37444 glutaminase GA isoform a 1 3 4
127 GLUL chrl: 179581414-179610285 28871 glutamate-ammonia ligase (glutamine synthase) 4 3 6
128 GAD1 chr2:171865616-171930193 64577 glutamate decarboxylase 1 isoform GAD67 0 0 7
129 GAD2 chrl 0:26499600-26607493 107893 glutamate decarboxylase 2 2 1 5
130 ALPL chrl :21295402-21384379 88977 tissue non-specific alkaline phosphatase 2 2 15
131 ABAT chrl 6:8725743-8855729 129986 4-aminobutyrate aminotransferase precursor 7 2 25
132 ALDH5A1 chr6:24593204-24652837 59633
aldehyde dehydrogenase 5A1 precursor, isoform 
1 2 4 10
GABA receptor associated proteins
133 GPH chrl 4:64955277-65648556 693279 gephyrin 1 2 21
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GABA receptor associated proteins -  continued.
134 GABARAP chrl 7:7334305-7356318 22013 GABA(A) receptor-associated protein 2 3 5
135 ARHGEF9 chrX:61711639-61851784 140145 Cdc42 guanine exchange factor 9 0 0 5
Glutamate receptors
136 GRIA1 chr5:152888816-153229374 340558 glutamate receptor, ionotropic, AMPA 1 3 1 33
137 GRIA2 chr4:158709543-158872724 163181 glutamate receptor, ionotropic, AMPA 2 0 1 8
138 GRIA3 chrX:121005913-121330548 324635 glutamate receptor 3 isoform flip precursor 4 5 54
139 GRIA4 chrl 1:105009442-105398183 388741 glutamate receptor, ionotrophic 1 1 20
140 GRIK1 chr21:29836313-30242677 406364 glutamate receptor, ionotropic, kainate 1 4 5 41
141 GRIK2 chr6:101882752-102571956 689204 glutamate receptor 6 isoform 1 precursor 3 0 57
142 GRIK3 chrl :36684276-36937388 253112 glutamate receptor 7 precursor 2 0 21
143 GRIK4 chrl 1:120058680-120404621 345941 glutamate receptor KA1 precursor 3 5 37
144 GRIK5 chrl 9:47187783-47271797 84014 GRIK5 0 1 4
145 GRIN1 chr9:135381185-135429808 48623 glutamate receptor, N-methyl D-aspartate 1 0 0 4
146 GRIN2A chrl 6:9812721-10253169 440448 glutamate receptor, N-methyl D-aspartate 2A 5 2 30
147 GRIN2B chrl 2:13595411 -14034289 438878 N-methyl-D-aspartate receptor subunit 2B 11 6 54
148 GRIN2C chrl 7:73425403-73458354 32951 N-methyl-D-aspartate receptor subunit 2C 0 3 4
149 GRIN2D chrl 9:53579944-53649205 69261 N-methyl-D-aspartate receptor subunit 2D 3 3 8
150 GRIN3A chr9:99701473-99890700 189227 glutamate receptor, ionotropic, 3 7 19
151 GRIN3B chrl 9:951436-960723 9287 glutamate receptor, ionotropic, 0 0 8
152 GRM1 chr6:146321224-146749304 428080 glutamate receptor, metabotropic 1 5 5 18
153 GRM2 chr3:51692046-51721176 29130 glutamate receptor, metabotropic 2 precursor 0 0 2
154 GRM3 chr7:85875259-86116220 240961 glutamate receptor, metabotropic 3 precursor 2 0 15
155 GRM4 chr6:34026484-34158298 131814 glutamate receptor, metabotropic 4 4 0 10
156 GRM5 chrl 1:87919131 -88479343 560212 glutamate receptor, metabotropic 5 1 2 33
157 GRM6 chr5:178508933-178545725 36792 glutamate receptor, metabotropic 6 precursor 4 3 8
158 GRM7 chr3:6848405-7768404 919999 glutamate receptor, metabotropic 7 isoform b 9 5 93
159 GRM8 chr7:125623146-126447799 824653 glutamate receptor, metabotropic 8 5 15 134
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Glutamate transporters
160 SLC1A3 ch r5:36642256-36743935 101679 solute carrier family 1 (glial high affinity) 0 1 21
161 SLC1A2 chrl 1:35236697-35414899 178202 solute carrier family 1, member 2 0 2 18
162 SLC1A1 chr9:4470489-4587260 116771 solute carrier family 1, member 1 4 2 25
163 SLC1A6 chrl 9:14911991-14954730 42739 solute carrier family 1 (high affinity 2 0 5
164 SLC1A7 chrl :52913474-52988197 74723 solute carrier family 1 (glutamate transporter), 13 4 11
165 SLC17A6 chrl 1:22313976-22375352 61376 differentiation-associated Na-dependent 1 1 10
166 SLC17A7 chii 9:54614470-54646596 32126 solute carrier family 17, member 7 3 4 6
167 SLC17A8 chrl 2:99243462-99328305 84843 Na-dependent inorg. phosphate cotransporter 8 0 1 9
Extra metabolism - over GABA
168 GLUD1 chrl 0:88,454,821 -88,539,200 84379 glutamate dehydrogenase 1 0 0 4
169 GLUD2 chrX: 118,859,216-118,901,549 42333 glutamate dehydrogenase 2 0 0 3
adenosine
170 ADORA1 chrl :200,328,038-200,444,789 116751 adenosine A1 receptor 3 3 11
171 ADORA2A chr22:23,133,645-23,182,878 49233 adenosine A2a receptor 2 0 2
172 ADORA2B chrl 7:16,028,796-16,099,776 70980 adenosine A2b receptor 0 1 6
173 ADORA3 chr1:111,320,781-111,365,470 44689 adenosine A3 receptor 1 2 5
174 ADK chrl 0:75,235,567-75,833,663 598096 adenosine kinase isoform b 2 6 18
175 ADA chr20:43,913,592-43,985,805 72213 adenosine deaminase 1 0 7
176 AHCY chr20:33,563,751 -33,626,799 63048 S-adenosylhomocysteine hydrolase 0 2 3
177 NT5E chr6:86,135,404-86,221,092 85688 5' nucleotidase, ecto 1 1 5
178 NT5C1A chrl :39,518,086-39,571,004 52918 5'-nucleotidase, cytosolic IA 1 2 6
179 NT5C1B chr2:18,708,649-18,775,350 66701 5' nucleotidase, cytosolic IB isoform 1 0 1 7
180 CNT1 chrl 5:83,137,680-83,238,795 101115 solute carrier family 28 (Na-coupled 5 9 34
181 CNT2 chrl 5:43250489-43294189 43700 solute carrier family 28 (Na-coupled 1 1 3
182 CNT3 chr9:82,330,210-82,460,532 130322 concentrative Na+-nucleoside cotransporter 2 2 13
183 ENT1 chr6:44,214,247-44,268,733 54486 solute carrier family 29 , member 1 0 2 10
184 ENT2 chrl 1:65,885,352-65,934,651 49299 solute carrier family 29,member 2 0 0 1
185 ENT3 chrl 0:72,403,634-72,487,743 84109 solute carrier family 29, member 3 2 9 15
186 ENT4 chr7:5,046,912-5,108,028 61116 solute carrier family 29, member 4 1 3 10
Serotonin
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189 HTR1D chrl:22,967,863-23,010,697 42834 Serotonin receptor 1D 0 1 2
190 HTR1E chr6:87,623,005-87,741,992 118987 Serotonin receptor 1E 0 0 11
191 HTR1F chr3:87,940,800-87,981,901 41101 Serotonin receptor 1F 0 0 1
192 HTR2A chrl 3:45,185,513-45,288,176 102663 Serotonin receptor 2A 4 1 15
193 HTR2B chr2:232,155,493-232,212,363 56870 Serotonin receptor 2B 2 0 5
194 HTR2C chrX:112,562,803-112,928,877 366074 Serotonin receptor 2C 1 7 14
195 HTR3A chrl 1:113,363,561-113,418,684 55123 Serotonin receptor 3A 0 2 10
196 HTR3B chrl 1:113,293,240-113,374,934 81694 Serotonin receptor 3B 2 2 8
197 HTR3C chr3:185,071,747-185,119,372 47625 Serotonin receptor 3 subunit C 1 2 4
198 HTR3D chr3:185,050,244-185,098,069 47825 Serotonin receptor 3 family member D 0 1 4
199 HTR3E chr3:185,118,879-185,165,695 46816 Serotonin receptor 3 subunit E 0 1 6
200 HTR4 chr5:147,839,242-148,082,226 242984 Serotonin receptor 4 1 0 16
201 HTR5A chr7:154,234,349-154,287,937 53588 Serotonin receptor 5A 2 2 5
202 HTR6 chrl: 19,441,254-19,495,530 54276 Serotonin receptor 6 0 1 4
203 HTR7 chrl 0:92,145,154-92,302,248 157094 Serotonin receptor 7 isoform d 0 0 7
204 TPH2 chrl 2:70,598,892-70,732,488 133596 neuronal tryptophan hydroxylase 0 2 8
205 MAOA ch rx :42626592-42662049 35457 monoamine oxidase A 0 0 5
206 SLC6A4 chrl 7:28,650,468-28,728,268 77800 solute carrier family 6 member 4 0 1 5
Dopamine
207 DRD1 chr5:174,828,959-174,872,086 43127 dopamine receptor D1 1 0 6
208 DRD2 chrl 1:112,797,968-112,903,544 105576 dopamine receptor D2 9 2 16
209 DRD3 chr3:115,148,457-115,238,657 90200 dopamine receptor D3 0 1 6
210 DRD4 chii 1:607,536-650,933 43397 dopamine receptor D4 1 4 5
211 DRD5 Chr4:9,514,485-9,556,515 42030 dopamine receptor D5 0 0 2
212 SLC6A3 chr5:1,425,646-1,518,281 92635 solute carrier family 6 (neurotransmitter 0 3 17
Adrenoreceptors
213 ADRA1A chr8:26,607,576-26,764,832 157256 a-1A-adrenergic receptor isoform 1 6 1 18
214 ADRA1B chr5:159,304,634-159,400,446 95812 a-1B-adrenergic receptor 0 1 8
215 ADRA1D chr20:4,176,815-4,244,659 67844 a-1D-adrenergic receptor 0 0 10
216 ADRA2A chrl 0:112,481,507-112,525,157 43650 a-2A-adrenergic receptor 0 1 3
217 ADRA2B chr2:96,243,378-96,286,644 43266 a-2B-adrenergic receptor 0 1 2
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Adrenoreceptors - continued
218 ADRA2C chr4:3,778,806-3,821,625 42819 a-2C-adrenergic receptor 0 1 4
219 ADRB1 chrl 0:115,448,401-115,490,115 41714 beta-1-adrenergic receptor 0 1 3
220 ADRB2 chr5:148,214,685-148,256,696 42011 adrenergic, beta-2-, receptor, surface 6 4 7
221 TH chrl 1:2,129,468-2,177,344 47876 tyrosine hydroxylase isoform a 1 2 10
222 DDC chr7:50,247,884-50,390,500 142616 dopa decarboxylase (aromatic L-amino acid 1 1 8
223 DBH chr9:131,823,217-131,886,199 62982 dopamine beta-hydroxylase precursor 0 3 16
224 VMAT2 chrl 0:118,645,769-118,721,682 75913 solute carrier family 18 (vesicular monoamine), 2 2 9
225 SLC6A2 chrl 6:55,449,147-55,535,178 86031 solute carrier family 6 member 2 2 4 12
AED metabolisers - primary
226 NR1I2 chr3:120,800,231 -120,878,232 78001 pregnane X receptor isoform 2 1 0 7
227 CYP1A2 chrl 5:72,737,000-72,784,758 47758 cytochrome P450, family 1, subfamily A, 0 0 2
228 CYP2A6 chrl 9:46,021,283-46,068,180 46897 cytochrome P450, family 2, subfamily A, 5 0 2
229 CYP2B6 chrl 9:46,169,043-46,236,141 67098 cytochrome P450, family 2, subfamily B, 6 0 6
230 CYP2C9 chrl 0:96,343,026-96,433,734 90708 cytochrome P450, family 2, subfamily C, 0 7 9
231 CYP2C19 chrl 0:96,167,049-96,297,258 130209 cytochrome P450, family 2, subfamily C, 6 5 8
232 CYP2D6 chr22:40,747,095-40,791,440 44345 cytochrome P450, subfamily IID, polypeptide 6 9 1 3
233 CYP2E1 chrl 0:134,794,157-134,845,911 51754 cytochrome P450, family 2, subfamily E, 6 2 6
234 CYP3A4 chr7:98,946,000-99,013,205 67205 cytochrome P450, subfamily IIIA, polypeptide 4 0 0 2
235 CYP3A5 chr7:98,837,213-98,909,003 71790 cytochrome P450, subfamily IIIA, polypeptide 5 1 1 3
AED metabolisers - secondary
236 UGT1A4 chr2:234935732-234967509 31777 UDP glycosyltransferase 1 family, polypeptide 3 9 27
237 UGT2B7 chr4:70,257,769-70,314,249 56480 UDP glycosyltransferase 2 family, polypeptide 0 4 6
238 EPHX1 chrl :222,967,606-223,027,892 60286 epoxide hydrolase 1, microsomal (xenobiotic) 8 5 10
239 GSS chr20:34221912-34269277 47365 glutathione synthetase 3 0 0
240 GSTA1 chr6:52703224-52715493 12269 glutathione S-transferase A1 3 0 1
241 GSTA2 chr6:52662016-52675160 13144 glutathione S-transferase A2 3 0 4
242 GSTA4 chr6:52889586-52906976 17390 glutathione S-transferase A4 3 0 5
243 ODC1 chr2:10602246-10610192 7946 ornithine decarboxylase 1 6 0 5
-0
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AED metabolisers -  secondary -  continued.
244 ABCB1 chr7:86,724,976-86,974,593 249617 ATP-binding cassette sub-family B member 1 2 1 11
245 ABCC1 chrl 6:15,989,872-16,222,627 232755 ATP-binding cassette, sub-family C, member 1 5 4 26
246 ABCC2 chrl 0:101,187,159-101,296,168 109009 ATP-binding cassette, sub-family C 7 4 7
247 ABCC3 chrl 7:49,166,865-49,263,700 96835 ATP-binding cassette, sub-family C, member 3 4 2 14
248 ABCC4 chrl 3:93,350,089-93,671,684 321595 ATP-binding cassette, sub-family C, member 4 7 1 31
249 ABCC5 chr3:184,938,638-185,076,588 137950 ATP-binding cassette, sub-family C, member 5 4 2 6
250 ABCC6 chii 6:16,190,343-16,303,668 113325 ATP-binding cassette, sub-family C, member 6 5 3 7
251 ABCC10 chr6:43,426,343-43,485,018 58675 ATP-binding cassette, sub-family C, member 10 2 3 5
252 ABCA2 chr9:135,238,978-135,300,667 61689 ATP-binding cassette, sub-family A, member 2 1 3 6
253 RALBP1 chrl 8:9,445,529-9,548,105 102576 ralA binding protein 1 0 1 9
254 MVP chrl 6:29,849,423-29,916,979 67556 major vault protein 0 1 3
255 LRPPRC chr2:44,069,421 -44,217,679 148258 leucine-rich PPR motif-containing protein 1 4 27
256 ABCG2 chr4:89,449,811-89,558,406 108595 ATP-binding cassette, sub-family G, member 2 2 1 7
AED transport - secondary
257 SLC02A1 chr3:134,952,450-135,089,637 137187 solute carrier organic anion transporter family, 0 2 22
258 SLC01A2 chrl 2:21,293,093-21,459,638 166545
organic anion transporting polypeptide A 
isoform 0 4 13
259 SLC02B1 chrl 1:74,568,470-74,663,605 95135 solute carrier organic anion transporter family, 3 1 18
260 SLC03A1 chrl 5:90,106,713-90,456,547 349834 solute carrier organic anion transporter family, 7 4 64
261 SLC04A1 chr20:61,980,145-62,049,996 69851 solute carrier organic anion transporter family 1 1 6
262 SLC01C1 chrl 2:20,719,665-20,817,585 97920 solute carrier organic anion transporter family, 1 1 9
263 SLC05A1 chr8:70,614,535-70,817,169 202634 organic anion transporter polypeptide-related 3 3 23
264 SLC06A1 chr5:101,763,869-101,930,907 167038 solute carrier organic anion transporter family, 1 0 6
Keppra related
265 SV2A chrl: 146687880-146704100 16220 synaptic vesicle glycoprotein 2 0 0 8
266 SV2B chrl 5:89373312-89568278 194966 synaptic vesicle protein 2B homolog 1 0 25
267 SV2C chr5:75405020-75667264 262244 synaptic vesicle protein 2C homolog 0 2 19
268 SYT1 chrl 2:78,093,750-78,367,311 273561 synaptotagmin I 2 0 10
269 SYT2 chrl: 199,833,144-199,987,802 154658 synaptotagmin II 3 2 16
270 SYN1 chrX:46,458,244-46,545,239 86995 synapsin I isoform la 0 1 9
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Keppra related - continued
271 STX1A chr7:72,505,636-72,566,059 60423 syntaxin 1A (brain) 0 2 6
272 STX1B2 chrl 6:31,019,427-31,077,835 58408 syntaxin 1B2 0 1 2
273 SYP chrX:48,050,498-48,102,895 52397 synaptophysin 0 0 3
274 SNAP25 chr20:10,174,476-10,303,065 128589 synaptosomal-associated protein 25 isoform 3 3 17
275 VAMP2 chrl 7:8,243,029-8,286,858 43829 VAMP2 0 2 3
276 VTI1A chr10:113,851,602-114,182,119 330517 SNARE Vti1a-beta protein 6 0 28
277 VTI1B chrl 4:66,087,909-66,151,589 63680 vesicle transport through interaction with 0 0 6
278 RAB3A chrl 9:18,148,610-18,195,839 47229 RAB3A, member RAS oncogene family 1 4 7
279 RAB3B chrl :51,734,754-51,846,266 111512 RAB3B, member RAS oncogene family 0 1 5
280 RAB3C chr5:57,874,823-58,183,290 308467 RAB3C, member RAS oncogene family 5 3 27
281 RIMS1 chr6:72,572,324-73,126,014 553690 regulating synaptic membrane exocytosis 1 1 3 79
282 RNF40 chrl 6:30,789,689-30,842,596 52907 ring finger protein 40 isoform 1 0 1 2
283 NSF chrl 7:45,123,036-45,329,632 206596 N-ethylmaleimide-sensitive factor 3 2 3
284 CPLX1 chr4:748,575-829,775 81200 complexin 1 2 5 8
285 CPLX2 chr5:175,184,532-175,311,946 127414 complexin 2 2 8 17
286 CSNK1A1 chr5:148,884,058-148,979,167 95109 casein kinase 1, a 1 1 2 5
287 CAMK2A chr5:149,607,564-149,717,846 110282 CaM kinase II a 0 4 14
288 TRAPPC4 chrl 1:118,406,892-118,452,034 45142 trafficking protein particle complex 4 0 2 6
289 LRRC7 chrl :69,575,773-69,977,842 402069 leucine rich repeat containing 7 0 1 23
290 RPH3A chrl 2:111,621,694-111,767,197 145503 rabphilin 3A homolog (mouse) 2 1 13
291 PNUTL1 chr22:18,056,540-18,105,396 48856 PNUTL1 0 0 3
292 STXBP1 chr9:125,730,612-125,851,040 120428 syntaxin binding protein 1 0 1 3
293 CAMK2B chr7:43,979,676-44,126,004 146328 Ca/calmodulin-dependent protein kinase IIB 0 2 13
294 CAMK2D chr4:114,812,392-115,161,548 349156 Ca/calmodulin-dependent protein kinase II 4 5 26
295 EPIM chrl 2:129617247-129686907 69660 epimorphin isoform 2 0 2 4
296 PIK3CA chr3:180,167,223-180,293,408 126185 phosphoinositide-3-kinase, catalytic, a 1 4 10
297 PIK3CG chr7:106056455-106118121 61666 phosphoinositide-3-kinase, catalytic, gamma 2 1 5
298 RAB3GAP chr2:136,000,621 -136,158,313 157692 RAB3 GTPase-activating protein 0 1 6
299 RYR3 chrl 5:31309233-31894358 585125 ryanodine receptor 3 11 5 190
300 STX10 chrl 9:13105876-13132160 26284 syntaxin 10 0 2 4
301 STX11 chr6:144442239-144500071 57832 syntaxin 11 0 0 6
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Keppra related - continued
303 stx3a chrl 1:59288249-59355536 67287 syntaxin 3A 1 1 6
304 stx4a chrl 6:31070963-31097544 26581 syntaxin 4A (placental) 0 0 2
305 stx5a chrl 1:62339729-62384920 45191 syntaxin 5A 1 1 3
306 STX6 chrl :178174484-178241361 66877 syntaxin 6 1 1 6
307 STX7 chr6:132751725-132824736 73011 syntaxin 7 2 2 18
308 STX8 chrl 7:9344355-9689841 345486 syntaxin 8 1 2 42
309 SYN2 chr3:12010876-12217885 207009 synapsin II 4 5 8
310 SYN3 chr22:31223859-31737237 513378 synapsin III 3 10 83
311 SYNGR1 chr22:37979055-38034619 55564 synaptogyrin 1 isoform 1a 0 1 7
312 SYNGR3 chrl 6:1970027-1994276 24249 synaptogyrin 3 0 6 8
313 UNC13b chr9:35142055-35405331 263276 UNC13 (C. elegans)-like 0 0 10
Apoptosis
314 CSTB chr21:44,030,033-44,072,461 42428 cystatin B 3 4 10
315 CASP2 chr7:142,436,331 -142,495,714 59383 caspase 2 isoform 1 preproprotein 0 3 8
316 CASP3 chr4:186,224,740-186,286,491 61751 caspase 3 preproprotein 0 0 4
317 CASP6 chr4:111,048,604-111,103,449 54845 caspase 6 isoform a preproprotein 2 2 6
318 CASP8 chr2:202,280,755-202,374,974 94219 caspase 8, apoptosis-related cysteine protease 2 2 8
319 CASP10 chr2:202,230,397-202,316,653 86256 caspase 10 apoptosis-related cysteine protease 2 1 3
320 FADD chrl 1 -.69,755,576-69,799,794 44218 Fas-associated via death domain 0 0 3
321 BAG4 chr8:38,031,473-38,105,905 74432 BCL2-associated athanogene 4 0 1 2
322 CFLAR chr2:202,163,432-202,251,544 88112 CASP8 and FADD-like apoptosis regulator 1 1 3
323 BAX chrl 9:54,129,928-54,176,866 46938 BCL2-associated X protein isoform beta 3 5 9
324 APAF1 chrl 2:97,521,545-97,651,678 130133 apoptotic protease activating factor isoform c 1 1 6
325 BCL10 chrl :85,134,524-85,186,176 51652 B-cell CLL/lymphoma 10 0 0 5
326 AKT1 chrl 4:103197384-103241239 43855 v-akt murine thymoma viral oncgene homolog 1 0 6 8
327 AKT2 chrl 9:45421635-45493034 71399 v-akt murine thymoma viral oncgene homolog 2 0 1 4
328 BAK1 chr6:33577188-33604836 27648 BCL2-antagonist/killer 1 2 1 11
329 BBC3 chrl 9:52405924-52436291 30367 BBC3 0 0 4
330 BCL2 chii 8:58929548-59144899 215351 B-cell lymphoma protein 2 a isoform 1 4 29
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Apoptosis - continued
331 BCL2L1 chr20:30987263-31065656 78393 BCL2-like 1 isoform 1 1 2 3
332 BCL2L11 chr2:111966469-112026954 60485 BCL2-like 11 isoform 1 0 1 7
333 BCL2L2 chrl 4:21756164-21781086 24922 BCL2-like 2 protein 1 0 4
334 BIRC4 chrX:121,681,802-121,755,576 73774 baculoviral IAP repeat-containing protein 4 2 2 6
335 CAB39 chr2:231,760,203-231,908,325 148122 Ca binding protein 39 0 0 9
336 casp4 chr11:104341321 -104387006 45685 caspase 4 isoform a precursor 0 0 6
337 casp7 chrl 0:115094015-115165249 71234 caspase 7 isoform delta, large subunit 2 1 8
338 casp9 chrl: 15171494-15223487 51993 caspase 9 isoform a preproprotein 0 4 5
339 DAPK3 chrl 9:3,889,451 -3,940,826 51375 death-associated protein kinase 3 0 3 7
340 EIF4EBP1 chr8:68514-118365 49851 eukaryotic translation initiation factor 4E 0 0 0
341 FAS chr10:90,394,864-90,460,118 65254 FAS 2 2 7
342 FASLG chrl :169,847,560-169,895,386 47826 fas ligand 0 1 4
343 FRAP1 chrl: 10,856,137-11,052,110 195973 FRAP1 1 5 6
344 HYOU1 chr11:118442552-118475477 32925 oxygen regulated protein precursor 0 3 4
345 IRS2 chrl 3:108094185-108146916 52731 insulin receptor substrate 2 1 1 6
346 LYK5 chrl 7:62243596-62302540 58944 protein kinase LYK5 isoform 1 2 3 4
347 MAP3K5 chr6:136848757-137104226 255469 mitogen-activated protein kinase 5 2 0 23
348 MDM2 chrl 2:67478238-67530481 52243 mouse double minute 2 homolog isoform MDM2 2 3 4
349 PDK1 chr2:173613380-173676069 62689 pyruvate dehydrogenase kinase, isoenzyme 1 1 0 5
350 PRKAA1 chr5:40798377-40853977 55600 PK, AMP-activated, a 1 catalytic subunit 0 1 3
351 PRKAA2 chrl :56470913-56553947 83034 AMP-activated protein kinase a 2 catalytic 0 0 9
352 PTEN chrl 0:89277772-89400708 122936 PTEN 1 0 n 8
353 raptor chrl 7:79209187-79650286 441099 raptor 13 9 40
354 RHEB chr7:150545537-150618750 73213 Ras homolog enriched in brain 1 1 6
355 TNF chr6:31637666-31660409 22743 tumor necrosis factor a 7 3 8
356 TNFRSF1A chrl 2:6298185-6331472 33287 TNF receptor superfamily, member 1A 0 5 9
357 TSC1 chr9:131032782-131106053 73271 tuberous sclerosis 1 protein isoform 1 1 1 6
358 TSC2 chrl 6:2028516-2088636 60120 tuberous sclerosis 2 isoform 1 1 1 7
359 YWHAE chrl 7:1,434,435-1,530,108 95673 YWHAE 0 1 8
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Apoptosis - continued
360 YWHAG chr7:75,548,205-75,620,405 72200 YWHAG 1 2 4
361 YWHAZ chr8:101877497-101930260 52763 tyrosine 3/tryptophan 5 -monooxygenase 1 0 3
GSK
362 PTGS2 chrl: 183879960-183888548 8588 PTGS-endoperoxide synthase 2 precursor 1 0 3
363 SLC4A3 chr2:220694825-220709231 14406 solute carrier family 4, anion exchanger, memb 6 0 3
364 KCNV1 chr8:110935817-110943542 7725 K channel, subfamily V, member 1 3 0 5
365 NAT1 chr8:18077887-18091092 13205 N-acetyltransferase 1 1 0 5
366 GJA5 chr1:144735969-144752519 16550 gap junction protein, a 5 1 0 5
367 GJA10 chrl :38753032-38760583 7551 connexin 59 2 0 2
368 GJA3 chr13:18514119-18515427 1308 gap junction protein, a 3, 46kDa (connexin 1 0 6
369 CX62 chr6:90599785-90601417 1632 connexin 62 1 0 6
370 CX40.1 chrl 0:35898343-35901869 3526 connexin40.1 2 0 2
371 GJC1 chrl 7:38890071 -38894110 4039 GJC1 0 0 1
372 GJB7 chr6:87988295-88034592 46297 hypothetical protein LOC375519 2 0 2
373 PANX3 chrl 1:124019104-124027901 8797 pannexin 3 2 0 3
374 BZRP chr22:41778493-41790189 11696 peripheral benzodiazapine receptor isform PBR 3 0 4
375 CX3CL1 chrl 6:57181810-57194351 12541 chemokine (C-X3-C motif) ligand 1 1 0 4
376 CSEN chr2:95447851 -95536580 88729 Kv channel interacting protein 3 3 0 4
377 IL1B chr2:113682482-113689502 7020 interleukin 1, beta proprotein 1 0 1
378 PLD1 chr3:172639557-172776785 137228 phospholipase D1, phophatidylcholine-specific 1 0 6
379 IL6 chr7:22509091 -22513888 4797 interleukin 6 (interferon, beta 2) 1 0 5
380 KCNH2 chr7:150033789-150066755 32966 voltage-gated K channel, subfamily H, 1 0 5
381 RELN chr7:102672767-103190493 517726 reelin 4 0 49
382 SGCE chr7:93826570-93897507 70937 sarcoglycan, epsilon 1 0 4
383 PLAT chr8:42050122-42082562 32440 plasminogen activator, tissue type isoform 1 2 0 4
384 DAPK1 chr9:85569914-85780662 210748 death-associated protein kinase 1 6 0 28
385 IFNA1 chr9:21430439-21431315 876 interferon, a 1 3 0 3
386 KCNJ11 chrl 1:17371106-17374515 3409 K inwardly-rectifying channel J11 3 0 2
387 ATXN2 chrl 2:110301970-110449433 147463 ataxin 2 4 0 3
388 SYT10 chrl 2:33419614-33484021 64407 synaptotagmin 10 2 0 2
389 ATP10A chrl 5:23469780-23656231 186451 ATPase, Class V, type 10A 8 0 26
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GSK - continued
390 SLC12A6 chrl 5:32241721 -32326986 85265 SLC12A6 4 0 2
391 A2BP1 chrl 6:6069424-7762298 1692874 ataxin 2-binding protein 1 isoform 1 12 0 0
392 MC3R chr20:55509210-55510293 1083 melanocortin 3 receptor 2 0 5
Plasma proteins
393 ALB chr4:74736256-74753383 17127 albumin precursor 0 0 2
394 ORM1 chr9:112461380-112464802 3422 orosomucoid 1 precursor 0 0 6
395 ORM2 chr9:112468113-112471581 3468 orosomucoid 2 0 0 5
Neuromodulators of synaptic transmission
396 NPY chr7:24,046,080-24,093,749 47669 neuropeptide Y 1 3 5
397 NPY1R chr4:164,802,743-164,851,375 48632 neuropeptide Y receptor Y1 0 0 3
398 NPY2R chr4:156,687,407-156,735,854 48447 neuropeptide Y receptor Y2 0 1 4
399 NPY3R chr2:137,062,688-137,106,494 43806 chemokine (C-X-C motif) receptor 4 isoform a 0 1 4
400 NPY4R func only 0 pancreatic polypeptide receptor 1 0 0 5
401 NPY5R chr4:164,822,717-164,870,711 47994 neuropeptide Y receptor Y5 0 0 4
402 NPY6R chr5:137209677-137231630 21953 neuropeptide Y receptor Y6 (pseudogene) 0 0 2
403 BDNF chrl 1 -.27,620,750-27,727,605 106855 brain-derived neurotrophic factor isoform c 0 2 7
404 NTRK2 chr9:82,721,744-83,114,528 392784 NTRK2 4 2 36
405 NGFR chrl 7:48,027,304-48,086,999 59695 nerve growth factor receptor precursor 0 0 10
406 GAL chrl 1:68,207,394-68,254,003 46609 galanin preproprotein 0 2 6
407 GALR1 chii 8:73,068,709-73,129,070 60361 galanin receptor 1 0 1 6
408 GALR2 chrl 7:74,648,014-74,690,696 42682 galanin receptor 2 0 3 3
409 GALR3 chr22:36,442,427-36,484,541 42114 galanin receptor 3 0 1 4
Others
410 NOVA1 chrl 4:24895216-25067088 171872 neuro-oncological ventral antigen 1 isoform 1 2 0 4
411 PAFAH1B1 chii 7:2,683,526-2,815,479 131953 platelet-activating factor acetylhydrolase, 0 3 6
412 PDYN chr20:1,934,402-1,989,702 55300 beta-neoendorphin-dynorphin preproprotein 0 0 4
413 CDK5 chr7:150,122,639-150,166,737 44098 cyclin-dependent kinase 5 2 2 4
414 EFHC1 chr6:52,311,947-52,424,054 112107 EF-hand domain (C-terminal) containing 1 6 4 23
Table 8.2 continued... Summary of candidate genes and SNP selection for large scale epilepsy project
P16 Gene Gene coordinate Size* Gene Descriptions #func non HM
#func
HM #tags
Mendelian/linkage - continued
416 ME2 chrl 8:46,637,588-46,745,620 108032 malic enzyme 2, NAD(+)-dependent, mto 1 2 3
417 LGI1 chr10:95,162,264-95,242,503 80239 leucine-rich, glioma inactivated 1 precursor 1 0 10
418 LGI2 Chr4:24,734,272-24,803,198 68926 leucine-rich repeat LGI family, member 2 2 1 11
419 LGI3 Chr8:22,006,282-22,056,282 50000 leucine-rich repeat LGI family, member 3 0 2 5
420 LGI4 chrl 9:40,287,256-40,337,944 50688 leucine-rich repeat LGI family, member 4 2 4 6
421 MASS1 chr5:89,918,689-90,564,105 645416 very large G-protein coupled receptor 1 9 8 34
SOX related
422 SOX2 chr3:182,730,634-182,773,134 42500 sex-determining region Y-box 2 0 0 3
Opioids/endocabinoids
423 OPRM1 chr6:154,371,433-154,618,991 247558 opioid receptor, mu 1 isoform MOR-1X 1 3 59
424 OPRK1 chr8:54,171,732-54,233,932 62200 opioid receptor, kappa 1 2 2 6
425 OPRD1 chrl :28,806,165-28,897,717 91552 opioid receptor, delta 1 0 1 7
426 PENK chr8:57,383,477-57,428,550 45073 proenkephalin 0 0 2
427 POMC chr2:25,338,322-25,385,987 47665 proopiomelanocortin 1 1 5
428 PCSK1 chr5:95,780,191 -95,863,025 82834 proprotein convertase subtilisin/kexin type 1 0 4 7
429 PCSK2 chr20:17,182,630-17,480,223 297593 proprotein convertase subtilisin/kexin type 2 9 4 29
430 CNR1 chr6:88,825,178-88,870,652 45474 central cannabinoid receptor isoform a 0 1 8
431 FAAH chrl :46,209,908-46,269,433 59525 fatty acid amide hydrolase 0 2 4
Neurosteroids
432 CYP11A1 chrl 5:72,325,920-72,395,784 69864 cytochrome P450, subfamily XIA precursor 3 2 5
433 SRD5A1 chr5:6,666,300-6,742,411 76111 steroid-5-a-reductase 1 4 1 5
434 AKR1C3 chrl 0:5,070,567-5,123,878 53311 aldo-keto reductase family 1, member C3 0 2 6
435 AKR1C2 chrl 0:4,965,965-5,034,207 68242 aldo-keto reductase family 1, member C2 2 3 9
Somatostatin
436 SST chr3:188,687,617-188,729,019 41402 somatostatin 1 0 3
437 SSTR1 chrl 4:36,647,242-36,692,307 45065 somatostatin receptor 1 0 0 7
438 SSTR2 chrl 7:71,738,282-71,785,183 46901 somatostatin receptor 2 0 3 6
439 SSTR3 chr22:35,825,283-35,871,392 46109 somatostatin receptor 3 1 2 8
440 SSTR4 chr20:22,991,120-23,032,287 41167 somatostatin receptor 4 0 0 4
Table 8.2 continued... Summary of candidate genes and SNP selection for large scale epilepsy project
P17 Gene Gene coordinate Size* Gene Descriptions #func non HM
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HM #tags
Somatostatin - continued
441 SSTR5 chrl 6:1,048,869-1,089,964 41095 somatostatin receptor 5 0 2 6
cholecystOkinin
442 CCK chr3:42,239,909-42,286,987 47078 cholecystokinin preproprotein 0 1 6
443 CCKAR chr4:26,213,900-26,262,925 49025 cholecystokinin A receptor 0 0 5
444 CCKBR chrl 1:6,225,274-6,277,665 52391 cholecystokinin B receptor 2 1 13
neurotachkynin
445 TAC1 chr7:96,953,105-97,001,513 48408 tachykinin 1 isoform beta precursor 0 0 4
446 TACR1 chr2:75,230,766-75,420,810 190044 tachykinin receptor 1 isoform long 4 1 34
447 TACR2 chrl 0:70,489,184-70,540,682 51498 tachykinin receptor 2 0 3 7
448 TACR3 chr4:104,949,444-105,119,793 170349 tachykinin receptor 3 0 2 11
Zinc transporter protein
449 GJB2 chr13:18,539,608-18,585,037 45429 qap junction protein, beta 2, 26kDa (connexin 0 0 3
450 GJE1 chr7:99,112,564-99,158,640 46076 gap junction protein, epsilon 1, 29kDa 1 2 6
451 GJB6 chrl 3:18,574,101 -18,623,067 48966 qap junction protein, beta 6 (connexin 30) 0 0 7
452 GJB1 chrX:69,289,866-69,331,835 41969 gap junction protein, beta 1, 32kDa (connexin 0 2 7
453 CX36 chrl 5:32750734-32772745 22011 connexin-36 0 0 6
454 GJA1 chr6:121,717,363-121,771,448 54085 connexin 43 1 0 10
455 GJA7 chrl 7:43,337,159-43,378,350 41191 qap junction protein, a 7, 45kDa (connexin 0 0 3
456 GJA12 chrl :225,292,183-225,342,156 49973 connexin46.6 0 0 1
457 PANX1 chrl 1:93,530,246-93,623,288 93042 pannexin 1 3 2 7
458 PANX2 chr22:48,771,217-48,820,747 49530 pannexin 2 2 3 8
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